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“It is my great concern to separate psychedelics from the ongoing 
debates about drugs, and to highlight the potential inherent to these 
substances for self-awareness, as an adjunct in therapy, and for 
fundamental research into the human mind.”  
Albert Hofmann   
 
 
 
“LSD is a catalyst or amplifier of mental processes. If properly used, it 
could become something like the microscope or telescope of psychiatry. 
Whether or not LSD research and therapy will return to society, the 
discoveries that psychedelics made possible have revolutionary 
implications for our understanding of the psyche, human nature, and the 
nature of reality.” 
Stanislav Grof 
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1. Overview 
 
My PhD thesis consisted of two different scientific parts, each supervised by one of 
my advisors, Prof. Dr. med. Matthias Liechti and Prof. Dr. sc. nat. Katharina Rentsch. 
 
One part was to develop liquid chromatography tandem mass spectrometry (LC-
MS/MS) methods to measure d-lysergic acid diethylamide (LSD) and its main 
metabolites in plasma, serum, and urine samples. We established the 
pharmacokinetics of LSD and collected data from emergency toxicological cases. 
Therefore we have developed and validated two analytical methods using LC-MS/MS 
which resulted in several publications. All analytical work was performed in the 
Toxicology Lab of the Laboratory Medicine at the University Hospital Basel under the 
supervision of Prof. Dr. sc. nat. Katharina Rentsch. 
The second part included planning, conduction, and analysis of clinical phase I trials 
with LSD. We investigated the acute psychological and physiological effects of LSD 
in healthy humans what resulted in several publication. These projects were 
supervised by Prof. Dr. med. Matthias Liechti at the Department of Clinical 
Pharmacology and Toxicology of the University Hospital Basel. One LSD study 
included a functional magnetic resonance imaging (fMRI) assessment, to investigate 
the neural correlates of altered states of consciousness and emotion processing 
under the influence of LSD. The fMRI study was done in close collaboration with the 
team of Prof. Dr. med. Stefan Borgwardt from the Department of Psychiatry of the 
University of Basel. 
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2. Introduction 
 
2.1 Background 
 
Lysergic acid diethylamide (LSD) is a semisynthetic compound related to its 
precursors lysergic acid and lysergic acid amide which are naturally occurring in 
different fungi (e.g. claviceps purpurea) and plant seeds (e.g. argyreia nervosa). The 
chemical structure of LSD is related to the endogenous neurotransmitter serotonin 
and other psychedelic drugs such as psilocin, the active compound of the “magic 
mushrooms” (e.g. psilocybe cubensis), and dimethyltryptamine, the active compound 
of “ayahuasca” (Figure 1). The synthesis of LSD yields four stereoisomeric alkaloids, 
d- and l-LSD, and d-iso-LSD and l-iso-LSD, whereof only d-LSD possesses the 
powerful mind-altering effects in animals and humans (1-3). d-LSD is one of the most 
potent substances, doses above 0.01 mg (10 µg) already produce measurable 
effects, and from 40 µg upwards induce intense behavioral and perceptual alterations 
(4, 5). LSD interacts with several brain receptors. Specifically, LSD binds to several 
subtypes of the serotonin receptor (5-HT2A, 5-HT1A, 5-HT2C), has additional affinity for 
dopamine D1 and D2 receptors (6-8), and indirectly alters glutamatergic 
neurotransmission via the 5-HT2A receptor (9). The 5-HT2A receptor is also 
considered the receptor that primarily mediates the hallucinogenic effects of LSD and 
other serotonergic hallucinogens including psilocin and dimethyltryptamine (10-13).  
Research with a hallucinogen like LSD always raises some safety concerns. 
However, LSD possesses little if any abuse liability, is not self-administered by 
animals, and there is no human LSD dependence syndrome (14). Repeated LSD 
administration leads to pronounced tolerance to its psychological and physiological 
effects in less than seven days (15, 16). Further, there is cross-tolerance after 
repeated administration of psilocybin and other LSD derivatives in humans (17, 18). 
The tolerance is transient and absent three days after discontinuation. Long-term use 
in humans is not associated with any evidence of generalized brain damage related 
to the number of LSD consumptions (19). The chance of precipitating a long-term 
psychotic reaction is limited to subjects with a personal or familiar history of psychotic 
disorders (20). Under controlled and supportive conditions, the LSD experience may 
even have lasting positive effects on attitude and personality (21).  
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Dimethyltryptamine 
Psilocin 
Serotonin 
d-lysergic acid diethylamide 
Figure 1 gives the structure of d-lysergic acid diethylamide, the neurotransmitter 
serotonin (embedded), and the hallucinogens dimethyltryptamine and psilocin. 
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2.2 The History of LSD 
 
LSD was first synthesized in 1938 here in Basel, and its highly specific actions on the 
brain and human consciousness were discovered by chance by Albert Hofmann. On 
the 16th of April in 1943, he decided to resynthesize LSD to repeat tests at the 
pharmacological department of Sandoz. He got contaminated by accident, and 
suddenly felt a strong restlessness combined with a slight dizziness whereon he 
interrupted his work and returned home. He described the following hours as a “not-
unpleasant intoxicated dreamlike state, with very stimulated imagination and 
kaleidoscope-like play of colors” (22). On the 19th of April 1943 he decided to do a 
self-experiment with 250 µg of the d-LSD tartrate salt. He described the following trip 
as follows: “A demon had invaded me and had taken possession of my body, mind 
and soul. I jumped up and screamed in order to free myself from him, but then sank 
down again powerless on the sofa. A dreadful fear grasped me that I was becoming 
insane. I was taken to another world, another place, another time. My body seemed 
to me to be without sensation, lifeless, strange. Was I dying? Was this the transition? 
Then, the horror softened and gave way to a feeling of fortune and gratitude, the 
more normal perceptions and thoughts returned and my assurance increased that the 
danger of insanity was conclusively past. Now I gradually began to enjoy the 
unprecedented colors and plays of shapes that persisted behind my closed eyes. It 
was particularly remarkable how every acoustic perception…became transformed 
into optical perceptions. Exhausted I then slept and woke up the next morning with a 
clear head, even though still somewhat tired physically. A sensation of well-being and 
renewed life flowed through me.”(22) He wrote a report about his experience to his 
seniors who repeated his self-experiment, although with lower doses. 
From 1949-1966, d-LSD tartrate (LSD-25) was marketed by Sandoz under the brand 
name Delysid®, and was mostly used in basic psychiatric research and 
psychotherapy (9, 23-26). Its subjective psychotomimetic effects were compared to 
those in patients with schizophrenia and led to its use as an experimental substance 
for model psychosis (2, 27-29). It was thus provided to psychiatrists and researchers 
with the purpose to study these psychotic phenomena and giving them the possibility 
of gaining insight into the subjective character of mental disorders. 
10 
 
 
Soon, a potential therapeutic use was recognized and led to first therapeutic studies 
at the Psychiatric University Hospital in Zurich (30). In the following years, beneficial 
effects were documented in the treatment of alcoholism (31), anxiety associated with 
terminal illness (26, 32, 33) and in the treatment of cluster headache (34).  
In hand with the use in a therapeutic setting, LSD was also investigated in 
social/group settings. Social cognition including emotion recognition and empathy 
describes the ability to infer another’s thoughts, feelings, and intentions and is thus a 
highly relevant topic not only for social interactions but especially for its use in a 
psychotherapeutic setting. However, various studies examining social interactions 
under the influence of LSD showed inconsistent results. This was not surprising, 
since experiments were carried out in small groups (3 or 4 subjects), in different 
populations (healthy, alcoholics, addicts, reformatory inmates or schizophrenics) and 
with variable doses (25 – 200 µg) (35-39). Further, social effects were measured 
using a variety of tools and included investigations of social perception (rating of 
liking others in the group or being liked by them) (39), prosocial effects like increased 
solidarity, tension release, and decreased antagonism (38). Subject’s social 
interactions within the group settings were mostly set up around a specific task e.g. 
discussing the solution of a human relation problem. The behavior of the group and 
its individuals towards problem evaluation and decisions were recorded, and 
categorized with the Bales Interaction Process Analysis (35, 36, 38). Thereby, the 
social interactions were found to be altered in a dose dependent manner. For small 
doses of LSD (25 - 50 µg) interaction was increased, whereas it leveled out on 
moderate doses (75 – 100 µg), and finally decreased on high doses up to 200 µg 
where subjects were less proactive in conversations (35-39). Changes in socio-
emotional behavior were observed in all groups but with different outcomes (35-39). 
Alcoholics rose in positive emotional behavior whereas schizophrenics rose in 
positive as well as negative behaviors (36). Overall LSD was reported as an effective 
tool for increasing social interaction and gaining insight, making it thereby a useful 
therapeutic agent. Besides the psychological and socio-emotional effects, 
researchers were interested in the metabolism of LSD and its dose-relation to these 
effects. 
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For the determination of the metabolic faith, 14C-labeled LSD was administered to 
animals, and measurements of radioactivity were used for the quantification, which 
was the method with the highest sensitivity and specificity during this research era 
(40-44). Experiments with 14C labeled LSD in rats, mice, guinea pigs, and cats 
showed a rapid uptake in to the blood, distribution among the organs where LSD 
undergoes rapid chemical alteration, followed by a steady elimination in to the bile 
and the small intestine (40-44). Enterohepatic re-absorption was found to be 
negligible (44, 45). There was also a difference in metabolism across the various 
species. In rats, mice, guinea pigs, and cats, the biliary/faecal excretion dominated 
(40-44) whereas urinary excretion was dominant in rhesus monkeys (43). In rodents, 
the major metabolites in bile and urine were found to be 13- and 14-hydroxy-LSD 
glucuronides (43). In faeces the deconjugated forms, 13- and 14-hydroxy-LSD were 
dominating, probably cleaved by gut bacteria. In rhesus monkeys, 13- and 14-
hydroxy-LSD accounted only for a minor part of the metabolites, but the major 
metabolites could not be clearly identified. However, the formation of an additional 
metabolite formed out of 2-oxo-LSD was described, and named “naphthostyril 
compound” (43). This compound could be the precursor of the recently identified 
major human metabolite, 2-oxo-3-hydroxy-LSD (46). A further identified metabolite 
was de-ethyl-LSD, or lysergic-acid-monoethylamide (LAE). In vitro studies with liver 
microsomes additionally yielded nor-LSD as potential metabolite, however it could 
not be confirmed in-vivo (47). Out of the various LSD metabolites, 13-hydroxy-LSD 
and LAE were found to be active in animals (43). 
 
In humans, the metabolism of LSD is largely unknown and was less investigated 
compared to the one in animals. The only two studies were done in the 1960s and 
1970s. Single intravenous doses of 2 μg/kg in five healthy male subjects, and single 
oral doses of 160 μg in 13 healthy male subjects were administered (48, 49). The 
only small pharmacokinetic study was done with the results from the study by 
Aghajanian et al. following the intravenous dose of 2 μg/kg and they proposed a 
three-compartmental model (48, 50-52). Plasma concentrations were 6-7 ng/ml 30 
min after intravenous administration, 4 - 6 ng/ml at 30 - 120 min, and approximately 1 
ng/ml at 8 h. The elimination half-life of LSD was found to be 3 h (48, 50). This was 
also the first time that the effects of LSD, represented by a score of impairment in 
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solving a mathematical task, were linked to the plasma concentration (48, 50-52). 
The group of Upshall et al., which orally administered 160 μg of LSD, measured 
plasma concentrations in a fasted state, following a light breakfast, or a full breakfast. 
They observed a difference in plasma concentrations between men in a fasted state 
and men who had a full breakfast, suggesting, that the amount and composition of 
food has an effect on LSD plasma levels (49). The effects of two in-vivo identified 
metabolites were also investigated in humans. Intramuscular application of up to 
1’200 µg LAE led to strong psychological effects, comparable to those after oral 
administration of 100 µg LSD (53). The effects were described faster in onset, but 
lasted only up to 2.5 hours. In contrast, oral administration of 300 µg 2-oxo-LSD did 
not induce any psychological effects (44).  
Both human studies used fluorimetric assays for the measurements of their plasma 
samples. They made use of LSD’s fluorescence and its UV-light catalyzed hydration 
to the non-fluorescent lumi-LSD (10-Hydroxy-9,10-dihydro-LSD) (48, 49). However, 
this method clearly lacked specificity (48, 49). Overall, human pharmacokinetic data 
is very sparse and new technologies such as LC-MS/MS allow to measure substance 
concentrations more precisely and also to further characterize metabolites. Indeed, 
more recent in-vitro studies using human liver microsomes and analysis of human 
urine samples have confirmed the presence of LAE, 2-oxo-LSD, 13- and 14-hydroxy-
LSD, and further identified nor-LSD, lysergic-acid-ethyl-2-hydroxyethylamide (LEO), 
tri-oxo-LSD and 2-oxo-3-hydroxy-LSD as potential human metabolites (54, 55). 
However, systematic information about their presence after controlled intake is still 
missing. 
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Contrary to the unknown pharmacokinetic parameters, the pharmacodynamics, 
including subjective and autonomic effects, were widely investigated. The dose range 
for a typical LSD reaction was estimated to be 50 - 200 µg. A variety of different 
doses and routes of application have been used in different study populations 
including healthy subjects and patients (2, 14, 29). Therefore, descriptions of the 
psychological effects were varying and depended on the investigated study 
population, route of administration, dose of LSD, setting of the experiment, and 
expectations of subjects and investigators. Generally, symptoms could be classified 
among three characteristics: Somatic, perceptual, and psychologic effects.  
 
In humans, LSD produces changes in perception, cognition, and emotions that last 
for up to 12 hours (9, 14, 23).  Similar to other serotonergic drugs, mild or moderate 
anticipatory anxiety is common at the onset of the drug effect (56). During the time of 
full effect, mood changes are very frequent, mostly towards positive mood states (2, 
14). Perceptual changes include illusions, pseudo-hallucinations, intensified color 
perception, synesthesia, and alterations in time perception (2, 14, 29). Alterations of 
thinking may include imaginative thoughts, broader and unusual associations, re-
experiencing biographic memories, or mystical-type experiences (2, 14).  
Furthermore, LSD acutely impairs psychomotoric function including coordination and 
reaction time (2, 14, 29). Under controlled and supportive conditions, these 
phenomena are mostly experienced in a positive way and may have lasting positive 
effects on attitude and personality including greater appreciation of music, art, and 
nature, greater tolerance of others, and increased creativity and imagination (21). 
However, dysphoria, anxiety, and mild transient ideas of reference or paranoid 
thinking may also occur in some subjects. However, they are mostly attributable to 
uncontrolled conditions and can be readily managed with reassurance in a controlled 
setting (2, 14, 23, 29).  
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These numerous investigations prove that there is considerable previous experience 
with the use of LSD in humans, both with regard to research and clinical application. 
Psychotherapists have used LSD in thousands of patients and thus made LSD one of 
the most studied pharmacological substances with more than 4000 published reports 
(9, 14, 24). 
These scientific activities came to a halt as a result of the political concerns in 
response to the increasing abuse of LSD starting in the end of the 1960s. Since the 
1970s, clinical research using scheduled hallucinogenic substances like LSD has 
been prohibited in most countries, with only a few exceptions. From 1988 to 1993, 
LSD was legally used in Switzerland in LSD-assisted psychotherapy in 170 patients 
with a wide range of clinical disorders (57). Further uses of LSD were re-recognized 
and included its use in brain research (14), treatment of cluster headache (58, 59), 
alcoholism (60), and as an adjunct to psychotherapy (61). A first placebo-controlled 
pilot study using LSD in patients suffering from anxiety associated with advanced-
stage life threatening diseases showed a potential therapeutic value (61). 
Although some of the earlier research produced promising results, it became also 
clear that the initial studies conducted with LSD do not meet todays’ research 
standards. For instance, no optimal methodological procedures, e.g. double-blind, 
placebo-controlled studies, were used (14, 24). In addition, many of the techniques 
used today were not available or not as developed at that time. Specifically, 
comprehensive validated psychological test systems, sophisticated measures of 
physiological and endocrine parameters, neuroimaging or analytical techniques were 
unavailable or sparse. Hence, almost no scientific clinical pharmacological data on 
LSD is available. 
 
 
 
 
 
 
15 
 
 
2.3 The Future of LSD or Aims of the PhD Project 
 
Despite very intensive research during the 1950s to 1970s, there are still a lot of 
research questions to be answered. First, most previous investigations do not meet 
our present scientific and ethical standards and have therefore to be replicated. The 
results from earlier studies were primarily observational and thus very subjective. 
Second, technological progress allows us to use new and more modern approaches 
such as imaging techniques. Third, LSD use is still very prevalent. Among young 
adults (15- to 34-year-olds), lifetime prevalence of LSD use varies from 0.1% to 5.4% 
in the EU (62) and up to 7% in the US population (63).  Here in Basel, we registered 
over 13 cases with an acute LSD intoxication on the emergency department of the 
University Hospital Basel between October 2013 and September 2015 (64-66). 
Because of this renewed interest and the lack of state of the art human 
pharmacological data, we decided to conduct two placebo-controlled studies in 
healthy subjects.  
We aimed to better characterize the pharmacology of LSD using sensitive and 
validated analytical and psychometric tools. One aim of our project was to develop 
and validate LC-MS/MS methods to characterize the single-dose kinetics of LSD and 
establish pharmacokinetic information which is important for the evaluation of clinical 
study findings such as subjective effects, autonomic effects, and functional magnetic 
resonance imaging results. Additionally, our methods were used to analyze samples 
of LSD emergency toxicological cases on the emergency department of the 
University Hospital Basel. The detailed analytical methods and the 
development/validation procedures are described in detail in the following 
publications 1 and 6 (65, 67). We also investigated the subjective effects, effects on 
mood, perception, emotion recognition and empathy using sensitive, validated 
psychometric tools. Investigation of the LSD effect on autonomic parameters included 
assessment of blood pressure, heart rate, body temperature, and pupil diameter.  
Further, we aimed to define the neuronal correlates of the effects of LSD using 
functional magnetic resonance imaging (fMRI) techniques. Thereby, the studies also 
provided basic data for the understanding of the role of the serotonin 5-HT2A receptor 
in the regulation of mood in general and on emotion recognition and empathy.  
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Our studies generated objective, high-quality scientific information on the effects of 
LSD in healthy subjects, data that cannot be obtained with observational studies. 
Overall, our placebo-controlled studies using LSD in healthy subjects were primarily 
descriptive in nature and with a focus on the tolerability and safety which is needed 
for future projects. For both clinical studies we used a double-blind placebo-controlled 
cross-over design with two treatment conditions (LSD and placebo). Thus, subjects 
served as their own controls omitting within-subject variability and markedly 
increased study power. The treatment order was counter-balanced with washout 
periods of at least 7 days between the test days. The placebo condition mainly 
served as a control condition for the subjective and somatic measures. Study 1 used 
a dose of 200 µg LSD and placebo in 16 subjects (8 men, 8 women), and Study 2 
used 100 µg LSD and placebo in 24 subjects (12 men, 12 women). Detailed 
information about the inclusion and exclusion criteria for each study is explained in 
the following publications 3 and 4 (68-71). All data were obtained with the same 
psychometric questionnaires which were already used with other psychoactive and 
stimulant drugs in our group (72-74) and by others (12, 75-77). Detailed description 
of each test is part of the respective publications 3, 4, and 5 (69, 70, 78). Both 
studies were conducted in accordance with the Declaration of Helsinki and were 
approved by the local ethics committee. The administration of LSD to healthy 
subjects was authorized by the Swiss Federal Office for Public Health (BAG). The 
studies in the 1950s to 1970s have all used d-LSD tartrate (LSD-25, molecular weight 
398), whereas we used d-LSD hydrate (molecular weight 323) what corresponds to a 
higher dose of LSD-25 (+23%). 
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Development and validation of a rapid turboflow LC-MS/MS
method for the quantification of LSD and 2-oxo-3-hydroxy LSD
in serum and urine samples of emergency toxicological cases
Patrick C. Dolder & Matthias E. Liechti &
Katharina M. Rentsch
Received: 25 September 2014 /Revised: 24 November 2014 /Accepted: 2 December 2014 /Published online: 27 December 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract Lysergic acid diethylamide (LSD) is a widely used
recreational drug. The aim of the present study is to develop a
quantitative turboflow LC-MS/MS method that can be used
for rapid quantification of LSD and its main metabolite 2-oxo-
3-hydroxy LSD (O-H-LSD) in serum and urine in emergency
toxicological cases without time-consuming extraction steps.
The method was developed on an ion-trap LC-MS/MS instru-
ment coupled to a turbulent-flow extraction system. The val-
idation data showed no significant matrix effects and no ion
suppression has been observed in serum and urine. Mean
intraday accuracy and precision for LSD were 101 and
6.84 %, in urine samples and 97.40 and 5.89 % in serum,
respectively. For O-H-LSD, the respective values were 97.50
and 4.99 % in urine and 107 and 4.70 % in serum. Mean
interday accuracy and precision for LSDwere 100 and 8.26%
in urine and 101 and 6.56 % in serum, respectively. For O-H-
LSD, the respective values were 101 and 8.11 % in urine and
99.8 and 8.35 % in serum, respectively. The lower limit of
quantification for LSD was determined to be 0.1 ng/ml. LSD
concentrations in serum were expected to be up to 8 ng/ml. 2-
Oxo-3-hydroxy LSD concentrations in urine up to 250 ng/ml.
The new method was accurate and precise in the range of
expected serum and urine concentrations in patients with a
suspected LSD intoxication. Until now, the method has been
applied in five cases with suspected LSD intoxication where
the intake of the drug has been verified four times with LSD
concentrations in serum in the range of 1.80–14.70 ng/ml and
once with a LSD concentration of 1.25 ng/ml in urine. In
serum of two patients, the O-H-LSD concentration was deter-
mined to be 0.99 and 0.45 ng/ml. In the urine of a third patient,
the O-H-LSD concentration was 9.70 ng/ml.
Keywords LSD . O-H-LSD . LC-MS . Lysergic acid
diethylamide . 2-Oxo-3-hydroxy LSD . Blood . Urine
Introduction
Lysergic acid diethylamide (LSD) is a psychoactive substance
changing the state of consciousness and perception. Its psy-
chedelic effects made it popular as a recreational drug, espe-
cially in the early 1970s, but still today LSD is widely used
[1]. Additionally, LSD (200 μg) has also recently been used in
a clinical study as adjunct to psychotherapy [2]. LSD is one of
the most potent psychotropic drugs and is used in low doses.
Typical recreational doses of LSD range from only 25 to
200 μg with long-lasting, dose-dependent psychotropic ef-
fects [1]. Hence, low blood and urine concentrations are
posing a challenge to all analytical methods.
LSD can only be detected in blood up to 8 h after admin-
istration due to serum concentrations in the low nanogram per
milliliter range. 2-Oxo-3-hydroxy LSD (O-H-LSD) is the
main metabolite present in urine at concentrations 16–34
times higher than LSD [3, 4]. To our knowledge, O-H-LSD
has only been detected once in blood in a postmortem case [5].
According to Li et al. and Klette et al. LSD and O-H-LSD
were regarded as stable under storage conditions of −20 °C [6,
7].
Most published methods for LSD detection use either GC-
MS or LC-MS/MS with a single-stage quadrupole [4, 5,
8–12]. The aim of the present study was to develop a
turboflow LC-MS/MS method with the purpose of rapid
quantification of LSD and its main metabolite in serum and
P. C. Dolder :K. M. Rentsch (*)
Laboratory Medicine, University Hospital, Petersgraben 4,
4031 Basel, Switzerland
e-mail: katharina.rentsch@usb.ch
P. C. Dolder :M. E. Liechti
Division of Clinical Pharmacology and Toxicology, Department of
Biomedicine and Department of Clinical Research, University
Hospital and University of Basel, Hebelstrasse 20, 4031 Basel,
Switzerland
Anal Bioanal Chem (2015) 407:1577–1584
DOI 10.1007/s00216-014-8388-1
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urine in emergency toxicological cases without time-
consuming extraction steps.
The method was developed using an ion-trap LC-MS/MS
instrument in selected reaction monitoring (SRM) mode after
atmospheric pressure ionization (APCI) for the quantification
of LSD and O-H-LSD in urine and serum samples. Poch et al.
used a similar APCI LC-MS/MS ion-trap instrument, but
mainly for the detection of O-H-LSD [3].
Favretto et al. improved the method, but switched to
electrospray ionization for suitable analysis of LSD and O-
H-LSD in blood, urine, and vitreous humor [13]. Our method
was established and successfully applied in five emergency
toxicological cases with a suspected LSD intoxication. Addi-
tionally, the method will be used for the analysis of both blood
and urine samples from a double-blind, placebo-controlled
clinical trial.
Materials and methods
Chemicals and reagents
HPLC-grade purity acetonitrile, acetone, methanol, 2-
propanol, formic acid, and acetic acid were all purchased from
Merck (Darmstadt, Germany). Ammonium acetate and am-
monium carbonate were obtained in HPLC grade fromMerck
(Darmstadt, Germany). Distilled water was obtained from an
in-house installed purifier (ELGA, Bucks, UK).
Drug-free serum lyophilisate and urine negative control as
blank matrices were obtained from Bio Rad Laboratories
(Irvine, CA, USA). LSD and LSD-d3 were obtained from
Lipomed (Arlesheim, Switzerland) and 2-oxo-3-hydroxy
LSD (O-H-LSD) from Cerilliant (Round Rock, TX, USA).
LC-MS analysis
Equipment
The sample extraction system (Transcend TLX1 HPLC, Ther-
mo Scientific, Basel, Switzerland) consisted of a Thermo PAL
autosampler and two Accela 600 pumps as eluting and load-
ing pumps. The autosampler and the sample extraction system
were all controlled by Aria software (version 1.6.3) from
Thermo Scientific (Basel, Switzerland). A cyclone and a
C18XL turboflow column (Thermo Scientific, Basel Switzer-
land) for extraction, and a 3 μmBetasil Phenyl/Hexyl column
(Thermo Scientific, Basel, Switzerland) for chromatographic
separation were used.
The online extraction system was coupled to a LTQ XL
mass spectrometer from Thermo Scientific (Basel, Switzer-
land) using atmospheric pressure ionization (APCI), due to its
performance regarding matrix effects [14, 15].
For the instrument control, the corresponding software
package consisting of LTQ (v.2.6) for ion detection, Xcalibur
(v.2.1.0) for method programming, and LC-Quan (v.2.6.1) for
quantification (all Thermo Scientific, Basel, Switzerland) was
used.
LC method
The method was based on a previously published method
[16]. Four mobile phases were used in gradient mode. For
extraction, loading B consisted of 10 mM ammonium carbon-
ate in water; eluting Awas 5 mM ammonium acetate in water
containing 0.10 % formic acid and eluting B 5 mM ammoni-
um acetate in methanol containing 0.50 % formic acid,
respectively.
Loading B was used as alkaline loading buffer, eluting A
and B for chromatographic separation. Loading and Eluting C
(acetonitrile /acetone/2-propanol, 1:1:1 (V/V/V)) were used to
clean the extracting and the analytical columns.
The gradient system with a total run time of 12 min is
depicted in Table 1. Under the following gradient conditions,
LSD and LSD-d3 showed a retention time of 7.63 min, while
O-H-LSD had a retention time of 6.34 min.
MS conditions
For the quantification of LSD and its metabolite, APCI was
used as the ionization source in positive ion mode. Discharge
current and discharge voltage were set to 5 μA and 4.2 kV,
respectively. The vaporizer temperature was optimized to
452 °C whereas sheath and auxiliary gas provided best results
with flow rates of 40 and 20 arbitrary units (AU). The capil-
lary temperature was set to 275 °C.
LSD and O-H-LSD were quantified using single reaction
monitoring (SRM) of the corresponding mass transitions
(LSD m/z 324.6→223.23, O-H-LSD m/z 356.33→338.33,
LSD-d3 m/z 327.21→226.2). The system was tuned and
optimized for the detection of LSD.
Standard solutions
LSD and LSD-d3 were bought as 1 mg/ml reference standards
in acetonitrile, while O-H-LSD as 0.1 mg/ml reference stan-
dard in acetonitrile. Stock solutions in acetonitrile containing
100,000 ng/ml LSD, LSD-d3, or 10,000 ng/ml O-H-LSD,
respectively, were prepared in duplicate and stored at −20 °C
in order to have different sets for quality control (QC) and
calibration samples, respectively. Working solutions of each
analyte at 1000, 100, 10, and 1 ng/ml in water were used for
the preparation of QC and calibration samples as well as for
matrix and selectivity experiments.
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Sample preparation
To 100 μl of serum, 100 μl acetonitrile for protein precipita-
tion and 10 μl of a LSD-d3 internal standard solution
(100 ng/ml) were added. An identical volume of urine was
diluted with 50 μl of an ammonium acetate buffer (50 mM,
pH 4) and 10 μl of the internal standard solution. The samples
were then vigorously vortexed, centrifuged for 10 min at
13,200g and the supernatant afterwards transferred into
autosampler vials.
Calibration
Calibration curve in serum was realized by spiking serum
samples with LSD and O-H-LSD to concentrations of 0.10,
0.25, 0.50, 0.75, 1, 2.50, 5, 7.50, and 10 ng/ml plus a blank
(matrix only) and zero sample (matrix plus internal standard).
The highest calibration point in serum was adopted from the
maximum plasma concentration out of available i.v. kinetic
data [17].
The calibration curve in urine was realized by spiking
urine samples with O-H-LSD to concentrations of 1.50, 5,
10, 25, 50, 100, 125, 250, and 500 ng/ml. LSD concen-
trations were 0.10, 0.50, 1, 2, 5, 10, 12, 25, and 50 ng/ml,
respectively. The highest calibrator in urine was adopted
from published data containing various analyzed urine
samples [4].
Both calibration curves were fitted linearly using a
weighting factor (1/x2).
In order to demonstrate accuracy and precision of the
method, five QC’s in urine and six QC’s in serum were used
with every run. The concentrations of the QC samples can be
seen in Tables 2 and 3.
Selectivity
Following the FDA validation guidelines [18], six urine and
six serum samples from different patients and healthy volun-
teers were collected and analyzed to establish selectivity and
check for unwanted interferences within both matrices.
Matrix effects and recovery
Matrix effects, recovery, and process efficiency were mea-
sured and calculated according to Matuszewski et al. [19].
Matrix effects in urine and serum were calculated as ratio of
the peak area before extraction and divided by the peak area
after extraction. In contrast to Matuszewski et al., the extrac-
tion step consisted of simple protein precipitation as bypassing
the extraction step on our ion-trap system was not possible.
Six serum and six urine samples were spiked once with LSD
and O-H-LSD before and after extraction. The peak areas of
the spiked samples were then compared with the area of the
spiked mobile phase. Urine samples were spiked to 25 ng/ml
LSD resp. 250 ng/ml O-H-LSD, serum samples to 10 ng/ml
each. Recovery values were calculated as areas of standards
spiked before extraction divided by the areas of standards
spiked after extraction. The process efficiency was also
adopted from Matuszewsky et al. and calculated as ratio
between the area of the standard spiked before extraction,
and the areas of the standard in neat solution.
Limit of quantification
Drug-free serum and urine samples were spiked with dif-
ferent concentrations of LSD and O-H-LSD for the deter-
mination of the lower limit of quantification (LLOQ). The
parent substance and metabolite ratio was determined 1:1
Table 1 Detailed extraction and
analytical separation steps of the
liquid chromatography method
Time (min) Extraction Analytical separation
Flow (μl/min) %A %B %C Flow (μl/min) %A %B %C
0.00 2 – 100 – 0.30 99 1 –
0.83 0.50 – 100 – 0.30 99 1 –
0.92 0.50 – – 100 0.30 80 20 –
1.58 0.05 – – 100 0.30 55 45 –
2.03 0.50 – – 100 0.30 40 60 –
4.03 0.03 – – 100 0.30 2 98 –
9.03 0.01 – – 100 0.50 2 98 –
11.03 2. – – 100 0.50 2 98 –
11.37 2 – – 100 0.50 – – 100
11.70 2 – 100 – 0.50 – 100 –
12.20 2 – 100 – 0.50 99 1 –
12.53 2 – 100 – 0.30 99 1 –
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in serum and assumed 1:10 in urine samples [4]. The
LLOQ concentrations had to give a response at least five
times greater than the blank. Additionally, precision had to
be <20 % and the accuracy between 80 and 120 % using at
least five determinations per matrix and concentration.
Carryover
Carryover was determined by quantification of different
blanks, running between patient samples, calibrations, and
quality controls.
Reproducibility
According to the FDA guidelines, a minimum of five deter-
minations per concentration are recommended for determina-
tion of precision and accuracy [18].
The reproducibility of quantification was determined by
measuring serum (n=6) and urine (n=5) quality controls (QC)
once on 1 day (intraday precision and accuracy) and on six
different days (interday precision and accuracy). All values
had to fulfill the criteria of a variation coefficient (CV) below
15 %, resp. below 20 % at the LLOQ and accuracy between
80 and 120 %. For serum, six quality controls from LLOQ to
Table 2 Intraday precision and accuracy data of LSD and 2-oxo-3-hydroxy LSD measured in serum and urine at different concentrations
Weighed-in concentration [ng/ml] Measured concentration [ng/ml] Mean precision SD [%] Mean accuracy±SD [%]
Serum Urine Serum Urine Serum (n=6) Urine (n=6) Serum (n=6) Urine (n=6)
LSD 0.10 0.10 0.098±0.006 0.106±0.007 6.3 6.5 98.40±4.8 106±7.7
0.40 0.25 0.38±0.03 0.28±0.03 6.6 12.3 96.20±6.5 112±13.1
0.80 0.60 0.82±0.03 0.53±0.03 4.6 5.0 103±6.3 88.80±4.1
4 3.30 3.92±0.22 3.32±0.20 5.7 6.1 97.80±4.7 101±7.0
8 33 7.52±0.49 31.70±1.39 6.6 4.4 93.9±5.8 96.0±4.1
10 9.53±0.53 5.5 95.3±5.7
O-H-LSD 0.10 1.50 0.104±0.008 1.45±0.05 8.0 3.6 104±8.3 96.4±3.2
0.40 2.50 0.44±0.02 2.20±0.16 3.8 7.2 110±4.2 88.20±6.5
0.80 6 0.88±0.02 6.25±0.07 2.5 1.2 110±2.8 104±4.7
4 33 4.04±0.38 33.90±2.5 9.5 7.3 101±9.6 103±8.2
8 333 8.20±0.28 321±18 3.4 5.7 102±3.5 96.20±6.0
10 11.29±0.11 0.9 113±1.1
LSD lysergic acid diethylamide, O-H-LSD 2-oxo-3-hydroxy lysergic acid diethylamide
Table 3 Interday precision and accuracy data of LSD and 2-oxo-3-hydroxy LSD measured in serum and urine at different concentrations
Weighed-in concentration [ng/ml] Measured concentration [ng/ml] Mean precision SD [%] Mean accuracy±SD [%]
Serum Urine Serum Urine Serum (n=6) Urine (n=6) Serum (n=6) Urine (n=6)
LSD 0.10 0.10 0.11±0.01 0.10±0.02 4.60 15.00 110±5.10 104±14.60
0.40 0.25 0.39±0.02 0.26±0.02 4.20 8.80 97.5±4.10 105±9.30
0.80 0.60 0.82±0.07 0.55±0.02 8.50 4.00 103±8.70 91.1±3.60
4 3.30 3.97±0.34 3.32±0.22 8.60 6.70 99.2±8.60 101±6.50
8 33 7.41±0.59 32.8±2.3 7.90 6.90 92.7±7.30 99.3±6.30
10 10.1±0.55 5.50 101±5.50
O-H-LSD 0.10 1.50 0.10±0.08 1.58±0.19 8.10 12.50 105±8.43 105±13.10
0.40 2.50 0.39±0.03 2.64±0.35 8.40 13.40 98.3±8.20 105±14.10
0.80 6 0.79±0.08 5.56±0.16 9.80 3.00 98.5±9.70 92.6±2.70
4 33 3.79±0.35 34.8±2.2 9.20 6.60 94.8±8.70 105±6.40
8 333 8.14±0.58 327±16.8 7.20 5.10 102±7.30 98.3±5.00
10 – 10.1±0.76 7.60 – 101±7.60 –
LSD lysergic acid diethylamide, O-H-LSD 2-oxo-3-hydroxy lysergic acid diethylamide
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the highest calibrator (0.10, 0.40, 0.80, 4, 8, 10 ng/ml) were
measured once a day. For validation in urine, five QCs from
1.5 to 333 ng/ml were used.
Results
Selectivity
None of the blank urine or serum samples showed any inter-
ference within the measured mass range and time frame.
Matrix effects and recovery
The matrix effects in urine were 138% for LSD and 122% for
O-H-LSD. Recovery in urine was calculated to be 90.00 and
87.80 %, respectively. Process efficiency in urine was 124 %
for LSD and 107 % for O-H-LSD. Serum showed higher
matrix effects with 128 % for LSD and 78.70 % for O-H-
LSD. Recovery in serum was 64.00 % for LSD and 32.00 %,
for O-H-LSD. The process efficiencies in serum were calcu-
lated to be 128 % for LSD and 79 % for O-H-LSD. No ion
suppression was found for LSD or O-H-LSD in serum and
urine, but as mentioned by Johansen and Jensen [10] LSD-d3
would correct for any ion suppression. In various negative
samples, small LSD concentrations below the LLOQ could be
identified which derived from the deuterated internal standard.
Following these findings, LSD-d3 was measured ten times at
different concentrations. The working solution of the standard
(100 ng/ml) contained 0.12 % undeuterated LSD. This impu-
rity in the peak area of LSD was subtracted from all calibra-
tors, quality controls, and unknown samples.
Lower limits of quantification
The lowest accurate and precisely measurable concentration
was 0.10 ng/ml and thereby determined as LLOQ for LSD and
O-H-LSD in serum. In urine samples, the LLOQ was deter-
mined at 0.10 ng/ml for LSD and 1.50 ng/ml for O-H-LSD.
Carryover
No carryover was found for LSD and O-H-LSD in serum
samples. In contrast, a slight carryover (0.10 %) was found
for O-H-LSD in urine samples following the highest QC
(333 ng/ml) and the highest calibration (500 ng/ml) in urine.
As a consequence, a second consecutive blank was inserted
between and the carryover was reduced to 0.01 %.
Reproducibility
Calibration curves in urine were linear for both substances,
LSD and O-H-LSD with R2 greater than 0.98. Mean intraday
accuracy and precision in serum were 97.40 resp. 5.89 % for
LSD and 107 resp. 4.70 % for O-H-LSD (see Table 2). Mean
interday accuracy and precision for LSD and O-H-LSD were
101 resp. 6.56 % and 99.80 resp. 8.35 %, respectively (see
Table 3).
Linearity
LSD and O-H-LSD calibration curves in serum were linear
over the range from 0.10 to 10 ng/ml with a mean correlation
coefficient (R2) of 99.86 %. The calibration curves of the
mean values are shown in Fig. 1. Error bars indicate the
standard error of the mean.
Calibration curves of LSD and O-H-LSD in urine were
linear over the concentration range from 1.50 ng/ml to
333 ng/ml. R2 was found to be 99.93 %. The detailed calibra-
tion curve is shown in Fig. 2.
Toxicological cases
In the period from January to September 2014, five patients
were admitted to the emergency department (ED) of the
University Hospital Basel with suspected LSD intoxication.
In all five cases, LSD consumption could be confirmed.
Routinely, a LC-MS/MS method screening over 700 sub-
stances in serum was run to detect the intake of other medi-
cation and designer drugs.
As a summary, all in vivo measured concentrations in the
matrices available from the emergency department can be
found in Table 4.
Case 1
A 17-year-old girl was brought to the EDwith acute confusion
and loss of sense of time and orientation. She admitted con-
sumption of two sugar cubes and one blot with LSD (estimat-
ed dose, 750 μg). A plasma sample for drug screening was
taken approximately 3 h after ingestion. The patient was under
chronic treatment with trazodone for depression. An addition-
al LC-MS/MS screen in serum showed the presence of THC
and trazodone. Quantification of LSD revealed a level of
14.70 ng/ml and a quantifiable O-H-LSD level of 0.99 ng/ml
in serum. The only other published case where O-H-LSD
could be detected in blood so far, was in a reanalyzed fatal
case 10 years after collection [5]. Figure 3 shows the chro-
matogram of LSD, LSD-d3 and O-H-LSD in the serum of this
patient.
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Case 2
A 17-year-old male was brought by the ambulance to the ED
with thoracic pressure, restlessness, and dyspnea. He admitted
the intake of one sugar cube with LSD (estimated dose
250 μg) at 8 p.m. with concomitant consumption of cannabis.
He reported onset of the symptoms at 10 p.m., 2 h post-
consumption. In the emergency department, the patient was
treated with lorazepam and acetaminophen. Serum analysis
revealed a LSD concentration of 1.80 ng/ml in a blood sample
taken at 11 p.m.
Case 3
A 21-year-old male was admitted to the ED by ambulance and
the police because of aggressive and uncooperative behavior
after consumption of an alleged LSD blot. No information
about the time-point of the LSD ingestion was available from
anamnesis. Serum analysis showed an LSD concentration of
6.10 ng/ml and an O-H-LSD concentration of 0.45 ng/ml. An
additional LC-MS/MS screening revealed the presence of
THC, cocaine, and amphetamine.
Case 4
A 45-year-old male presented himself to the ED with
agitation, disorientation, and intense visual hallucinations.
He was partying for 2 days and consumed alcohol, LSD,
cocaine, and cannabis. The time-point of the LSD intake
was not reported. The LC-MS/MS screening confirmed the
intake of THC and cocaine. Quantification of the serum
LSD level detected 4.10 ng/ml LSD, but no quantifiable O-
H-LSD.
0
1
2
3
4
5
6
7
8
9
10
11
12
0 1 2 3 4 5 6 7 8 9 10 11
Fig. 1 Shows the mean
calibration curve of LSD in serum
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measurements. The determination
coefficient was 0.9995
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Fig. 2 Shows the mean
calibration curve of 2-oxo-3-
hydroxy LSD in urine from the
validation measurements. The
determination coefficient was
0.9993
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Case 5
A 36-year-old male presented himself to the ED with tactile
and visual hallucinations after consumption of an alcoholic
beverage in a club. He suspected someone to have mixed
some drugs in his drink. A screening for LSD in urine revealed
1.30 ng/ml LSD and 9.70 ng/ml O-H-LSD, respectively. An
additional LC-MS/MS screening in urine confirmed the pres-
ence of THC. No time-point of the drink consumption or start
of the LSD effect was reported.
Discussion and conclusion
The development of a sensitive method for the measurement
of LSD and its metabolite is an analytical challenge due to its
low concentrations in serum and urine.
Purification procedures with solid-phase or liquid-liquid
extraction can certainly lead to better sensitivity of the LC-
MS/MS method, but form a time-consuming procedure [5].
The short run time of 12 min was mainly given by retention
times of LSD, LSD-d3, and O-H-LSD. The additional time
following the LSD and LSD-d3 peak was necessary to ensure
clean peak separation and flushing the columns to minimize
carryover.
Our purpose was to establish a fast and reliable method
for application in emergency toxicological cases where
time is crucial. With a short method run of 12 min and
minimum sample preparation, results will be more quickly
available so that a fast diagnosis is possible. The method
was applied in five toxicology cases where consumption of
LSD could be confirmed four times in serum and once in
urine.
Due to the fast method and obviation of purification steps, a
slight loss in sensitivity was accepted. LLOQ and LOD in
serum were hence higher than in other comparable methods
[5, 8–10, 13]. Some showed LOQ’s as low as 0.02 ng/ml for
LSD but needed sample preparation and a longer run time [5].
In contrast, our method was mainly developed to rapidly
detect levels of LSD that occur during acute intoxication.
The range of expected LSD concentrations in serum was
difficult to determine because only few pharmacokinetic data
is available. In fact, only one pharmacokinetic study with
controlled administration of LSD exists. In this study, peak
plasma concentrations of LSD were 4–6 ng/ml 1–2 h after
administration of LSD (intravenously at 2 μg/kg) [17]. There-
fore, we chose 10 ng/ml as highest calibrator to cover typically
used oral doses of LSD (100–400 μg) [1]. However, one case
Table 4 Measured concentration of LSD and 2-oxo-3-hydroxy LSD in serum and/or urine in different patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Serum LSD 14.70 ng/ml 1.80 ng/ml 6.10 ng/ml 4.10 ng/ml N/A
Serum O-H-LSD 0.99 ng/ml <LLOQ 0.45 ng/ml <LLOQ N/A
Urine LSD N/A N/A N/A N/A 1.30 ng/ml
Urine O-H-LSD N/A N/A N/A N/A 9.70 ng/ml
N/A matrix was not available from the emergency department; <LLOQ value was below the lower limit of quantification
Fig. 3 Chromatogram and the respective structural formulas of LSD, LSD-d3, and 2-oxo-3-hydroxy LSD in the serum sample of patient 1
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was found with a LSD concentration of 14 ng/ml in plasma
among the intoxication cases presented here.
This sample had to be diluted (1:1 with distilled water) in
order to determine the correct result. Expected urine concen-
trations and the calibration range were established considering
already published data [3, 4]. Our method fulfilled all criteria
for measurement of emergency toxicological cases. All four
cases showed concentrations of LSD in serum in the range of
1.80–14.70 ng/ml. Additionally, to our knowledge, for the
first time, we describe the quantification of O-H-LSD in two
patients in a concentration well above the LLOQ of our
method.
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Abstract
Background: The pharmacokinetics of oral lysergic acid diethylamide are unknown despite its common recreational use and 
renewed interest in its use in psychiatric research and practice.
Methods: We characterized the pharmacokinetic profile, pharmacokinetic-pharmacodynamic relationship, and urine recovery 
of lysergic acid diethylamide and its main metabolite after administration of a single oral dose of lysergic acid diethylamide 
(200 μg) in 8 male and 8 female healthy subjects.
Results: Plasma lysergic acid diethylamide concentrations were quantifiable (>0.1 ng/mL) in all the subjects up to 12 hours after 
administration. Maximal concentrations of lysergic acid diethylamide (mean ± SD: 4.5 ± 1.4 ng/mL) were reached (median, range) 
1.5 (0.5–4) hours after administration. Concentrations then decreased following first-order kinetics with a half-life of 3.6 ± 0.9 
hours up to 12 hours and slower elimination thereafter with a terminal half-life of 8.9 ± 5.9 hours. One percent of the orally 
administered lysergic acid diethylamide was eliminated in urine as lysergic acid diethylamide, and 13% was eliminated as 
2-oxo-3-hydroxy-lysergic acid diethylamide within 24 hours. No sex differences were observed in the pharmacokinetic profiles 
of lysergic acid diethylamide. The acute subjective and sympathomimetic responses to lysergic acid diethylamide lasted up to 
12 hours and were closely associated with the concentrations in plasma over time and exhibited no acute tolerance.
Conclusions: These first data on the pharmacokinetics and concentration-effect relationship of oral lysergic acid diethylamide 
are relevant for further clinical studies and serve as a reference for the assessment of intoxication with lysergic acid diethylamide.
Keywords: LSD, O-H-LSD, pharmacokinetics, pharmacodynamics, plasma, urine
Trial registration: Registration identification number: NCT01878942
ClinicalTrials.gov: http://clinicaltrials.gov/ct2/show/NCT01878942.
Introduction
Lysergic acid diethylamide (LSD) is a prototypical hallucinogen 
(Nichols, 2004; Passie et al., 2008). LSD became famous as a psyche-
delic in the 1960s, and its recreational use continues (Passie et al., 
2008). However, no clinical research has been conducted with LSD 
since the 1970s until recently (Gasser et al., 2014; Kupferschmidt, 
2014). Almost no scientific clinical pharmacological data on LSD 
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are available. Specifically, the pharmacokinetics (PK) of oral LSD 
in humans are unknown. A small PK study administered single 
intravenous doses of 2 μg/kg in 5 healthy male human subjects 
(Aghajanian and Bing, 1964). Blood samples were taken up to 8 
hours after administration. Plasma concentrations were 6 to 
7 ng/mL 30 minutes after intravenous administration, 4–6 ng/mL 
at 30–120 min, and approximately 1 ng/mL at 8 hours. The mean 
plasma elimination half-life of LSD was estimated at 175 minutes 
in this previous study. In another study, single oral doses of 160 μg 
were administered to 13 male human subjects, and blood was 
sampled nonsystematically at various time points up to a maxi-
mum of 2.5 to 5 hours. Plasma levels peaked 40 to 130 minutes 
after LSD administration, and peaks ranged from 1.8 to 8.8 ng/mL 
(Upshall and Wailling, 1972). The dataset and short sampling time 
did not allow the calculation of PK parameters.
The aim of the present study was to characterize the single-
dose kinetics and PK-pharmacodynamic relationships of LSD 
in healthy male and female subjects. For clinical and forensic 
toxicologists, it is important to know the toxicokinetics of LSD 
and how plasma concentrations of LSD are linked to its dynamic 
effects and signs of intoxication.
LSD was administered in a single oral dose of 200 μg. The 
same dose was used in a clinical study (Gasser et al., 2014). The 
dose used was within the range of doses (50–400 μg) taken for 
recreational purposes and expected to induce a full “LSD reac-
tion” (Nichols, 2004; Passie et  al., 2008). The study also evalu-
ated the acute subjective, autonomic, and endocrine effects of 
LSD. The pharmacodynamics are reported in detail elsewhere 
(Schmid et  al., 2014), but the PK-pharmacodynamic relation-
ships are presented herein.
Methods
Study Design
The study used a double-blind, placebo-controlled, cross-over 
design with 2 experimental test sessions in balanced order. The 
washout periods between sessions were at least 7 days. The study 
was conducted in accordance with the Declaration of Helsinki 
and International Conference on Harmonization Guidelines in 
Good Clinical Practice and approved by the Ethics Committee 
of the Canton of Basel, Switzerland and the Swiss Agency for 
Therapeutic Products (Swissmedic). The administration of LSD 
to healthy subjects was authorized by the Swiss Federal Office 
for Public Health, Bern, Switzerland. The study was registered 
at ClinicalTrials.gov (NCT01878942). All of the subjects pro-
vided written informed consent after being given written and 
oral descriptions of the study, the procedures involved, and the 
effects and possible risks of LSD administration.
Participants
Sixteen healthy subjects (8 men and 8 women; mean age ± SD: 
28.6 ± 6.2 years; range: 25–51 years) were included. The exclusion 
criteria are reported in detail elsewhere (Schmid et al., 2014) and 
included age <25 or >65  years, pregnancy, personal or family 
(first-degree relative) history of psychotic or major affective dis-
order, regular use of medications, chronic or acute physical ill-
ness, lifetime prevalence of illicit drug use >10 times (except for 
tetrahydrocannabinol), illicit drug use within the last 2 months, 
and illicit drug use during the study. Nine subjects were halluci-
nogen-naive, and the other 7 had limited prior experience with 
hallucinogenic drugs, including 1 subject who had used LSD 
once and 2 subjects who had used LSD twice. The subjects were 
asked to abstain from excessive alcohol consumption between 
test sessions and particularly limit their use to 1 drink on the 
day before the test sessions. Additionally, the participants were 
not allowed to drink xanthine-containing liquids after mid-
night before the study day. Three subjects were light smokers 
(<10 cigarettes/d) and were told to maintain their usual smok-
ing habits but not smoke during the sessions. We performed 
urine drug tests at screening and before each test session using 
TRIAGE 8 (Biosite, San Diego, CA). No alcohol test was performed.
Study Outline
The test sessions began at 8:15 AM. A urine sample was taken to 
verify abstinence from drugs of abuse, and a pregnancy test was 
performed in women. An indwelling intravenous catheter was 
placed in an antecubital vein for blood sampling, and the sub-
jects completed baseline measurements. LSD (200 µg) or placebo 
was administered at 9:00 AM. A standardized lunch and dinner 
was served at 1:30 PM and 5:30 PM, respectively. The subjects 
were sent home the next day at 9:30 AM after the 24-hour blood 
sample collection
Drugs
Gelatin capsules that contained 100  µg LSD (D-LSD hydrate 
with a purity (high-performance liquid chromatography) >99%; 
Lipomed AG, Arlesheim, Switzerland), and corresponding pla-
cebo capsules were prepared with authorization from the Swiss 
Federal Office for Public Health. LSD was administered in a single 
absolute dose of 200 µg, corresponding to a dose of 2.84 ± 0.5 µg/
kg body weight (mean ± SD; range: 2.04–3.85 μg).
Blood and Urine Sampling
Blood was collected into lithium heparin tubes 1 hour before and 
0.5, 1, 1.5, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours after LSD admin-
istration. Urine (entire volume) was collected during 3 sampling 
periods: 0 to 8, 8 to 16, and 16 to 24 hours after LSD administra-
tion. Blood samples were immediately centrifuged, and plasma 
and urine were rapidly stored at -20°C until analysis within 2 
to 6  months. Long-term stability (6  months) has been shown 
for LSD and 2-oxo-3-hydroxy-LSD (O-H-LSD) when kept under 
refrigerated or frozen conditions (Klette et al., 2002; Martin et al., 
2013). The recovery (ng) of LSD and O-H-LSD was determined by 
multiplying the analyte urine concentrations (ng/mL) with the 
urinary volume (mL) of the respective sampling interval.
Analysis of LSD and O-H-LSD
LSD and O-H-LSD concentrations in plasma and urine were 
determined using a validated liquid-chromatography-tandem 
mass-spectrometry method as reported in detail in the supple-
mentary Material online and elsewhere (Dolder et al., 2015). The 
lower limit of quantification was 0.1 ng/mL, and the upper limit 
of quantification was 10 ng/mL for LSD and O-H-LSD in both 
plasma and urine.
PK
The plasma concentration data were analyzed using noncom-
partmental methods using Phoenix WinNonlin 6.4 (Certara, 
Princeton, NJ). Cmax and Tmax values were obtained directly from 
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the observed data. The area under the concentration-time 
curve (AUC) from 0 to 24 hours after dosing (AUC24) was cal-
culated using the linear-up log-down trapezoidal method. The 
terminal elimination rate constant (λz) for LSD was estimated 
by log-linear regression after semilogarithmic transformation 
of the data using at least the last 3 data points of the termi-
nal linear phase of the concentration-time curve. The terminal 
half-life was calculated using λz and the equation t1/2 = ln2/λz. 
The AUC to infinity was then determined by extrapolation of 
the AUC24 using λz. We also determined a separate half-life for 
the Tmax to 12 hour interval, because the rate of elimination 
changed at 12 hours in many subjects (see supplementary 
Figure S1 for all plots), and the decrease in plasma concentra-
tions followed first-order kinetics in all subjects from Tmax to 
12 hours. For this phase, we estimated the elimination rate 
constant (λ) for LSD using at least 3 data points of the con-
centration-time curve. Thus, this half-life does not describe 
the slower decrease in the concentration of LSD observed in a 
subset of subjects beyond 12 hours or 16 hours. Individual con-
centration-time curves show that a slower terminal decrease 
in LSD concentrations occurred only beyond 12 hours (after 
eating dinner and during the night) and not concentration-
dependent (ie, was not observed below a certain threshold 
concentration of LSD; see supplementary Figure S1). Renal 
clearance (mL/h) was calculated as urinary recovery24 urine (ng)/
AUC24 (ng∙h/mL).
Statistical Analyses
The analysis of the pharmacokinetic parameters was descrip-
tive, and geometric means and 90% CIs are shown to account for 
nonnormally distributed data. The study included 8 subjects of 
each sex; the data are also presented for male and female sub-
jects separately. However, the study was not sufficiently pow-
ered (power: 52%) to exclude sex differences in the PK of LSD 
(PASS Power Analysis, Kaysville, UT).
The primary pharmacodynamic study results were reported 
elsewhere (Schmid et  al., 2014). The a priori hypothesis relat-
ing to the PK-pharmacodynamics as defined in the study pro-
tocol was that the pharmacodynamic effects of LSD would 
show no acute pharmacological tolerance (ie, no clockwise 
hysteresis in the concentration-effect relationship). To assess 
PK-pharmacodynamic relationships, the LSD-induced effect was 
determined as a difference from placebo in the same subject at 
the corresponding time point to control for circadian changes 
(Schmid et al., 2014). The pharmacodynamic changes after LSD 
administration for each time point were plotted against the 
respective plasma concentrations of LSD and graphed as hyster-
esis curves for each subject. Because pupil size measurements 
were unavailable at the same time points as plasma levels, pupil 
size values at 7 and 11 hours were matched with concentrations 
at 8 and 12 hours. No pupil size measurement was available for 
the 24-hour time point; therefore, we used the baseline value 
at t = 0 hours, assuming a return to baseline by 24 hours. The 
area within the hysteresis (AH) was calculated as AUCC0-Cmax – 
AUCCmax-C24 using the trapezoidal rule. AH < 0 indicates counter-
clockwise hysteresis (lag time between concentration and effect 
due to absorption/distribution processes). AH > 0 indicates clock-
wise hysteresis (tolerance).
To estimate the plasma concentration of LSD at which 50% 
of the maximal response to LSD is reached (EC50), a sigmoi-
dal concentration-response (variable slope) model was fitted 
to the plasma concentration-effect data: E = (Emax × Cp
h) / (Cp
h + 
EC50
h), in which E is the observed effect, Cp is the plasma LSD 
concentration, Emax is the maximal effect, and h is the Hill slope 
using WinNonlin. Because of the hysteresis observed for most 
plasma-concentration effect curves, an indirect descriptive link 
model would be needed in which the plasma concentrations are 
linked to the pharmacodynamic parameter by an effect com-
partment, providing an estimate of the equilibration half-life 
between plasma and the effect compartment. However, because 
insufficient data pairs for the absorption phase (0-Cmax) were 
available, we directly linked dynamic effects to the plasma con-
centrations using only data from Cmax up to 24 hours after drug 
administration for this analysis. Statistical analyses were con-
ducted using NCSS 2004 software (Statistical Software, Kaysville, 
UT).
Pharmacodynamic Measurements
Pharmacodynamic measures were included in this study to 
evaluate PK-pharmacodynamic relationships. Subjective effects 
were assessed repeatedly over time using visual analog scales 
(VASs) (Hysek et  al., 2014), including “any drug effect,” “good 
drug effect,” and “bad drug effect.” The VASs were presented as 
100-mm horizontal lines marked with “not at all” on the left and 
“extremely” on the right. The VASs were administered 0, 0.5, 1, 
1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, and 24 hours after drug 
administration. Vital signs, including blood pressure, heart rate, 
and body (tympanic) temperature, were assessed repeatedly 0, 
0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after drug adminis-
tration using previously reported methods (Hysek et al., 2014). 
Additionally, pupil size (dark-adapted maximal pupil diameter) 
was measured 1, 2.5, 4, 7, and 11 hours after drug administration 
using an infrared pupillometer (PRL-200, NeurOptics, Irvine, CA) 
under standardized dark-light conditions as previously reported 
(Hysek and Liechti, 2012).
Results
PK
Figure 1 shows the plasma-concentration-time curves for LSD 
and O-H-LSD. The PK parameters are shown in Table  1. The 
plasma concentrations of LSD (>0.1 ng/mL) could be measured 
in all of the subjects up to 12 hours, in 14 subjects up to 16 
hours, and in 11 subjects up to 24 hours after administration. 
Concentrations of LSD decreased following first-order kinet-
ics up to 12 hours with a half-life of 3.6 ± 0.9 hours (Figure 1b). 
In some subjects, a slower decrease in plasma concentrations 
was observed late in time between 12 and 24 hours. This slower 
decrease occurred after the subjective effects of LSD had mostly 
subsided and the individual concentration-time curves showed 
that the slower decrease was dependent on time >12 hours (after 
eating dinner and during the night) and not on concentration 
(ie, below a certain concentration of LSD) (see supplementary 
Figure S1). The terminal half-life was 8.9 ± 5.9 hours including 4 
subjects (S4-S7, see supplementary Figure S1) in whom concen-
trations of LSD at 24 hours showed no further decrease com-
pared with the 16-hour concentrations.
The O-H-LSD concentration-time profiles could be deter-
mined for only 8 subjects, because metabolite concentrations 
were not present or fell below the lower limit of quantification in 
one-half of the subjects (Figure 1c-d). We could not show a differ-
ence in the pharmacokinetic profiles of LSD between male and 
female subjects (Table 1). The concentrations of LSD and O-H-LSD 
in urine and the urine recovery of LSD and O-H-LSD are shown in 
Table 2. The mean molar concentrations of O-H-LSD (molecular 
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Table 2. Urinary Elimination of LSD and O-H-LSD
N=
LSD O-H-LSD
0–8 hours 8–16 hours 16–24 hours 0–24 hours 0–8 hours 8–16 hours 16–24 hours 0–24 hours
Urinary concentrations (ng/mL)
 all 16 0.96 ± 0.8 1.1 ± 1.8 0.70 ± 0.6 8.3 ± 4.7 17.7 ± 11 14.4 ± 10
 male 8 0.78 ± 0.4 0.82 ± 0.2 0.66 ± 0.6 6.6 ± 3.4 22.7 ± 14 11.2 ± 7
 female 8 1.1 ± 1.0 1.5 ± 2.6 0.74 ± 0.7 9.9 ± 5.4 12.7 ± 5.3 17.6 ± 12
Urinary volume (L)
 all 16 1.4 ± 0.7 0.79 ± 0.4 0.47 ± 0.3
 male 8 1.8 ± 0.8 0.86 ± 0.5 0.63 ± 0.2
 female 8 1.1 ± 0.5 0.71 ± 0.4 0.30 ± 0.2
Urinary recovery (nM) Ae0-24
 all 16 3.6 ± 2.6 2.0 ± 1.7 0.82 ± 0.5 6.4 ± 2.9 28.3 ± 15 35.9 ± 27 15.3 ± 7.8 79.5 ± 41
 male 8 3.8 ± 2.4 2.0 ± 0.8 1.1 ± 0.6 6.8 ± 2.6 29.3 ± 19 49.6 ± 33 17.1 ± 8.6 96.1 ± 51
 female 8 3.5 ± 2.8 2.0 ± 2.3 0.58 ± 0.3 6.0 ± 3.3 27.3 ± 13 22.3 ± 9* 13.4 ± 6.8 62.9 ± 18
Abbreviations: Ae, amount eliminated in nM; LSD, lysergic acid diethylamide; O-H-LSD, 2-oxo-3-hydroxy-LSD.
*Significant difference from men (P < .05). Values are mean ± SD.
Figure 1. Pharmacokinetics (PK) of lysergic acid diethylamide (LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD). (a) Individual LSD plasma concentration-time curves with the 
geometric mean shown in the inset. Filled circles indicate male subjects, and open circles indicate female subjects. (b) Semilogarithmic plot of the individual concen-
trations of LSD. Curves are shown separately for each individual in the supplementary Material (supplementary Figure S1). First-order kinetics were observed in all 16 
subjects up to 12 hours. LSD levels fell below the lower limit of quantification (0.1 ng/mL) in 2 subjects at 16 hours and 5 subjects at 24 hours. Slower elimination was 
observed between 12 and 24 hours. (c) Individual O-H-LSD plasma concentration-time curves in 8 subjects in whom metabolite concentrations could be determined, 
with the geometric mean shown in the inset. (d) Semilogarithmic plot of the individual concentrations of O-H-LSD. Curves are shown separately in supplementary 
Figure S2. LSD was administered at t = 0 hours.
Table 1. Pharmacokinetic Parameters for LSD and O-H-LSD
N=
Cmax (ng/ml) 
Geometric  
Mean (95%CI)
tmax (h) Median 
(range)
t1/2 (h) 
Tmax-12 h 
Mean ± SD
t1/2 (h) Terminal 
Mean ± SD
AUC24 (ng·h/ 
mL) Geometric 
Mean (90%CI)
AUC∞ (ng·h/ 
mL) Geometric 
Mean (90%CI)
CLR (mL/min) 
Mean ± SD
LSD All 16 4.3 (3.8–4.9) 1.5 (0.5–4) 3.6 ± 0.9 8.9 ± 5.9 26 (22–30) 28 (24–33) 79 ± 36
LSD Male 8 4.4 (3.6–5.3) 1.5 (0.5–4) 3.5 ± 1.0 10.2 ± 6.7 25 (18–35) 28 (20–38) 88 ± 36
LSD Female 8 4.2 (3.4–5.3) 1.5 (0.5–3) 3.8 ± 0.8 7.6 ± 5.1 26 (23–30) 28 (25–32) 71 ± 36
aO-H-LSD All 8 0.4 (0.3–0.5) 4 (2.5–6) 3.4 (2.6–4.3) 3.8 (2.8–5.3)
Abbreviations: AUC, area under the plasma concentration-time curv; AUC∞, AUC from time zero to infinity; AUC24, from time 0–24; CLR, renal clearance; Cmax, maxi-
mum observed plasma concentration; T1/2, plasma half-life; Tmax, time to reach Cmax; 
aO-H-LSD levels were above the limit of detection in only 8 subjects).
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weight: 355.4) were 23.2, 49.9, and 40.6 pM/mL and 8, 14, and 19 
times higher than the mean molar concentrations of LSD (molec-
ular weight: 323.4; 3.0, 3.5, 2.2 pM/mL) in the 0 to 8, 8 to 16, and 
16 to 24 hour sampling intervals, respectively. Of the nonmetabo-
lized LSD that was recovered from urine, 56% appeared in urine 
within the first 8 hours after administration and 45% of the O-H-
LSD appeared in urine 8 to 16 hours after LSD administration. 
Of the orally administered LSD hydrate (200 μg or 618 nM), 13% 
was eliminated in urine as O-H-LSD (28.3 μg or 79.5 nM) within 
24 hours. Only 1% (2.1 μg or 6.4 nM) of the dose of LSD was elim-
inated in urine as LSD within 24 hours. The renal clearance of 
LSD was 1.32 ± 0.6 mL/min or approximately 1.6% of the apparent 
total clearance after oral administration (CL/F), assuming an oral 
bioavailability of 71% (see Discussion). No significant differences 
in LSD or O-H-LSD urine concentrations were observed between 
male and female subjects (Table 2). The urine recovery of O-H-LSD 
was greater in male subjects than in female subjects during the 
8 to 16 hour sampling period, but no significant differences were 
observed in the overall 0 to 24 hour sampling (Table 2).
PK-Pharmacodynamic Relationship
Figure 2 shows the effects of LSD as a function of plasma con-
centration. There was a close relationship between the LSD con-
centration and its dynamic effects overt time. No hysteresis was 
found for heart rate (Figure 2a), blood pressure (Figure 2b), or bad 
drug effect (Figure 2g). The 95% CIs of the mean of the area within 
the hysteresis loops (AH) overlapped with 0 for heart rate (4.4 
beats × ng/min × mL [-13 to +22]), blood pressure (-5 mgHg × ng/
min × mL [-24 to +13]), and bad drug effect (5% × ng/min × mL 
[-29 to +38]), indicating no hysteresis. Counterclockwise hyster-
esis (negative AH value) was observed, attributable to relatively 
higher plasma levels compared with the dynamic effects dur-
ing the assumed drug absorption phase (0–2 hours) for body 
temperature (Figure  2c), pupil size (Figure  2d), any drug effect 
(Figure 2e), and good drug effect (Figure 2f). Mean AH values (95% 
CI) were the following: body temperature (-1°C × ng/min × mL 
[-1.5 to -0.5]), pupil size (-1.4  mm × ng/min × mL [-2.2 to -0.7]), 
any drug effect (-78% × ng/min × mL [-113 to -43]), and good drug 
effect (-106% × ng/min × mL [-151 to -61]). The decline of the 
response to LSD and plasma concentration over time followed a 
sigmoidal Emax dose-response curve for any drug effect and good 
drug effect. The EC50 mean ± SD values were 1.3 ± 0.7 ng/mL for 
any drug effect and 1.0 ± 0.5 ng/mL for good drug effect. Heart 
rate, blood pressure, body temperature, and bad drug effect 
linearly increased with plasma concentrations of LSD and did 
not show an Emax (Figure 2a-c, g). Not enough values were avail-
able to fit changes in pupil size. No clockwise hysteresis was 
observed for any of the concentration-effect curves, meaning 
that the dynamic values were higher later in time at a given 
Figure 2. Lysergic acid diethylamide (LSD) effects plotted against LSD plasma concentrations (geometric means). The pharmacodynamic values are the mean ± SEM 
differences from placebo at each time point in 16 subjects. The time of sampling is noted next to each point (in hours after LSD administration). Heart rate (a), mean 
arterial pressure (b), and bad drug effect (g) showed no hysteresis. Counterclockwise hysteresis was observed for body temperature (c), pupil size (d), any drug effect (e), 
and good drug effect (f), consistent with a delay between plasma concentration and effect. For most dynamic variables, maximal plasma concentrations (at approxi-
mately 2 hours) coincided with maximal dynamic effects. The dynamic changes then gradually decreased over time with decreasing plasma levels. No evidence of 
acute tolerance (clockwise hysteresis) was observed for any of the dynamic effects of LSD.
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plasma concentration and consistent with no acute tolerance to 
the effects of LSD. LSD produced acute adverse effects, including 
difficulty concentrating, headache, exhaustion, and dizziness 
lasting up to 24 hours and as reported elsewhere (Schmid et al., 
2014). There were no severe adverse effects.
Discussion
The present study determined the single-dose PK of oral LSD in 
humans. The concentrations of LSD were maximal after 1.5 hours 
(median) and gradually declined to very low levels by 12 hours. We 
observed first-order kinetics of LSD up to 12 hours in all subjects 
and an inconsistent slower decrease in concentrations thereafter 
in some subjects. This could be attributable to redistribution from 
tissue or due to less precise quantification of the very low plasma 
levels of LSD at 12 to 24 hours (ie, close to the lower limit of quan-
tification). The half-life of 3.6 hours during the first 12 hours after 
drug administration is close to the 3 hours previously observed 
in a small study that used intravenous LSD administration 
(Aghajanian and Bing, 1964). Only 1% of the orally administered 
LSD was eliminated renally. LSD is almost completely metabo-
lized in rats, guinea pigs, and monkeys (Axelrod et al., 1957; Siddik 
et al., 1979). In humans, the major metabolite of LSD detectable in 
urine is O-H-LSD (Klette et al., 2000; Poch et al., 2000; Canezin et al., 
2001). In the present study, O-H-LSD was detected in blood plasma 
at very low concentrations and in only one-half of the subjects. 
The urine concentrations of O-H-LSD in the present study were 
approximately 10, 15, and 20 times higher than those of LSD at 0 
to 8, 8 to 16, and 16 to 24 hours after LSD administration. Similarly, 
in LSD-positive forensic urine samples, O-H-LSD concentrations 
are higher than those of LSD, and O-H-LSD can be detected for 
a longer time than LSD after LSD administration (Reuschel et al., 
1999; Klette et  al., 2000; Poch et  al., 2000). In the present study, 
13% of the orally administered LSD was recovered from urine 
as O-H-LSD within 24 hours. LSD is metabolized to O-H-LSD by 
cytochrome P450 enzymes, but the specific enzymes and mech-
anisms are unknown (Klette et al., 2000). To our knowledge, it is 
unknown whether O-H-LSD is pharmacologically active.
The oral bioavailability of LSD can be crudely estimated 
using the previous data on intravenous LSD administration 
(Aghajanian and Bing, 1964) and our data on oral LSD. After intra-
venous LSD administration (2 μg/kg of the free base in 5 male 
subjects), a mean total plasma exposure (AUC∞) of 31.4 ng∙mL/h 
was obtained (15.7 ng∙mL/h per μg/kg free base), calculated based 
on the published plasma concentration profile (Aghajanian and 
Bing, 1964). After oral LSD administration in the present study 
(2.5  μg/kg free base in 8 male subjects), the mean AUC∞ was 
28 ng∙mL/h (11.2 ng∙mL/h per μg/kg free base). Based on these 
data, the oral bioavailability of LSD is approximately 71%. In the 
present study, LSD was administered after a light meal. When 
ingested with a “full breakfast,” oral LSD was reported to result 
in lower plasma concentrations compared with administration 
on an empty stomach (Upshall and Wailling, 1972). However, 
these observations were made in only 2 to 3 subjects (Upshall 
and Wailling, 1972) and would need confirmation. Remaining to 
be tested is whether food reduces or delays the absorption of oral 
LSD. Additionally, the PK profiles were similar in male and female 
subjects. However, the study was too underpowered to statisti-
cally exclude sex differences in the PK of LSD.
We found a close relationship between the plasma con-
centrations of LSD and physiologic response or psychotropic 
effects of LSD over time. Estimated EC50 values for the psycho-
tropic effects were in the range of 1.0 to 1.3 ng/mL (approxi-
mately 3–4 nM). The unbound fraction of LSD in human plasma 
is unknown. In cats, the unbound fraction was 0.2, and LSD 
concentrations in cerebrospinal fluid were similar to free LSD 
plasma concentrations (Axelrod et al., 1957). Thus, LSD concen-
trations of 0.6 to 0.8 nM could be expected in cerebrospinal fluid. 
These values are in the range of the binding affinity of LSD at 
the 5-hydroxytryptamine-2A (5-HT2A) receptor (Ki  = 0.4–1.3 nM, 
respectively) (Titeler et al., 1988; Egan et al., 1998) and also close 
to the EC50 for the functional stimulant activity of LSD at the 
receptor in vitro (EC50 = 7.2 nM) (Egan et al., 1998). Pupil size was 
also strongly increased at low concentrations of LSD. We pre-
viously showed that pupil diameters were significantly larger 
compared with placebo until the last pupil measurement at 11 
hours after LSD administration. In contrast, elevations in blood 
pressure, heart rate, and body temperature were only significant 
up to 5 hours after LSD administration compared with placebo, 
as reported elsewhere (Schmid et  al., 2014). Additionally, the 
increases in heart rate, blood pressure, body temperature, and 
bad drug effects showed no ceiling effect in the concentration-
effect curves, in contrast to the other dynamic effects of LSD. 
Heart rate, body temperature, blood pressure, and bad drug 
effects would likely increase further with higher doses of LSD, 
whereas the pupillary or good subjective effects can be expected 
to be similar to those seen in the present study. The hyperten-
sive effects of LSD may result from 5-HT2A and/or α1-adrenergic 
receptor-mediated vasoconstrictive effects at higher doses (Dyer 
and Gant, 1973; Blessing and Seaman, 2003).
No evidence of acute tolerance was observed, which would 
become apparent as clockwise hysteresis in the concentration-
response curve and has been shown for 3,4-methylenediox-
ymethamphetamine (MDMA) (Hysek et  al., 2011). In contrast 
and as typically expected for most drugs, counterclockwise 
hysteresis was observed early in time until the end of the 
assumed drug absorption phase. No similar studies on the 
PK-pharmacodynamic relationship of LSD have been performed. 
Only one other small study measured plasma LSD concentra-
tions and concomitant pharmacodynamic effects (Aghajanian 
and Bing, 1964). LSD was administered intravenously in 5 male 
subjects. To obtain a crude index of performance, subjects 
were given one of a series of equivalent tests, consisting of 
simple addition problems, after each blood sample was drawn 
(Aghajanian and Bing, 1964). After the distribution phase (30 
minutes after intravenous LSD administration), the impair-
ments in performance declined in parallel with the plasma 
levels of LSD, also suggesting a close temporal relationship 
between the PK and pharmacodynamics of LSD (Aghajanian 
and Bing, 1964). In contrast to the single-dose administration in 
the present study, tolerance to the subjective effects of LSD with 
repeated daily LSD administration has been reported (Abramson 
et al., 1956; Belleville et al., 1956). However, a gradual increase 
in head twitches and catatonic postures and no tolerance was 
observed up to 3 to 4  days after continuous LSD administra-
tion in rats (Ellison et al., 1980). Also in contrast to our findings 
with LSD, we observed pronounced acute tolerance to the psy-
chotropic and cardiostimulant effects of MDMA using the same 
methodology (Hysek et al., 2011). As a result, the pharmacody-
namic effects of MDMA last significantly shorter than would 
be expected based on plasma levels. The subjective and cardi-
ostimulant effects of MDMA last only 5 hours despite its long 
half-life of 10 hours (Hysek et al., 2011). In contrast, the subjec-
tive drug effects of LSD lasted for 12 hours in most subjects and 
up to 16 hours in some subjects in the present study despite 
LSD’s shorter half-life. Thus, subjects with MDMA in blood may 
no longer be clinically intoxicated, whereas subjects with quan-
tifiable LSD concentrations in plasma are clinically intoxicated. 
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A mechanistic explanation for this acute tolerance in the case 
of MDMA is that it mainly produces its acute effects through 
the release of endogenous serotonin and norepinephrine (ie, 
as an indirect serotonergic and noradrenergic agonist). In con-
trast, LSD is thought to produce its psychotropic hallucinogenic 
effects through a direct interaction with the 5-HT2A receptor (ie, 
as a direct serotonergic agonist), resulting in pharmacodynamic 
effects to which no acute tolerance was observed in our study.
In summary, we show first data on the PK and 
PK-pharmacodynamic relationship of oral LSD in human sub-
jects. The PK profiles exhibit first-order kinetics of LSD up to 
12 hours. LSD produces physiological and psychotropic effects 
lasting up to 12 hours, closely related to the plasma concentra-
tions of LSD and inhibiting no acute tolerance. The findings are 
important for further clinical studies and serve as a reference 
for the assessment of intoxication with LSD.
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Abstract
Rationale Lysergic acid diethylamide (LSD) is used
recreationally and in clinical research. Acute mystical-type
experiences that are acutely induced by hallucinogens are
thought to contribute to their potential therapeutic effects.
However, no data have been reported on LSD-induced mys-
tical experiences and their relationship to alterations of con-
sciousness. Additionally, LSD dose- and concentration-
response functions with regard to alterations of consciousness
are lacking.
Methods We conducted two placebo-controlled, double-
blind, cross-over studies using oral administration of 100
and 200 μg LSD in 24 and 16 subjects, respectively. Acute
effects of LSD were assessed using the 5 Dimensions of
Altered States of Consciousness (5D-ASC) scale after both
doses and theMystical Experience Questionnaire (MEQ) after
200 μg.
Results On the MEQ, 200 μg LSD induced mystical experi-
ences that were comparable to those in patients who
underwent LSD-assisted psychotherapy but were fewer than
those reported for psilocybin in healthy subjects or patients.
On the 5D-ASC scale, LSD produced higher ratings of blissful
state, insightfulness, and changed meaning of percepts after
200μg comparedwith 100 μg. Plasma levels of LSDwere not
positively correlated with its effects, with the exception of ego
dissolution at 100 μg.
Conclusions Mystical-type experiences were infrequent after
LSD, possibly because of the set and setting used in the pres-
ent study. LSD may produce greater or different alterations of
consciousness at 200 μg (i.e., a dose that is currently used in
psychotherapy in Switzerland) compared with 100 μg (i.e., a
dose used in imaging studies). Ego dissolution may reflect
plasma levels of LSD, whereas more robustly induced effects
of LSD may not result in such associations.
Keywords LSD . Altered states of consciousness . Mystical
experiences
Introduction
Lysergic acid diethylamide (LSD) is the prototypical halluci-
nogen (Nichols 2016; Passie et al. 2008). LSD became fa-
mous, with a high cultural influence, in the 1960s. LSD con-
tinues to be used for recreational and personal purposes
(Krebs and Johansen 2013). Additionally, there is much inter-
est in its therapeutic potential (Baumeister et al. 2014;
Davenport 2016; Gasser et al. 2014; Gasser et al. 2015;
Krebs and Johansen 2012; Kupferschmidt 2014). Only one
modern study has tested the therapeutic effects of LSD in
patients (Gasser et al. 2014), whereas several clinical trials
have recently evaluated the therapeutic potential of psilocybin
(Bogenschutz et al. 2015; Carhart-Harris et al. 2016a; Garcia-
Romeu et al. 2015; Griffiths 2016; Grob et al. 2011; Guss
2016), a similar serotonergic hallucinogen (Rickli et al.
2016). A series of studies showed that psilocybin acutely
The studies were registered at ClinicalTrials.gov (NCT02308969,
NCT01878942).
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induced mystical experiences in healthy subjects and patients
(Garcia-Romeu et al. 2015; Griffiths et al. 2008; Griffiths et al.
2011; Griffiths et al. 2006; MacLean et al. 2011).
Additionally, greater acute effects of psilocybin on the
Mystical Experience Questionnaire (MEQ; Barrett et al.
2015; Griffiths et al. 2006; MacLean et al. 2012) were asso-
ciated with positive long-term effects onmood and personality
in healthy subjects (Griffiths et al. 2008; Griffiths et al. 2011;
Griffiths et al. 2006; MacLean et al. 2011) and better thera-
peutic outcomes in patients with anxiety, depression, and sub-
stance use disorder (Garcia-Romeu et al. 2015; Griffiths 2016;
Griffiths et al. 2008; Griffiths et al. 2011; Griffiths et al. 2006;
MacLean et al. 2011). Early studies reported on mystical
experiences after experimental administration of LSD, but
methodological details are missing (Turek et al. 1974).
Whether and the extent to which LSD produces mystical-
type effects in the MEQ are currently unknown. Therefore,
we characterized the effects of 200 μg LSD on the MEQ
and evaluated the way in which mystical experiences are
related to LSD-induced increases in 5 Dimensions of
Altered States of Consciousness (5D-ASC) scale scores
and plasma levels of LSD.
Clinical experimental research with LSD has recently seen a
resurgence (Carhart-Harris et al. 2016b; Carhart-Harris et al.
2015; Carhart-Harris et al. 2016c; Dolder et al. 2015b; Dolder
et al. 2016; Kaelen et al. 2015; Kaelen et al. 2016; Lebedev et al.
2016; Roseman et al. 2016; Schmid et al. 2015; Speth et al.
2016; Strajhar et al. 2016; Tagliazucchi et al. 2016; Terhune
et al. 2016). An increasing amount of data has been generated
on the effects of LSD (75 μg) on various neuronal correlates of
brain activation (Carhart-Harris et al. 2016c; Kaelen et al. 2016;
Lebedev et al. 2016; Roseman et al. 2016). Researchers have
correlated subjective drug effects with brain functional magnetic
resonance imaging (fMRI) data (Carhart-Harris et al. 2016c;
Kaelen et al. 2016; Lebedev et al. 2016; Roseman et al. 2016).
This approach likely produces significant findings for subjective
effects that show large between-subject variance but not for sub-
jective effects of the substance that are consistently present in all
subjects. Lower doses of LSD may also result in more variable
responses across subjects compared with higher doses.
Furthermore, higher doses of LSD (e.g., 200 μg) that are cur-
rently used therapeutically (Gasser et al. 2014) may produce
more pronounced but also qualitatively different subjective ef-
fects (Dolder et al. 2016). Importantly, plasma concentrations of
LSD have not been determined in any of the published LSD
fMRI studies to date; therefore, unclear is the way in which
LSD exposure in the body is linked to subjective effects in these
studies. Therefore, a second goal of the present study was to
describe the subjective peak effects of two doses of LSD (100
and 200 μg) using the 5D-ASC scale (Studerus et al. 2010). The
5D-ASC scale has been used in all of the recent experimental
studies with LSD (Carhart-Harris et al. 2016b; Carhart-Harris
et al. 2016c; Schmid et al. 2015; Tagliazucchi et al. 2016) and
with many other psychedelics, providing an opportunity to com-
pare findings between studies and across substances and research
groups. Thus, the present study assessed LSD dose- and plasma
concentration-response functions using the 5D-ASC scale in 40
subjects (Dolder et al. 2015b; Dolder et al. 2016; Schmid et al.
2015), thus allowing comparisons with other studies that used
the 5D-ASC scale but did not determine plasma LSD concentra-
tions (Carhart-Harris et al. 2016b; Carhart-Harris et al. 2016c;
Kaelen et al. 2016; Lebedev et al. 2016; Roseman et al. 2016;
Speth et al. 2016; Tagliazucchi et al. 2016; Terhune et al. 2016).
A third goal of the present studywas to assess associations across
subjects between the peak and total plasma exposure to LSD and
its effects on 5D-ASC scale scores (Studerus et al. 2010). The
effects of 100 μg LSD on 5D-ASC scale scores are reported for
the first time in the present study, whereas the effects of 200 μg
have been previously published (Schmid et al. 2015). However,
the latter study did not evaluate dose- or concentration-response
functions. Other data that were generated in the present study
have been previously reported including acute and subacute ad-
verse effects (Dolder et al. 2015b; Dolder et al. 2016; Schmid
et al. 2015; Strajhar et al. 2016).
Material and methods
Study design
We performed two similar studies using double-blind, place-
bo-controlled, cross-over designs with two experimental test
sessions (LSD and placebo) in a balanced order. Study 1 used
a dose of 100 μg LSD and placebo in 24 subjects. Study 2
used 200 μg LSD and placebo in 16 subjects. The washout
periods between sessions were at least 7 days. The studies
were conducted in accordance with the Declaration of
Helsinki and approved by the local ethics committee. The
administration of LSD to healthy subjects was authorized by
the Swiss Federal Office for Public Health, Bern, Switzerland.
All of the subjects provided written consent before participat-
ing in either of the studies, and they were paid for their par-
ticipation. The studies were registered at ClinicalTrials.gov
(NCT02308969, NCT01878942).
Participants
Forty healthy participants were recruited from the University
of Basel campus via online advertisement. Twenty-four sub-
jects (12 men, 12 women; 33 ± 11 years old [mean ± SD];
range, 25–60 years) participated in study 1, and 16 subjects (8
men, 8 women; 29 ± 6 years old; range, 25–51 years) partic-
ipated in study 2. The inclusion and exclusion criteria were
identical for both studies. Subjects younger than 25 years of
age were excluded from participating in the study. Additional
exclusion criteria were age >65 years, pregnancy (urine
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pregnancy test at screening and before each test session), per-
sonal or family (first-degree relative) history of major psychi-
atric disorders (assessed by the semi-structured clinical inter-
view for Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, Axis I disorders by the study physician
and an additional interview by a trained psychiatrist), use of
medications that may interfere with the study medication,
chronic or acute physical illness (abnormal physical exam,
electrocardiogram, or hematological and chemical blood anal-
yses), tobacco smoking (>10 cigarettes/day), lifetime preva-
lence of illicit drug use >10 times (except for tetrahydrocan-
nabinol), illicit drug use within the last 2 months, and illicit
drug use during the study (determined by urine drug tests).
The subjects were asked to abstain from excessive alcohol
consumption between test sessions and particularly limit their
use to one standard drink on the day before the test sessions.
Additionally, the participants were not allowed to drink
xanthine-containing liquids after midnight before the study
day. Eleven subjects had used a hallucinogen, including
LSD (six participants), one to three times, and most of the
subjects (29) were hallucinogen-naive. We performed urine
drug tests at screening and before each test session, and no
substances were detected during the study.
Study procedures
Each study included a screening visit, a psychiatric interview,
two 25-h experimental sessions, and an end-of-study visit. The
experimental sessions were conducted in a quiet standard hos-
pital patient room. The participants were resting in hospital beds
except when going to the restroom. Only one research subject
and one or two investigators were present during the experi-
mental sessions. The participants could interact with the inves-
tigator, rest quietly, and/or listen to music via headphones, but
no other entertainment was provided. LSD or placebo was ad-
ministered at 9:00 AM. The subjects were never alone during
the first 12 h after drug administration, and the investigator was
in a room next to the subject for up to 24 h while the subjects
were asleep (mostly from 1:00 AM to 8:00 AM).
Study drug
LSD (d-LSD hydrate, HPLC purity >99 %, Lipomed AG,
Arlesheim, Switzerland) was administered in single oral doses
of 100 or 200 μg as gelatin capsules. Note that these LSD
hydrate doses correspond to LSD tartrate doses of 123 and
246 μg, respectively. In the 1960–1970s, small doses of
LSD tartrate of 25–150 μg were typically used in “psycholytic
therapy” and higher doses of >200 μg in “psychedelic” ther-
apy (Pahnke et al. 1970). The dose used in a recent LSD-
assisted psychotherapy study was 200 μg LSD hydrate
(Gasser et al. 2014). Both doses used in the present study were
within the range of doses that are taken for recreational
purposes (Passie et al. 2008). Corresponding placebo capsules
were used.
Measures
Mystical-type experiences In study 2, mystical experiences
were assessed using a German version (Supplementary
Appendix 1) of the 43-item MEQ (Griffiths et al. 2006;
MacLean et al. 2012; Pahnke 1969) embedded in the 100-
item States of Consciousness Questionnaire (SOCQ; (Griffiths
et al. 2006). The original English questionnaire was indepen-
dently forward-translated into German by two translators with
German as their mother tongue. Discrepancies between the two
forward-translated versions and a previous German version
were then discussed and selected items backtranslated. The
version was then pretested for comprehension by persons with
previous LSD or MDMA use.
The MEQ has been used in numerous experimental and
therapeutic trials with psilocybin (Garcia-Romeu et al. 2015;
Griffiths et al. 2008; Griffiths et al. 2011; Griffiths et al. 2006;
MacLean et al. 2011). The MEQ items provide scale scores for
each of seven domains of mystical experiences: internal unity,
external unity, sacredness, noetic quality (as real as or more real
than everyday reality), deeply felt positive mood, transcendence
of time and space, and ineffability/paradoxicality (difficulty de-
scribing the experience in words). The total of all scale scores
was used as an overall measure of the mystical-type experience.
We also derived the four scale scores of the newly validated
revised 30-item MEQ: mystical, positive mood, transcendence
of time and space, and ineffability (Barrett et al. 2015). A com-
plete mystical experience was defined as scores ≥60 % on all
MEQ30 factors (Barrett et al. 2015). TheMEQwas administered
24 h after drug administration, and the participants were asked to
retrospectively rate drug effects during peak drug effects. For
comparison, we included MEQ ratings that were obtained 6 h
after administration of 3,4-methylenedioxymethamphetamine
(MDMA) and methylphenidate in another study using a similar
research setting (Schmid et al. 2014). Additionally, we included
MEQ ratings from patients who were treated with 200 μg LSD
for anxiety related to life-threatening illness in another study
(Diesch 2015; Gasser et al. 2014; Gasser et al. 2015). All of these
additional MEQ findings have not been previously published in
scientific journals and were obtained in studies that were previ-
ously described in detail (Diesch 2015; Gasser et al. 2014;Gasser
et al. 2015; Schmid et al. 2014).
Alterations of consciousness The 5D-ASC scale was used in
both studies to assess the overall peak alterations of conscious-
ness. The 5D-ASC scale measures altered states of conscious-
ness and contains 94 items (visual analog scales). The instru-
ment consists of five subscales/dimensions (Dittrich 1998)
and 11 lower-order scales (Studerus et al. 2010). The 5D-
ASC dimension “Oceanic Boundlessness” (27 items)
Psychopharmacology
37
measures derealization and depersonalization associated with
positive emotional states, ranging from heightened mood to
euphoric exaltation. The corresponding lower-order scales in-
clude “experience of unity,” “spiritual experience,” “blissful
state,” and “insightfulness.” The dimension “Anxious Ego
Dissolution” (21 items) summarizes ego disintegration and
loss of self-control phenomena associated with anxiety. The
corresponding lower-order scales include “disembodiment,”
“impaired control of cognition,” and “anxiety.” The dimen-
sion “Visionary Restructuralization” (18 items) consists of the
lower-order scales “complex imagery,” “elementary imagery,”
“audio-visual synesthesia,” and “changed meaning of per-
cepts.” Two additional dimensions describe “Auditory
Alterations” (15 items) and “Reduction of Vigilance” (12
items). The scale is well-validated and widely used to charac-
terize the subjective effects of various psychedelic drugs
(Carhart-Harris et al. 2016b; Hasler et al. 2004; Hysek et al.
2011; Schmid et al. 2015; Vollenweider et al. 2007;
Vollenweider and Kometer 2010). In addition to the subscale
analyses, we also analyzed the effects on ego dissolution item
71 (the boundaries between myself and my surroundings
seemed to blur) because the concept of ego dissolution was
often used in recent imaging studies (Tagliazucchi et al. 2016).
The 5D-ASC scale was administered 24 h after drug admin-
istration, and the participants were asked to retrospectively
rate the drug effects. 5D-ASC ratings were also performed at
3 and 10 h in study 1.
Analysis of plasma LSD concentrations
Blood was collected into lithium heparin tubes before and 0.5,
1, 1.5, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD admin-
istration. The 0.5, 1.5, and 2.5 h samples were not collected in
study 1. Blood samples were immediately centrifuged, and the
plasma was rapidly stored at −20 °C and later analyzed using
liquid-chromatography-tandem mass-spectrometry as previ-
ously reported (Dolder et al. 2015a; Steuer et al. 2016).
Maximal plasma concentrations (Cmax) and total exposure (ar-
ea under the plasma concentration-time curve [AUC]) were
estimated using compartmental modeling in Phoenix
WinNonlin 6.4 (Certara, Princeton, NJ, USA). A one-
compartment model was used with first-order input, first-
order elimination, and no lag time.
Statistical analyses
The data analysis was performed using Statistica 12 software
(StatSoft, Tulsa, OK, USA). Differences between LSD and
placebo or between the 100 and 200 μg doses of LSD were
compared using dependent or independent t tests, respectively.
Associations between outcome measures were assessed using
Pearson correlations. Significance was assumed at p < 0.05.
Results
Mystical-type experiences
LSD (200 μg) significantly increased all MEQ scores com-
pared with placebo (Fig. 1a, Table 1). The effects of MDMA
and methylphenidate on MEQ scores are included for com-
parison (Fig. 1a). The effects of LSD (200 μg) and placebo on
MEQ scores in 11 patients during LSD-assisted psychothera-
py (Gasser et al. 2014) are also shown in Fig. 1b. LSD-
induced mystical experiences were comparable in healthy
subjects in the laboratory setting in the present study and in
patients in the therapeutic setting (Fig. 1b). Only two subjects
in each of the studies had a complete mystical experience. The
MEQ30 total scores were <5 % in both settings after placebo
administration (Fig. 1b).
Alterations of consciousness
LSD induced pronounced peak alterations of waking con-
sciousness, with significant increases in all dimensions and
subscales of the 5D-ASC scale (Fig. 2). The 200 μg dose of
LSD produced significantly greater scores on the overall ASC
scale, the dimension of visionary restructuralization, and the
blissful state, insightfulness, and changed meaning of percepts
subscales comparedwith the 100μg dose (Fig. 2, Table 1). The
mean ± SEM ego dissolution (item 71) scores were 49 ± 6 and
53 ± 10 after the 100 and 200 μg doses, respectively (Table 1).
There were only minimal differences between the 5D-ASC
ratings at 3, 10, and 24 h (supplementary Fig. S1 online).
Plasma LSD concentrations
Plasma concentrations varied between subjects, especially at
the lower 100 μg dose. The median (range) Cmax values were
1.4 ng/ml (0.32–3.7) and 3.2 ng/ml (1.9–7.1) for the 100 and
200 μg doses, respectively. The corresponding AUC values
were 8.5 ng × h/ml (1–19) and 20.7 ng × h/ml (11–39).
Associations between alterations of consciousness
and mystical-type experiences
Table 2 shows the cross-tabulation of all correlations between
the 5D-ASC scale and MEQ30 subscale ratings. LSD-induced
alterations of consciousness (ASC total score) were significant-
ly correlated with ratings of mystical experience (MEQ30 total
score) on the MEQ (Rp = 0.87, p < 0.001, n = 16; Fig. 3).
Scores on the MEQ positive mood scale were strongly associ-
ated with scores on the ASC experience of unity and blissful
state scales (Rp = 0.85 and 0.80, respectively; both p < 0.001,
n = 16; Table 2).
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Correlations between plasma LSD concentrations
and LSD-induced alterations of consciousness
and mystical-type experiences
The Cmax and AUC values for LSD were not positively
correlated with ratings of peak subjective effects on the
5D-ASC scale or MEQ across subjects or within dose
groups (Table 3). For example, LSD induced consistently
high ratings of audio-visual synesthesia in almost all of
the subjects at the high dose (200 μg), resulting in little
within-subject variance and no association with plasma
exposure to LSD (Table 3, Fig. 4a). One exception was
ego dissolution (item 71) at the lower dose of LSD
(100 μg; Table 3, Fig. 4b). The ratings showed high
Fig. 1 Effects of LSD on theMystical Experience Questionnaire (MEQ).
a In the present study in healthy subjects, LSD (200 μg) significantly
increased scores on all scales of the MEQ43 and MEQ30 compared with
placebo (Table 1). The data are expressed as the mean ± SEM in 16
subjects. For comparison, 3,4-methylenedioxymethamphetamine
(MDMA; 75 mg) and methylphenidate (40 mg) produced small
increases in MEQ ratings in 30 different participants in another study in
the same research setting (Schmid et al. 2014). b Effects of LSD on the
MEQ in patients with anxiety in the context of life-threatening illness.
The data were analyzed identically to the data that were obtained in the
present study. The study and patient characteristics have been previously
published in detail (Diesch 2015; Gasser et al. 2014; Gasser et al. 2015;
Schmid et al. 2014). Similar to the present study, the MEQ was
administered on the day after LSD (200 μg) or active placebo (25 μg
LSD) administration and was embedded into the larger 100-item States of
Consciousness Questionnaire (SOCQ; Griffiths et al. 2006). The patient
data are expressed as the mean ± SEM in 11 subjects for LSD (200 μg,
same formulation as in the present study) and four subjects for placebo.
On the 43- and 30-item versions of the MEQ, LSD (200 μg) increased
MEQ rating scores in the patients in the therapeutic setting (b) to a similar
extent as in the healthy subjects in the present study (a). Notably, the
placebo response (a very low dose of LSD of 25 μg was used as the
active placebo) in the patients was small (b), which was also similar to
the response in healthy subjects in the present study (a)
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interindividual variance, and there was a significant pos-
itive correlation with the LSD AUC value in the 100 μg
dose group (Rp = 0.51, p < 0.05, n = 16; Table 3,
Fig. 4b). At the 200 μg dose, there were significant neg-
ative correlations between Cmax values for LSD and sub-
jective effects on the 5D-ASC scale including visionary
restructuralization, elementary imagery, and changed
meaning of percepts.
Discussion
The present study characterized LSD-induced mystical
experiences using the MEQ after a dose of 200 μg
and alterations of consciousness on the 5D-ASC scale
after a dose of 100 μg. The study also evaluated asso-
ciations between plasma LSD concentrations and these
subjective effects.
Table 1 Statistics for the effects
of LSD in the 5D-ASC and MEQ LSD 100 μg
T test vs. placebo
LSD 200 μg
T test vs. placebo
LSD 100 vs. 200 μg
T test
T= P= T= P= T= P=
5 Dimensions Altered States of Consciousness (ASC) scale
Total ASC score 9.72 <0.001 10.02 <0.001 2.23 <0.05
Oceanic boundlessness 8.44 <0.001 9.61 <0.001 1.89 NS
Anxious ego dissolution 6.43 <0.001 4.01 <0.001 1.50 NS
Visionary restructuralization 9.79 <0.001 15.32 <0.001 2.34 <0.05
Auditory alterations 3.72 <0.01 5.87 <0.001 0.42 NS
Reductions of vigilance 7.44 <0.001 5.93 <0.001 0.79 NS
Experience of unity 6.85 <0.001 7.77 <0.001 0.68 NS
Spiritual experience 4.31 <0.001 3.91 <0.001 1.10 NS
Blissful state 6.56 <0.001 8.27 <0.001 3.00 <0.01
Insightfulness 4.11 <0.001 5.81 <0.001 2.28 <0.05
Disembodiment 6.93 <0.001 5.87 <0.001 0.13 NS
Impaired control and cognition 7.01 <0.001 5.04 <0.001 0.86 NS
Anxiety 3.02 <0.001 2.04 NS 1.37 NS
Complex imagery 7.10 <0.001 7.48 <0.001 0.31 NS
Elementary imagery 9.96 <0.001 11.12 <0.001 0.57 NS
Audio-visual synsthesia 9.19 <0.001 12.52 <0.001 1.96 NS
Changed meaning of percepts 6.25 <0.001 9.66 <0.001 3.39 <0.01
Ego dissolution (item 71) 7.63 <0.001 5.32 <0.001 0.36 NS
Mystical Effects Questionnaire (MEC43)
Internal unity NA NA 6.22 <0.001 NA NA
External unity NA NA 6.08 <0.001 NA NA
Sacredness NA NA 6.80 <0.001 NA NA
Noetic quality NA NA 5.71 <0.001 NA NA
Deeply felt positive mood NA NA 11.43 <0.001 NA NA
Transcendence of time/space NA NA 10.63 <0.001 NA NA
Ineffability NA NA 16.22 <0.001 NA NA
Mystical Effects Questionnaire (MEQ30)
Mystical NA NA 5.99 <0.001 NA NA
Positive mood NA NA 13.13 <0.001 NA NA
Transcendence of time/space NA NA 11.12 <0.001 NA NA
Ineffability NA NA 25.14 <0.001 NA NA
MEC30 total score NA NA 14.91 <0.001 NA NA
Sixteen subjects participated in the high-dose study (200μg) and 24 subjects in the moderate-dose study (100μg).
Dependent T tests were performed to assess differences from placebo, and independent T tests were performed to
assess differences between doses of LSD
NA not assessed
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LSD produced mean MEQ30 total score ratings of 61 %
(range 40–98 %) and a complete mystical experience in only
two participants (12.5 %). The MEQ has typically been used
with psilocybin, and data on MEQ30 scores are available for
various doses of psilocybin, placebo, and methylphenidate
(active placebo; Barrett et al. 2015). Psilocybin (at the highest
studied dose of 30 mg/70 kg) produced a high mean MEQ30
total score rating of 77 % and complete mystical experiences
in as many as 67 % of healthy subjects (Barrett et al. 2015).
However, in this psilocybin study setting, inactive and active
placebo (methylphenidate) also produced high mean MEQ30
ratings of 23 and 33 %, respectively (Barrett et al. 2015). In
contrast, in the present study, placebo increased MEQ30
scores only to 1 %. Similarly, MDMA and methylphenidate
produced only small increases in MEQ scores in a similar
laboratory setting (Schmid et al. 2014). Another study evalu-
ated psilocybin-assisted psychotherapy in tobacco smokers
and also found complete mystical experiences in only 10 of
26 sessions (38 %) that were conducted in 14 patients with
high-dose psilocybin (30 mg/70 kg; Garcia-Romeu et al.
2015; Johnson et al. 2014). Accounting for the higher placebo
ratings in some of the psilocybin studies compared with our
study, LSD increased MEQ30 score differences from placebo
overall more than psilocybin and produced greater ineffability
and positive mood but lower effects on the mystical subscale
than psilocybin (Barrett et al. 2015).
Additionally, the MEQ has been used in patients with anx-
iety associated with life-threatening illness who were treated
with 200 μg LSD (Gasser et al. 2014; Gasser et al. 2015). In
this therapeutic setting, LSD produced similar mystical expe-
riences as in the present study and complete mystical experi-
ences in only two of 11 patients. MEQ scores were only within
the range of 3–9 % after active placebo administration (25 μg
LSD) on the MEQ subscales. Altogether, these findings indi-
cate that mainly the placebo response and/or the expectancy of
a mystical experience were greater in the study setting in some
psilocybin studies compared with the LSD studies.
Additionally, the participants in the psilocybin studies may
have been more spiritually inclined (Griffiths et al. 2006) than
our study participants leading to more mystical experiences
(Studerus et al. 2012). Furthermore, others may have provided
more extensive preparation of the subjects and interpersonal
support, contributing to mystical experiences.
The present findings do not support the view that LSD
produces lower overall effects than psilocybin at the doses
tested. In contrast, the high dose of LSD (200 μg) produced
greater placebo-adjusted positive mood ratings than psilocy-
bin on the MEQ30 (Barrett et al. 2015) and very pronounced
increases in 5D-ASC blissful state ratings and produced far
greater effects than the highest doses of psilocybin or dimeth-
yltryptamine (DMT) that were tested so far on this scale
(Gouzoulis-Mayfrank et al. 2005; Hasler et al. 2004).
Additionally, LSD-induced MEQ scores were highly correlat-
ed with 5D-ASC scores in the present study.
One could argue that mystical and spiritual experiences are
not the most prominent feature of the LSD response. Mean
ratings on the spiritual experience scale of the 5D-ASC were
22 and 33 % at the 100 and 200 μg doses, respectively, in the
Fig. 2 Effects of LSD on the 5 Dimensions of Altered States of
Consciousness (5D-ASC) scale. LSD mainly increased ratings of oceanic
boundlessness (OB) and visionary restructuralization (VR), with
significantly higher ratings for the ASC total score and VR dimension at
200 μg compared with 100 μg. LSD-induced increases in anxious ego
dissolution (AED) and auditory alterations (AA) were relatively small.
LSD also produced vigilance reduction (VIR). LSD-induced changes on
the 5D-ASC scale were significant compared with placebo for both doses
and all of the scales, with the exception of the effects of the 200 μg dose on
anxiety (Table 1). At 200 μg, LSD produced significant and relevantly
higher ratings of blissful state, insightfulness, and changed meaning of
percepts compared with 100 μg (one asterisk p < 0.05, two asterisks
p < 0.01, t tests). The data are expressed as the mean ± SEM in 24
subjects and 16 subjects for the 100 and 200 μg doses of LSD, respectively
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present study and approximately 23 % after 75 μg LSD in
another study (Carhart-Harris et al. 2016c). Mean ratings of
“the experience had a spiritual or mystical quality” were also
only approximately 28 % in an imaging study that evaluated
the effects of LSD (Tagliazucchi et al. 2016). However, a
direct within-subjects comparison of LSD and psilocybin
in the same research setting is needed to determine possible
differences in mystical-type responses between these sub-
stances. Whether mystical-type experiences (Barrett et al.
2015; Garcia-Romeu et al. 2015; MacLean et al. 2011) are
critical for the therapeutic potential of substance-assisted
psychotherapy requires further study. At least in the case
of LSD, the mystical experiences (MEQ scores) were high-
ly associated with other alterations of consciousness on the
5D-ASC scale, and LSD produced additional effects on
emotion processing that could facilitate psychotherapeutic
interventions (Dolder et al. 2016).
Recent experimental studies associated the subjective ef-
fects of LSD (75 μg, intravenous) on the 5D-ASC scale with
fMRI data but in the absence of data on plasma LSD levels
Fig. 3 LSD-induced alterations of consciousness are significantly
associated with the LSD-induced mystical experience. The data are
expressed as a percentage of ASC total scores on the 5D-ASC scale and
a percentage of total scores on theMEQ30 for each of 16 participants after
administration of 200 μg LSD. The lines indicate the regression and 95%
confidence intervals (Rp = 0.87, p < 0.001)
Table 2 Associations between
LSD-induced alterations in
consciousness (5D-ASC) and
mystical experiences (MEQ30)
Mystical Effects Questionnaire (MEQ30)
MEQ30 total
score
Mystical Positive
mood
Transcendence of
time/space
Ineffability
5D-ASC scale
Total ASC score 0.87 0.73 0.65 0.82 0.57
Oceanic boundlessness 0.93 0.88 0.83 0.74 0.45
Anxious ego
dissolution
0.60 0.39 0.35 0.68 0.55
Visionary
restructuralization
0.65 0.54 0.38 0.68 0.45
Auditory alterations 0.30 0.14 0.02 0.49 0.38
Reductions of
vigilance
0.61 0.41 0.47 0.64 0.47
Experience of unity 0.82 0.86 0.85 0.56 0.25
Spiritual experience 0.79 0.76 0.76 0.60 0.33
Blissful State 0.80 0.77 0.80 0.72 0.16
Insightfulness 0.77 0.79 0.68 0.52 0.42
Disembodiment 0.71 0.53 0.62 0.71 0.41
Impaired control and
cognition
0.63 0.37 0.45 0.79 0.46
Anxiety 0.45 0.32 0.19 0.47 0.51
Complex imagery 0.48 0.31 0.32 0.69 0.19
Elementary imagery 0.36 0.37 0.08 0.29 0.42
Audio-visual
synesthesia
0.23 0.07 0.22 0.45 −0.01
Changed meaning of
percepts
0.80 0.67 0.59 0.70 0.63
Ego dissolution (item
71)
0.74 0.73 0.74 0.65 0.12
Values are Pearson correlation coefficients in 16 subjects describing correlations between %5D-ASC and
%MEQ30 scores. Bold values for P < 0.05, italic values for P < 0.001
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(Carhart-Harris et al. 2016c; Kaelen et al. 2016; Lebedev et al.
2016; Roseman et al. 2016). Assuming high oral bioavailabil-
ity of LSD of 70–100 % (Dolder et al. 2015b), similar plasma
exposure (AUC) can be assumed after oral administration of
100 μg LSD (present study I) or intravenous administration of
75 μg LSD (all studies by Carhart-Harris and colleagues).
Supporting this assumption, the intravenous 75 μg dose of
LSD produced very similar mean ratings on the 5D-ASC scale
(Carhart-Harris et al. 2016b) to the present study that used an
oral dose of 100 μg. In contrast, the 200 μg dose produced
significantly greater ASC total scores and particularly greater
5D-ASC subscale scores of blissful state, insightfulness, and
changed meaning of percepts. As previously reported, the
200 μg dose of LSD also produced greater feelings of close-
ness to others, happiness, openness, and trust than the 100 μg
dose (Dolder et al. 2016). Altogether, the data indicate that the
200 μg dose produces overall greater effects and particularly
more positive and MDMA-like effects than lower doses
(Dolder et al. 2016). This is relevant because the higher dose
is currently being used in LSD-assisted psychotherapy
(Gasser et al. 2014; Gasser et al. 2015), and the lower dose
is being tested in experimental fMRI studies (Carhart-Harris
et al. 2016c). The 200 μg dose of LSD also produced greater
ASC scores than high doses of the serotonergic hallucinogens
DMTand psilocybin (Gouzoulis-Mayfrank et al. 2005; Hasler
et al. 2004; Vollenweider and Kometer 2010), ketamine
(Gouzoulis-Mayfrank et al. 2005; Studerus et al. 2010), and
MDMA (Hysek et al. 2011), although direct comparisons
within the same studies and subjects are missing.
The present analyses showed no positive correlations be-
tween LSD levels and effects across subjects, possibly be-
cause of the relatively high levels of LSD and generally
Fig. 4 Correlations between plasma LSD concentrations and subjective
peak effects. a At 200 μg, LSD induced high ratings of audio-visual
synesthesia in all but two of the 16 participants. There was little
variance in the response and no correlation between total plasma
exposure to LSD (area under the concentration-time curve [AUC]) and
audio-visual synesthesia (Rp = 0.0, p > 0.05, n = 16). b In contrast, ego
dissolution was present to highly variable degrees across subjects after
administration of 100 μg LSD. Total exposure to LSD (AUC) positively
correlated with LSD-induced ego dissolution (Rp = 0.51, p < 0.05,
n = 24). The lines indicate the regression and 95 % confidence intervals
Table 3 Associations between predicted maximal LSD plasma
concentrations (Cmax) and LSD exposure (AUC) and alterations in
consciousness (SD-ASC) and mystical experiences (MEQ30)
N = 24 N = 16
100 μg 200 μg
Cmax AUC Cmax AUC
5D-ASC scale
ASC total score 0.19 0.21 −0.35 0.15
Oceanic boundlessness 0.24 0.26 −0.35 0.10
Anxious ego dissolution 0.04 0.07 −0.10 0.32
Visionary restructuralization 0.12 0.15 −0.59 −0.16
Auditory alterations 0.02 0.12 −0.18 0.08
Reductions of vigilance −0.01 0.13 −0.10 0.38
Experience of unity 0.34 0.33 −0.03 0.33
Spiritual experience −0.02 0.06 −0.32 −0.03
Blissful state 0.25 0.14 −0.23 0.03
Insightfulness 0.24 0.20 −0.37 0.12
Disembodiment −0.04 0.08 −0.23 0.08
Impaired control and cognition −0.01 0.01 −0.20 0.18
Anxiety 0.22 0.30 0.01 0.38
Complex imagery 0.06 0.14 −0.28 −0.04
Elementary imagery −0.13 −0.03 −0.53 −0.15
Audio-visual synesthesia 0.23 0.26 −0.01 0.00
Changed meaning of percepts −0.03 −0.06 −0.62 −0.10
Ego dissolution (item 71) 0.40 0.51 −0.27 −0.14
MEQ30
MEC30 total score NA −0.30 0.17
Mystical NA −0.25 0.13
Positive mood NA −0.08 0.21
Transcendence of time/space NA −0.23 0.10
Ineffability NA −0.49 0.13
Values are Pearson correlation coefficients describing correlations, the
peak concentrations of LSD predicted by the one-compartment model,
and LSD-induced %5D-ASC and %MEQ30 scores. Bold values for
P < 0.05Cmax maximal LSD plasma concentration predicted by the one-
compartment pharmacokinetic model, AUC area under the LSD
concentration-time curve predicted by the model
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consistently high subjective response ratings in most subjects.
Thus, if relatively high and similar doses of LSD are used that
result in plasma levels clearly above the EC50 of a particular
response measure, then it is unlikely that the response varies
relevantly across subjects because responses are close to max-
imal. This would typically also be the case with measures with
a maximal effect limit such as VAS ratings and some physio-
logical effects like pupil size (Hysek and Liechti 2012).
In fact, responses to MDMA or LSD or other drugs in a
standardized experimental setting may vary only if the re-
sponse is not induced consistently in all subjects (e.g., at the
beginning of the response) and are mostly attributable to indi-
vidual differences in drug absorption/distribution (Hysek and
Liechti 2012) or when a response is evaluated that is not ro-
bustly induced or when a lower dose is used. Specifically,
correlations of plasma levels with the subjective and cardio-
vascular effects of MDMA across subjects are only weak dur-
ing the peak response but stronger at onset (Hysek and Liechti
2012). This is an important consideration. For example, LSD-
induced subjective ego dissolution was recently shown to be
associated with specific brain activation patterns in a study
that administered a relatively low dose of LSD of 75 μg intra-
venously (Tagliazucchi et al. 2016). Interestingly, LSD-
induced ego dissolution correlated with plasma LSD levels
after administration of an equivalent oral dose of 100 μg in
the present study, and this was the only pharmacodynamic
effect of LSD for which a positive association with plasma
levels could be demonstrated across subjects. This finding
needs to be kept in mind when interpreting associations be-
tween ego dissolution and fMRI parameters because the fMRI
findings may also reflect other processes that are related to the
plasma levels of LSD. Furthermore, the likelihood of detect-
ing correlations within a dose group increases for effects that
are not robustly induced in all subjects and thus for effects that
are not typically present in all subjects after LSD administra-
tion. Finally, unclear is the extent to which a full LSD re-
sponse was induced in the imaging studies that have been
conducted to date because all of these studies used relatively
low 75 or 100 μg doses. In the present study, the 200 μg dose
of LSD produced particularly marked increases in visionary
restructuralization including changed meaning of percepts
which were significantly greater after the 200 compared with
the 100 μg dose. Contrary to expectations, these perceptual
alterations were greater in participants with relatively lower
Cmax levels of LSD within the 200 μg dose group further
supporting the view that higher plasma levels of LSD may
not produce greater subjective alterations above a certain
threshold level and if high doses of LSD are used.
In conclusion, LSD (200 μg) rarely produced full mystical
experiences in the present study and in patients during LSD-
assisted psychotherapy compared with psilocybin in another
set and setting. This raises questions regarding expectancy
effects and placebo responses and the therapeutic role of
mystical experiences. LSD produced significantly greater
bliss, insightfulness, and changes in meaning of percepts at
200 μg compared with 100 μg, in addition to the previously
reported greater empathogenic effects. This could be relevant
for LSD-assisted psychotherapy (200 μg) and the interpreta-
tion of fMRI data (75–100 μg). Generally, no association was
found between plasma LSD levels and its robust effects when
analyzed across different subjects and within a dose group.
This may have implications for studies that interrelate differ-
ent effects of LSD, namely fMRI studies.
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Figure S1. Effects of LSD (100 µg) on the 5 Dimensions of Altered States of Consciousness 
(5D-ASC) scale repeatedly used at 3, 10, and 24h to retrospectively rate the LSD effects in 24 
subjects in Study 1. The aim of the repeated administration was to test whether self-ratings shortly 
after the peak response (3h), at the end of the response (10h) or on the next day (at 24h) differ from 
each other. We hypothesized that there would not be any relevant differences. ANOVA with time as 
between-subject factor (3, 10, and 24 h) on the total ASC score showed a significant effect of time 
(F2,46=5.50, P>0.01). Tukey post hoc tests showed higher ratings at 3h compared with 10 and 24h 
(both P<0.01) but no differences between the 10 and 24h ratings. ANOVA with time and dimension (5 
main dimensions) as factors showed a significant main effect of time (F2,46=6.17, P<0.01) and scale 
F4,92=19.87, P<0.001 and a significant time and dimension interaction (F8,184=3.5, P<0.001). Tukey 
post hoc test showed greater ratings at 3h compared with ratings at 10 h on all dimensions (all 
P<0.01, Figure S1) and compared with ratings at 24 h for AED, AA, and VIR (all P<0.01). Ratings at 
10 h did not differ from ratings at 24h with the exception of ratings for VR which were greater at 24 h 
compared with 10 h (P<0.05). ANOVA with time and scale (all 11 scales of the 5D-ASC) showed no 
significant main effect of time (F2,46=2.37, P=0.10), a significant main effect of scale (F10,230=18.90, 
P<0.001) and a significant time and scale interaction (F20,460=1.81, P<0.05). Post hoc tests showed 
that only ratings of “impaired control and cognition” were higher at 3h compared with 24h. There were 
no other differences between the ratings at 3, 10, and 24 h. Together the data indicates higher ratings 
of the overall effect when assessed during the response at 3h compared to ratings taken immediately 
after the response or on the next day. However, the differences were minimal and not present 
between ratings at 10 h and 24 h. OB, oceanic boundlessness; AED, anxious ego-dissolution; VR, 
visionary restructuralization; AA, auditory alterations; VIR, vigilance reduction. **P<0.01 and 
***P<0.001 for 3h vs. 10h; 
++
P<0.01 and 
+++
P<0.001 for 3h vs. 24h; 
#
P<0.05 for 10h vs. 24h (Tukey 
post hoc tests based on significant time and scale interactions in the ANOVA). The data are expressed 
as the mean ± SEM in 24 subjects.   
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LSD Acutely Impairs Fear Recognition and Enhances Emotional
Empathy and Sociality
Patrick C Dolder1, Yasmin Schmid1, Felix Müller2, Stefan Borgwardt2 and Matthias E Liechti*,1
1Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel,
Basel, Switzerland; 2Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
Lysergic acid diethylamide (LSD) is used recreationally and has been evaluated as an adjunct to psychotherapy to treat anxiety in patients
with life-threatening illness. LSD is well-known to induce perceptual alterations, but unknown is whether LSD alters emotional processing
in ways that can support psychotherapy. We investigated the acute effects of LSD on emotional processing using the Face Emotion
Recognition Task (FERT) and Multifaceted Empathy Test (MET). The effects of LSD on social behavior were tested using the Social Value
Orientation (SVO) test. Two similar placebo-controlled, double-blind, random-order, crossover studies were conducted using 100 μg LSD
in 24 subjects and 200 μg LSD in 16 subjects. All of the subjects were healthy and mostly hallucinogen-naive 25- to 65-year-old volunteers
(20 men, 20 women). LSD produced feelings of happiness, trust, closeness to others, enhanced explicit and implicit emotional empathy on
the MET, and impaired the recognition of sad and fearful faces on the FERT. LSD enhanced the participants’ desire to be with other people
and increased their prosocial behavior on the SVO test. These effects of LSD on emotion processing and sociality may be useful for
LSD-assisted psychotherapy.
Neuropsychopharmacology (2016) 41, 2638–2646; doi:10.1038/npp.2016.82; published online 22 June 2016
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INTRODUCTION
The classic serotonergic psychedelic/hallucinogen lysergic
acid diethylamide (LSD) was widely studied in humans in
the 1950s to 1970s. However, little to no clinical research on
LSD has been conducted since then (Nichols, 2016; Passie
et al, 2008). Today, LSD is again the focus of clinical
investigations, including experimental studies in healthy
subjects (Carhart-Harris et al, 2016,2015; Dolder et al, 2015b;
Schmid et al, 2015; Strajhar et al, 2016), and clinical trials that
evaluate LSD-assisted psychotherapy (Gasser et al, 2014).
LSD that was administered only a few times decreased
anxiety and increased quality of life over a period of
12 months in patients with anxiety associated with terminal
illness (Gasser et al, 2015). The acute LSD experiences were
hypothesized to lead to a restructuring of the person's
emotional trust and situational understanding (Gasser
et al, 2015). Similar to LSD, the serotonergic hallucinogen
psilocybin and serotonin (5-hydroxytryptamine (5-HT))
releaser 3,4-methylenedioxymethamphetamine (MDMA;
ecstasy) have been used to facilitate psychotherapy in
clinical trials (Grob et al, 2011; Mithoefer et al, 2010;
Oehen et al, 2013). Psilocybin reduced anxiety at 3 months
and additionally improved mood at 6 months after treatment
in patients with advanced-stage cancer (Grob et al, 2011).
Additionally, psilocybin was recently studied as a treatment
for tobacco (Johnson et al, 2014) and alcohol (Bogenschutz
et al, 2015) dependence. MDMA-assisted psychotherapy
reduced symptoms of post-traumatic stress disorder at
2 months (Mithoefer et al, 2010), and the benefits of MDMA
were reportedly sustained for several years (Mithoefer et al,
2013). These first findings from modern clinical studies with
psychedelics and MDMA should be confirmed in larger
trials. Exploring the mechanisms that may contribute to
these beneficial and lasting effects after only a few
administrations of the substances is also important.
Studies that use psychedelics and MDMA in healthy
subjects are well suited to assess the mechanism of action of
these substances. Both LSD and psilocybin appear to produce
effects that last beyond the acute drug response in both
patients and healthy subjects. Specifically, LSD increased
optimism and trait openness at 2 weeks (Carhart-Harris et al,
2016), and psilocybin produced positive changes in attitudes,
mood, and behavior at 2 (Griffiths et al, 2006) and 14 months
(Griffiths et al, 2011) after administration. Psilocybin
increased personality trait openness in participants who
had ‘mystical experiences’ during their psilocybin session
(MacLean et al, 2011). Therefore, some of the lasting
beneficial effects appear to be associated with an acute
psychedelic response, including a ‘peak’ or ‘mystical’
experience (Carhart-Harris et al, 2016; MacLean et al, 2011).
Both LSD and psilocybin are 5-HT2A receptor agonists,
and their psychedelic effects are mediated by 5-HT2A
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receptor stimulation (Vollenweider et al, 1998). The long-
term effects of LSD and psilocybin may be related to their
psychedelic and 5-HT2A receptor activation properties. In
contrast to the psychedelics LSD and psilocybin, MDMA
is considered an empathogen (entactogen) that mainly
enhances positive feelings, empathy, and prosociality
(Hysek et al, 2014a; Kirkpatrick et al, 2014) while having
few hallucinogen-like effects. Additionally, MDMA has been
shown to positively alter emotion processing (Bedi et al,
2010; Hysek et al, 2012,2014a; Kirkpatrick et al, 2012,2014;
Schmid et al, 2014). These acute effects of MDMA on
emotion processing and social behavior may be beneficial
during psychotherapy in the absence of a full psychedelic
peak experience. LSD also produced acute MDMA-like
subjective effects, including greater well-being, happiness,
closeness to others, openness, and trust (Schmid et al, 2015).
Thus, LSD and MDMA may have common effects on the
processing of emotional information with relevance to their
positive acute and possibly long-term effects during
psychotherapy. However, the effects of LSD in tests of
emotion processing are unknown. Therefore, the present
study investigated the acute effects of LSD using the Face
Emotion Recognition Task (FERT) and Multifaceted Em-
pathy Test (MET). The effects of LSD on social behavior
were also evaluated using the Social Value Orientation (SVO)
test. Additionally, we assessed the subjective mood effects of
LSD using Visual Analog Scales (VASs) and the Adjective
Mood Rating Scale (AMRS), vital signs, and adverse effects.
We hypothesized that LSD would impair the recognition of
negative emotions on the FERT and enhance emotional
empathy on the MET and prosociality on the SVO test.
MATERIALS AND METHODS
Study Design
We pooled data from two similar studies using double-blind,
placebo-controlled, crossover designs with two experimental
test sessions (LSD and placebo) in a balanced order. Study 1
used a dose of 100 μg LSD and placebo in 24 subjects. Study 2
used 200 μg LSD or placebo in 16 subjects. The washout
periods between sessions were at least 7 days. The studies
were conducted in accordance with the Declaration of
Helsinki and approved by the local ethics committee. The
administration of LSD to healthy subjects was authorized by
the Swiss Federal Office for Public Health, Bern, Switzerland.
All of the subjects provided written consent before
participating in either of the studies, and they were paid
for their participation. The studies were registered at
ClinicalTrials.gov (NCT02308969, NCT01878942). The sub-
jective, endocrine, and pharmacokinetic effects of LSD in
Study 2 were previously reported (Dolder et al, 2015b;
Schmid et al, 2015; Strajhar et al, 2016).
Participants
Forty healthy participants were recruited from the University
of Basel campus via online advertisement. Twenty-four
subjects (12 men, 12 women; 33± 11 years old (mean± SD);
range, 25–60 years) participated in Study 1, and 16 subjects
(8 men, 8 women; 29± 6 years old; range, 25–51 years)
participated in Study 2. The inclusion and exclusion criteria
were identical for both studies. Subjects younger than 25
years of age were excluded from participating in the study.
Additional exclusion criteria were age465 years, pregnancy
(urine pregnancy test at screening and before each test
session), personal or family (first-degree relative) history of
major psychiatric disorders (assessed by the semistructured
clinical interview for Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, Axis I disorders by the study
physician and an additional interview by a trained psychia-
trist), use of medications that may interfere with the study
medication, chronic or acute physical illness (abnormal
physical exam, electrocardiogram, or hematological and
chemical blood analyses), tobacco smoking (410 cigar-
ettes/day), lifetime prevalence of illicit drug use 410 times
(except for tetrahydrocannabinol), illicit drug use within the
last 2 months, and illicit drug use during the study
(determined by urine drug tests). The subjects were asked
to abstain from excessive alcohol consumption between test
sessions and particularly limit their use to one standard drink
on the day before the test sessions. Additionally, the
participants were not allowed to drink xanthine-containing
liquids after midnight before the study day. Eleven subjects
had used a hallucinogen including LSD (6 participants) one
to three times, and most of the subjects (29) were
hallucinogen-naïve (Supplementary Table S1). We per-
formed urine drug tests at screening and before each test
session, and no substances were detected during the study.
Study Procedures
Each study included a screening visit, a psychiatric interview,
two 25-h experimental sessions, and an end-of-study visit.
The experimental sessions were conducted in a quiet
standard hospital patient room. The participants were resting
in hospital beds except when going to the restroom. Only one
research subject and one investigator were present during
the experimental sessions. Participants could interact with
the investigator, rest quietly and/or listen to music via
headphones, but no other entertainment was provided. LSD
or placebo was administered at 0900 hours. The subjects
were never alone during the first 12 h after drug adminis-
tration, and the investigator was in a room next to the subject
for up to 24 h while subjects were asleep (mostly from 0100
to 0800 hours). Because subjective responses to LSD are
pronounced and peak at 2–3 h and last up to 12 h (Passie
et al, 2008; Schmid et al, 2015), effects on emotion processing
and prosociality were assessed 5 and 7 h after the 100 and
200 μg doses, respectively, when the subjective effects of LSD
amounted to approximately 50% of the peak responses
(Dolder et al, 2015b; Schmid et al, 2015).
Study Drug
LSD (D-LSD hydrate; Lipomed AG, Arlesheim, Switzerland)
was administered in single oral doses of 100 or 200 μg. Both
doses are within the range of doses that are taken for
recreational purposes (Passie et al, 2008).
Measures
Facial Emotion Recognition Task. We used the FERT,
which is sensitive to the effects of other psychoactive
LSD and emotion processing
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substances, including serotonin and norepinephrine uptake
inhibitors (Harmer et al, 2004), MDMA (Bedi et al, 2010;
Hysek et al, 2014b; Kirkpatrick et al, 2014; Schmid et al,
2014), and methylphenidate (Hysek et al, 2014b; Schmid
et al, 2014). The task included 10 neutral faces and 160 faces
that expressed one of four basic emotions (ie, happiness,
sadness, anger, and fear), with pictures morphed between 0%
(neutral) and 100% in 10% steps. Two female and two male
pictures were used for each of the four emotions. The stimuli
were presented in random order for 500 ms and then were
replaced by the rating screen where participants had to
indicate the correct emotion. The outcome measure was
accuracy (proportion correct). The FERT was performed 5
and 7 h after the 100 and 200 μg doses of LSD, respectively.
Multifaceted Empathy Test. The MET is a reliable and
valid task that assesses the cognitive and emotional aspects of
empathy (Dziobek et al, 2008). The MET has been shown to
be sensitive to oxytocin (Hurlemann et al, 2010), MDMA
(Hysek et al, 2014a; Kuypers et al, 2014; Schmid et al, 2014),
and psilocybin (Preller et al, 2015). The computer-assisted
test consisted of 40 photographs that showed people in
emotionally charged situations. To assess cognitive empathy,
the participants were required to infer the mental state of the
subject in each scene and indicate the correct mental state
from a list of four responses. Cognitive empathy was defined
as the percentage of correct responses relative to total
responses. To measure emotional empathy, the subjects were
asked to rate how much they were feeling for an individual in
each scene (ie, explicit emotional empathy) and how much
they were aroused by each scene (ie, implicit emotional
empathy) on a 1–9 point scale. The latter rating provides an
inherent additional assessment of emotional empathy, which
is considered to reduce the likelihood of socially desirable
answers. The three aspects of empathy were each tested with
20 stimuli with positive valence and 20 stimuli with negative
valence, resulting in a total of 120 trials. The MET was
performed 5 h and 30 min after the 100 μg LSD dose and 7 h
and 30 min after the 200 μg LSD, respectively.
SVO test. We used the paper version of the validated SVO
test to assess social behavior (Murphy et al, 2011). The SVO
measure was previously shown to be sensitive to MDMA
(Hysek et al, 2014a). In this economic resource allocation
task, prosociality is defined as behavior that maximizes the
sum of resources for the self and others and minimizes the
difference between the two. The test consists of six primary
and nine secondary SVO slider items with a resource
allocation choice over a defined continuum of joint payoffs
(Murphy et al, 2011). The participants were instructed to
choose a resource allocation that defined their most
preferred joint distribution between themselves and another
person. The allocated funds had real value, and four
randomly selected subjects received the funds they earned.
Mean allocations for the self and the other were calculated
(Hysek et al, 2014a; Murphy et al, 2011), and the inverse
tangent of the ratio of these two means produced an angle
that indicated the participants’ SVO index. A smaller SVO
angle indicates more individualistic or competitive behavior,
and a larger SVO angle indicates more prosocial or even
altruistic behavior. The SVO was performed 6 and 8 h after
the 100 and 200 μg doses of LSD, respectively.
Subjective mood. The VASs and the AMRS (Janke and
Debus, 1978) were repeatedly used to assess subjective effects
including aspects of empathy and sociality (Hysek et al,
2014a; Schmid et al, 2015) (Supplementary Material and
Methods).
Vital signs and adverse effects. Blood pressure, heart rate,
body temperature, pupil diameter, and adverse effects were
measured as described in the Supplementary Material and
Methods.
Drug concentrations. Blood samples for the analysis of
plasma LSD levels were collected in lithium heparin tubes
after completing the social cognitive tests 6 and 8 h after
administration of the 100 and 200 μg doses of LSD or
placebo, respectively. Plasma LSD concentrations were
determined using liquid-chromatography tandem mass
spectrometry (Dolder et al, 2015a).
Statistical Analyses
All of the data were analyzed using repeated measures
analysis of variance (ANOVA), with drug (LSD vs placebo)
as the within-subjects factor and dose (100 vs 200 μg) as the
between-subjects factor, followed by the Tukey’s post hoc test
based on significant main effects or interactions. Repeated
subjective measures were expressed as peak effects prior to
the ANOVAs. Additionally, differences at individual time
points were also compared using paired t-tests. Modulatory
effects by sex or previous hallucinogen use were excluded by
adding sex or substance use as an additional factor to the
ANOVAs. Sex or previous substance use did not moderate
outcome measures.
RESULTS
Facial Emotion Recognition
The effects of LSD on the FERT are shown in Figure 1. Data
were missing from 2 of the 24 subjects in the 100 μg LSD
dose group because of technical problems. LSD impaired the
recognition of fearful faces (main effect of drug: F1,36= 20.71,
po0.001), with no drug × dose interaction. Impairments
were found in both the 100 and 200 μg dose groups
compared with placebo (po0.01 and po0.05, respectively).
A significant main effect of drug (F1,36= 7.36, p= 0.01)
indicated that LSD also impaired the recognition of sad faces,
but post hoc comparisons of the two dose groups with
placebo did not reach significance. No significant effects of
LSD on the decoding of neutral, happy, or angry facial
expressions were found.
Empathy
The effects of LSD on explicit emotional and cognitive
empathy are shown in Figure 2. Data were missing from 2 of
the 24 subjects in the 100 μg LSD dose group because of
technical problems. There were significant main effects of
drug on explicit and implicit emotional empathy ratings
LSD and emotion processing
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(F1,36= 14.05, po0.001 and F1,36= 6.71, p= 0.01, respec-
tively), indicating that LSD increased both aspects of
emotional empathy. The post hoc tests showed that the
200 μg dose but not the 100 μg dose of LSD produced a
significant effect on explicit (po0.01) and implicit (p= 0.01)
empathy scores compared with placebo. The valence-specific
analysis showed that LSD significantly increased explicit and
implicit emotional empathy scores for positive emotional
stimuli ( F1,36= 24.32, po0.001 and F1,36= 10.47, po0.01,
respectively) but there were only trend effects for negative
emotional stimuli (F1,36= 3.29, p= 0.08 and F1,36= 2.82,
p= 0.1, respectively). LSD decreased cognitive empathy,
reflected by a significant main effect of drug (F1,36= 16.87,
po0.001). The post hoc tests showed that this effect was
significant for both the 100 and 200 μg doses compared with
the respective placebo conditions (both po0.05).
Social Value Orientation
A significant effect of drug was found on the SVO angle
(F1,38= 4.31, po0.05), indicating that LSD increased proso-
ciality. The post hoc tests showed that this effect did not
reach significance in the individual LSD dose groups and was
only evident in the larger total study sample.
Subjective Mood Effects
Subjective effects on the VASs are shown in Figure 3, and
maximal values are presented in Table 1. LSD increased
maximal VAS rating scores, including those reflecting
empathy and prosociality such as ‘feeling close to others’,
‘open’, ‘trust’, and ‘I want to be with others’, with greater
peak effects at the higher compared with the lower dose.
Ratings of ‘happy’ were similarly increased by both doses.
LSD produced small dose-dependent increases in ‘bad drug
effect’ and ‘fear’ (Figure 3, Table 1). On the AMRS, LSD
significantly increased ratings of ‘well-being’, ‘emotional
excitation’, ‘inactivity’, ‘introversion’, and ‘dreaminess’
compared with placebo (Figure 4 and Table 1). There was
a significant main effect of LSD on ‘fear’ but no significant
effects in the individual studies.
Vital Signs and Adverse Effects
Peak values and statistics are shown in Table 1. Compared
with placebo, LSD increased blood pressure, heart rate, and
body temperature as well as pupil size in the dark and after a
light stimulus (Table 1). These effects were similar for both
doses (no drug × dose interaction). Compared with placebo,
both doses of LSD increased the total acute (0–10 h) adverse
effects. Only the high dose increased the total subacute
(10–24 h) adverse effects. Adverse effects 24–72 h were
slightly increased in the total sample but not in the individual
studies (Table 1). The frequently reported adverse effects are
presented in Supplementary Table S2. There were no severe
adverse events.
Plasma Drug Levels and Correlations Between Effects
Plasma concentrations of LSD were 0.7±0.3 ng/ml (mean±SD)
6 h after administration of the 100 μg dose and 1.3±0.6 ng/ml
8 h after administration of the 200 μg dose. These time points of
blood sample collection were immediately after the social
cognitive tests performed in the respective dose groups. Plasma
Figure 1 Lysergic acid diethylamide (LSD) impaired fear recognition on
the Face Emotion Recognition Task . LSD also impaired the decoding of sad
faces (significant main effect of drug), but the effects did not reach statistical
significance in the individual dose groups. The data are expressed as
mean± SEM in 22 and 16 subjects in the 100 and 200 μg LSD dose groups,
respectively. *po0.05, **po0.01, significant difference from placebo.
Figure 2 Lysergic acid diethylamide (LSD) increased emotional empathy
and decreased cognitive empathy on the Multifaceted Empathy Test. The
data are expressed as mean± SEM in 22 and 16 subjects in the 100 and
200 μg LSD dose groups, respectively. *po0.05, **po0.01, significant
difference from placebo.
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LSD levels correlated with explicit emotional empathy scores on
the MET for positive (Spearman Rs=0.37, po0.05, n= 38) but
not for negative emotional situations. Plasma levels of LSD
were not associated with FERT or SVO test measures.
Plasma levels of LSD were associated with LSD-induced ratings
of trust (Spearman Rs=0.32, po0.05, n= 40). LSD-induced
VAS ratings for feelings of ‘closeness’ and ‘trust’ were associated
with greater explicit empathy for positive emotional stimuli
(Spearman Rs=0.35, po0.05 and Rs= 0.47, po0.01, respec-
tively, n=38).
DISCUSSION
LSD positively altered the processing of emotional informa-
tion by decreasing the recognition of fearful and sad faces
and enhancing emotional empathy and prosociality. We are
aware of no other published data on the acute effects of LSD
on emotion processing. However, MDMA produced very
similar effects to those of LSD in the present study. MDMA
reduced the recognition of sad and fearful faces but not
happy faces on the FERT (Bedi et al, 2010; Hysek et al,
2014b), increased explicit and implicit emotional empathy on
the MET (Hysek et al, 2014a; Kuypers et al, 2014) (mainly for
positive emotionally charged situations) (Hysek et al, 2014a;
Schmid et al, 2014), and increased prosociality on the SVO
test (Hysek et al, 2014a). LSD did not facilitate perception of
happiness in the FERT similar to MDMA (Bedi et al, 2010;
Hysek et al, 2014b), possibly because detection of positive
basic emotions is very accurate in healthy subjects and
difficult to enhance. Thus, the 5-HT2A receptor agonist LSD
and 5-HT releaser MDMA may produce overall similar
effects on the processing of emotional information. However,
in contrast to MDMA, LSD also impaired cognitive empathy
on the MET, and the higher dose also decreased the
recognition of neutral faces on the FERT, indicating
nonspecific performance effects. Similar to LSD, the
5-HT2A receptor agonist psilocybin decreased the recogni-
tion of negative facial expressions (Kometer et al, 2012) and
increased emotional empathy on the MET (Preller et al,
2015). Altogether, these findings indicate that LSD affects
emotion processing similarly to MDMA and psilocybin.
The marked acute psychedelic/hallucinogenic ‘peak
response’ to LSD and psilocybin has been considered
relevant to their lasting effects (Carhart-Harris et al, 2016;
Griffiths et al, 2011). The present study showed that LSD has
dose-dependent subjective effects on empathogenic mood,
including ‘feelings of closeness to others’, ‘wanting to be
with others’, ‘happiness,’ ‘openness,’ and ‘trust’ (Schmid
et al, 2015), in addition to more hallucinogen-specific
Figure 3 Subjective effects of lysergic acid diethylamide (LSD) over time on the Visual Analog Scales (VASs). LSD or placebo was administered at t= 0. The
data are expressed as mean± SEM in 24 and 16 subjects in the 100 and 200 μg LSD dose groups, respectively. LSD significantly increased ratings on all VASs
with significant dose–response effects, except for ratings of ‘happy’. The corresponding maximal effects and statistics are shown in Table 1. Emotion
recognition (Face Emotion Recognition Task), empathy (Multifaceted Empathy Test), and social value orientation (SVO) tests were conducted 5–6 and 7–8 h
after the administration of the 100 and 200 μg LSD dose, respectively. +/*po0.05, ++/**po0.01, +++/***po0.001 for the 100/200 μg LSD dose,
respectively, compared with placebo (T-tests).
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psychedelic peak effects. These acute subjective effects of
LSD and its effects on the emotion processing and behavioral
tests in the present study are very similar to those of the
prototypic empathogen MDMA. However, LSD induced
higher AMRS intro- than extroversion while MDMA
produced more extro- than introversion (Hysek et al,
2014a). Importantly, the subjective feelings of ‘happiness’,
‘trust’, ‘closeness to others’, and ‘desire to be with others’ at
the high dose of LSD were maintained up to 6–12 h, and the
effects of LSD on emotion processing and prosociality were
also observed late in time at 6–8 h after LSD administration
and after the peak response when a ‘plateau phase’ was
reached. At that time, the subjects were also less over-
whelmed by initially strong and mostly novel psychedelic
experiences, which may open a window for psychother-
apeutic interventions. The emotional effects during the
later phase of the acute LSD response (6–10 h) are likely
beneficial to acutely facilitating the therapeutic alliance.
Future research should address the relative contribu-
tions of the psychedelic peak experience vs empathogenic
Table 1 Values and Statistics for the Subjective and Cardiovascular Peak Effects
Placebo 100 μg
(mean±SE)
LSD 100 μg
(mean±SE)
Placebo 200 μg
(mean±SE)
LSD 200 μg
(mean±SE)
Drug Drug×Dose
F1,38= p= F1,38= p=
Subjective effects
Visual Analog Scales (VAS, %)
Any drug effect 0.9± 0.6 87.5± 3.3*** 0.1± 0.1 97.2± 1.7***# 1939 *** 6.21 *
Good drug effect 0.9± 0.6 85.2± 3.4*** 0.1± 0.1 96.8± 1.5***## 1661 *** 7.66 **
Bad drug effect 0.0± 0.0 17.3± 3.6** 0.1± 0.06 40.0± 8.2***### 51.17 *** 8.01 **
Fear 0.0± 0.0 8.4± 2.3 0.06± 0.1 31.3± 8.6***### 27.74 *** 9.24 **
Happy 1.2± 0.6 30± 3.4*** 5.0± 2.0 39.1± 4.2*** 141.5 *** 1 NS
Closeness to others 0.0± 0.0 15.2± 3.2*** 4.3± 1.8 32.3± 4.7***### 61.68 *** 5.38 *
Open 0.2± 0.2 17.0± 2.8*** 3.9± 1.5 41.0± 3.6***### 128.9 *** 18.4 ***
Trust 0.0± 0.0 22.0± 4.1*** 4.8± 2.1 39.8± 4.0***### 81.37 *** 4.2 *
I want to be hugged 0.0± 0.0 8.8± 2.7 3.4± 1.9 27.8± 6.8***### 23.52 *** 5.13 *
I want to hug someone 0.0± 0.0 10.4± 2.7* − 1.4± 3.3 27.6± 6.1***## 41.21 *** 9.13 **
I want to be alone 0.6± 0.6 7.7± 2.5 5.1± 1.9 17.6± 5.6 9.93 ** 0.76 NS
I want to be with other people 0.8± 0.8 12.8± 2.5** 10.8± 4.2 42.8± 5.5***### 79.87 *** 16.25 ***
Adjective Mood Rating Scale (AMRS, Δ score)
Well-being 0.0± 0.6 2.5± 1.0 1.8± 0.7 6.6± 1.6* 11.49 ** 1.11 NS
Emotional excitation − 0.3± 0.2 2.3± 0.5** − 0.3± 0.3 4.7± 1.0***## 53.5 *** 4.77 *
Inactivity 2.6± 0.7 9.0± 1.1** 1.3± 1.1 10.6± 2.7*** 30.82 *** 1.05 NS
Extroversion − 0.5± 0.3 − 0.1± 0.6 0.1± 0.5 1.5± 0.7 2.67 NS 0.77 NS
Introversion 0.4± 0.1 4.1± 0.6*** 0.5± 0.4 4.3± 0.8*** 51.92 *** 0.01 NS
Fear − 0.1± 0.1 0.9± 0.3 − 0.4± 0.3 1.3± 1.0 9.51 ** 0.72 NS
Dreaminess 0.2± 0.3 6.9± 0.7*** 0.8± 0.5 7.9± 0.6*** 160.2 *** 0.11 NS
Vital signs
Systolic blood pressure (mm Hg) 129± 2.0 142± 2.1*** 133± 3.8 148± 2.9*** 63.8 *** 0.13 NS
Diastolic blood pressure (mm Hg) 76.9± 1.5 85.7± 1.7*** 78.2± 2.0 87.6± 1.9*** 68.8 *** 0.08 NS
Heart rate (beats/min) 70.6± 1.8 79.1± 2.7** 72.8± 2.6 86.9± 4.29*** 33.7 *** 2.05 NS
Body temperature (Δ°C) 0.5± 0.1 0.8± 0.1** 0.3± 0.1 0.7± 0.1** 23.74 *** 0.22 NS
Pupil size (mm) 6.1± 0.2 6.9± 0.1*** 6.5± 0.2 7.2± 0.1*** 61.08 *** 0.81 NS
Pupil size after light (mm) 4.3± 0.2 5.2± 0.2*** 4.6± 0.2 5.6± 0.2*** 89.61 *** 0.02 NS
List of complaints (Δ LC total score)
Acute adverse effects (0–10 h) 0.5± 0.3 9.8± 1.8*** 0.1± 0.6 10.4± 3.0*** 38.37 *** 0 NS
Subacute adverse effects (10–24 h) − 0.2± 0.3 0.4± 0.2 − 0.4± 0.4 3.7± 1.4** 12.06 ** 6.76 *
Subacute adverse effects (24–72 h) − 0.5± 0.3 − 0.1± 0.2 − 0.8± 0.4 0.6± 0.9 6.03 * 1.83 NS
Values are mean± SEM of the peak or peak changes (Δ) from baseline in 40 subjects. Sixteen subjects participated in the high dose study (200 μg) and 24 subjects in the
moderate dose study (100 μg).
*for po0.05, **for po0.01, ***for po0.001 compared with placebo. # for po0.05, ## for po0.01, ### for po0.001 compared with LSD 100 μg.
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emotional effects of LSD to its potential therapeutic effects.
Additionally, it seems that only the higher 200 μg dose of
LSD produced robust empathogenic effects. Furthermore,
the relevance of deficits in cognitive empathy for the
therapeutic process is unclear.
The present study also showed that LSD was well tolerated
in a controlled setting in healthy subjects. Adverse effects of
LSD mainly included acute dizziness, headache, and fatigue/
exhaustion lasting up to 72 h. Both doses of LSD produced
comparable moderate sympathomimetic effects including
elevated blood pressure, heart rate, body temperature, and
mydriasis.
The present study used two doses of LSD within a
clinically relevant dose range. In fact, the higher dose was
identical to both the amount and pharmaceutical formula-
tion that were used in a clinical study in patients with anxiety
(Gasser et al, 2014) and continue to be used in patients in
Switzerland. Additionally, LSD was administered to subjects
across a relatively wide age range (25–60 years). Importantly,
the subjects typically had no or very limited hallucinogen
experience, which is possibly similar to cases in which LSD is
used therapeutically in patients. In contrast, other contem-
porary studies used lower doses of LSD in subjects with
extensive prior substance use (Carhart-Harris et al,
2016,2015). However, in the present study, previous
hallucinogen use (1–3 times including LSD in six subjects)
did not alter the responses to LSD.
In the present study, the tests were performed approxi-
mately 3 h after the peak effects (Dolder et al, 2015b; Schmid
et al, 2015). At the time of the peak response of LSD, test
administration would not have been feasible because of the
strong alterations in wake consciousness and impairments in
concentration (Schmid et al, 2015). The participants needed
to adjust to the altered state of consciousness; therefore,
testing occurred after a ‘plateau phase’ was reached. Never-
theless, at the time of testing, the subjective effects and plasma
concentrations of LSD were still at approximately 50% of the
peak responses and clearly effective in producing typical LSD
effects, providing a good time interval for conducting the
neurocognitive tasks (Carhart-Harris et al, 2016; Schmid et al,
2015). Additionally, the tests were performed later after the
high dose than after the low dose of LSD. However, at the
times of testing, plasma LSD concentrations were twice as
high after the 200 μg dose compared with the 100 μg dose, and
generating a dose/concentration–response effect was possible.
The study has limitations. First, the dose effects of LSD
were studied in different participants and not within-subject.
Second, we assessed only emotion recognition and no other
measures such as face muscle responses to emotions (Wardle
et al, 2014) and the stimuli were artificial (pictures) rather
than real people. With regard to the use of LSD in
psychotherapy, we only assessed ‘empathic concern for
others’ but not whether the participants ‘felt cared for or
understood by someone else’ (Wardle and de Wit, 2014). It is
possible that LSD affected attention and motivation and
thereby task performance. Thus, it will be important to
replicate and expand our findings using additional emotion
recognition tests (Wardle and de Wit, 2014), tests of
responses to emotions (Wardle and de Wit, 2014; Wardle
et al, 2014), and other measures of social interaction (Frye
et al, 2014).
Figure 4 Subjective effects on the Adjective Mood Rating Scale. Lysergic acid diethylamide (LSD) or placebo was administered at t= 0. The data are
expressed as mean± SEM changes from baseline (−1 h) in 24 and 16 subjects in the 100 and 200 μg LSD dose groups, respectively. Emotion recognition
(Face Emotion Recognition Task), empathy (Multifaceted Empathy Test), and social value orientation (SVO) tests were conducted 5–6 and 7–8 h after the
administration of the 100 and 200 μg LSD dose, respectively. The corresponding maximal effects and statistics are shown in Table 1. *po0.05, **po0.01,
***po0.001 compared with placebo (T-tests).
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In conclusion, LSD impaired emotion recognition of
negative emotions and enhanced emotional empathy,
particularly for positive emotional situations, and had
subjective and behaviorally tested prosocial effects. These
effects of LSD in healthy participants likely have translational
relevance to LSD-assisted psychotherapy in patients and can
be expected to reduce the perception of negative emotions
and facilitate the therapeutic alliance.
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Supplementary Information 
 
Material and methods 
 
Subjective effects 
 
The Visual Analog Scales (VASs) were repeatedly used to assess subjective effects over time. 
The VASs included “any drug effect,” “good drug effect,” “drug high,” “bad drug effect,” “fear,” “happy,” 
“closeness to others,” “open,” “trust”, “I want to be hugged”, “I want to hug someone”, “I want to be 
alone”, and “I want to be with others” and have previously been used (Hysek et al, 2014a; Schmid et 
al, 2015). The VASs were presented as 100-mm horizontal lines (0-+100%) marked from “not at all” on 
the left and “extremely” on the right. The VASs for “happy,” “closeness to others,” “open,” “trust”, “I 
want to be hugged”, “I want to hug someone”, “I want to be alone”, and “I want to be with others” were 
bidirectional ( 50%), marked from “not at all” on the left (-50), to “normal” in the middle (0), to 
“extremely” on the right (+50). The VASs were administered 1 h before and 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 16, and 24 h after drug administration.  
The 60-item Likert-scale short version of the Adjective Mood Rating Scale (AMRS) (Janke and 
Debus, 1978) was administered 1 h before and 3, 10, and 24 h after placebo or LSD. The AMRS 
contains subscales for well-being, emotional excitation, activity, inactivity, extro- and introversion, fear, 
and dreaminess. The AMRS has previously been shown to be sensitive to the effects of 
psychostimulants, empathogens, and hallucinogens (Hasler et al, 2004; Hysek et al, 2014b; Schmid et 
al, 2015). 
 
Vital signs, pupillary function, and adverse effects 
 
Blood pressure, heart rate and body temperature were assessed repeatedly 1 h before and 0, 
0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 24 h after drug administration. Blood pressure (systolic 
and diastolic) and heart rate were measured using an automatic oscillometric device (OMRON 
Healthcare Europe NA, Hoofddorp, Netherlands). The measurements were performed in duplicate at 
an interval of 1 min and after a resting time of at least 10 min. The averages were calculated for 
analysis. Core (tympanic) temperature was measured using an GENIUSTM 2 ear thermometer (Tyco 
Healthcare Group LP, Watertown, NY, USA). 
Pupillometry was performed 1 h before and 1, 2.5, 4, 7, and 11 h after drug administration using 
an infrared pupillometer (PRL-200, NeurOptics, Irvine, CA, USA) under standardized dark-light 
conditions as previously described (Hysek and Liechti, 2012). The dark-adapted maximal pupil 
diameter, minimal pupil diameter after a light stimulus, and constriction amplitude (difference between 
maximal and minimal pupil size) were recorded. 
Adverse effects were assessed using the 66-item List of Complaints (Zerssen, 1976) before and 
10, 24, and 72 h after drug administration for the 0-10, 10-24, and 24-72 h time intervals, respectively. 
Complaints are assessed as present or not present and there is no grading of the complaint. However, 
the scale yields a total adverse effects score, reliably measuring general discomfort. 
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Table S1. Life-time prevalence of substance use 
     
          
 
Subject MDMA  amphetamine cocaine  LSD  psilocybin  methylphenidate mescaline  THC 
Study 1                 
 
1 2 0 0 0 0 0 0 0 
 
2 1 0 0 0 0 0 0 0 
 
3 0 0 0 0 0 0 0 5-10 
 
4 3 0 1 0 0 0 0 10-20 
 
5 0 0 0 0 0 0 0 0 
 
6 0 0 0 0 0 0 0 0 
 
7 5 1 1 1 0 0 0 0 
 
8 1 0 0 0 0 2 0 0 
 
9 0 0 0 0 0 0 0 0 
 
10 0 0 0 0 0 0 0 5-10 
 
11 0 0 0 0 0 0 0 0 
 
12 5 0 0 0 0 0 0 5-10 
 
13 0 0 0 0 0 0 0 0 
 
14 0 0 0 0 0 0 0 5-10 
 
15 0 0 0 0 0 0 0 10-20 
 
16 0 0 0 0 1 0 0 5-10 
 
17 0 0 0 1 0 0 0 0 
 
18 0 0 0 1 1 0 0 0 
 
19 2 0 0 0 0 0 0 0 
 
20 0 0 0 0 0 0 0 2 
 
21 0 0 0 0 0 0 0 0 
 
22 0 0 0 0 0 0 0 0 
 
23 3 1 0 0 0 1 0 0 
 
24 0 0 0 0 0 0 0 0 
Study 2                  
 
1 4 0 0 0 0 2 0 1 
 
2 2 0 0 0 1 0 1 5-10 
 
3 4 0 0 1 0 2 0 10-20 
 
4 0 0 0 0 3 0 0 5-10 
 
5 2 0 0 0 0 0 0 50-100 
 
6 0 0 0 0 0 0 0 100-200 
 
7 3 0 2 2 0 0 0 100-200 
 
8 2 0 0 0 0 0 0 0 
 
9 1 0 0 0 2 0 0 5-10 
 
10 0 0 0 0 0 0 0 100-200 
 
11 0 0 0 0 0 0 0 20-50 
 
12 2 1 2 0 1 0 0 50-100 
 
13 8 0 0 2 0 0 0 50-100 
 
14 0 0 0 0 0 1 0 2 
 
15 3 1 1 0 0 1 0 1 
 
16 0 0 0 0 0 0 0 5-10 
                    
Values are times used in life            
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Table S2.  Percent of acute and sub-acute adverse drug effects up to 72 hours.     
    
Study 1 Placebo 100 µg 
 
LSD 100 µg 
         
 
        
 
0h 0-10h 10-24h 24-72h 
 
0h 0-10h 10-24h 24-72h 
          
 
        
Difficulty concentrating 0% 0% 0% 0% 
 
0% 54% 0% 0% 
Headache 0% 29% 13% 0% 
 
4% 58% 17% 21% 
Exhaustion 4% 13% 4% 0% 
 
4% 25% 4% 4% 
Dizziness 0% 0% 0% 0% 
 
0% 25% 0% 0% 
Lack of appetite 0% 0% 0% 0% 
 
0% 46% 0% 4% 
Dry mouth 4% 4% 0% 0% 
 
0% 29% 0% 0% 
Imbalance 0% 0% 0% 0% 
 
0% 42% 0% 0% 
Nausea 0% 0% 0% 0% 
 
0% 21% 0% 0% 
Fatigue 29% 29% 13% 4% 
 
17% 58% 29% 33% 
          
                    
Study 2 Placebo 200 µg 
 
LSD 200 µg 
 
0h 0-10h 10-24h 24-72h 
 
0h 0-10h 10-24h 24-72h 
          
 
        
Difficulty concentrating 0% 4% 4% 0% 
 
0% 42% 13% 8% 
Headache 4% 13% 8% 0% 
 
8% 38% 33% 8% 
Exhaustion 4% 4% 4% 0% 
 
4% 29% 42% 13% 
Dizziness 4% 0% 0% 0% 
 
0% 29% 8% 0% 
Lack of appetite 0% 0% 0% 0% 
 
4% 21% 13% 0% 
Dry mouth 0% 0% 0% 0% 
 
0% 21% 13% 4% 
Imbalance 0% 0% 0% 0% 
 
0% 21% 4% 0% 
Nausea 4% 4% 4% 0% 
 
8% 17% 0% 0% 
Fatigue 25% 17% 17% 0% 
 
38% 38% 46% 17% 
Data percent in 16 and 24 subjects for the high and low dose group, respectively.  
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eligibility (n=26) 
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eligibility (n=20) 
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•Not meeting inclusion criteria(n=4) 
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• Excluded from analysis (n=0) 
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Acute effects of LSD on amygdala activity during processing
of fearful stimuli in healthy subjects
F Mueller1,3, C Lenz1,3, PC Dolder2, S Harder2, Y Schmid2, UE Lang1, ME Liechti2 and S Borgwardt1
Lysergic acid diethylamide (LSD) induces profound changes in various mental domains, including perception, self-awareness and
emotions. We used functional magnetic resonance imaging (fMRI) to investigate the acute effects of LSD on the neural substrate of
emotional processing in humans. Using a double-blind, randomised, cross-over study design, placebo or 100 μg LSD were orally
administered to 20 healthy subjects before the fMRI scan, taking into account the subjective and pharmacological peak effects of
LSD. The plasma levels of LSD were determined immediately before and after the scan. The study (including the a priori-deﬁned
study end point) was registered at ClinicalTrials.gov before study start (NCT02308969). The administration of LSD reduced reactivity
of the left amygdala and the right medial prefrontal cortex relative to placebo during the presentation of fearful faces (Po0.05,
family-wise error). Notably, there was a signiﬁcant negative correlation between LSD-induced amygdala response to fearful stimuli
and the LSD-induced subjective drug effects (Po0.05). These data suggest that acute administration of LSD modulates the
engagement of brain regions that mediate emotional processing.
Translational Psychiatry (2017) 7, e1084; doi:10.1038/tp.2017.54; published online 4 April 2017
INTRODUCTION
Lysergic acid diethylamide (LSD), a potent psychoactive
substance,1 induces profound changes in various mental domains,
including perception, self-awareness and emotions.2,3 As with the
other psychedelics (for example, psilocybin and mescaline), these
effects are mainly mediated through agonism at the serotonin
5-HT2A receptor.
1,4 Currently, there are renewed efforts to use
substances like LSD and psilocybin in basic research and clinical
practice.2,3,5,6,7 Psilocybin has been studied as a treatment option
for addiction, depression and for anxiety in patients with advanced
stage cancer.8–11 LSD has been shown to reduce anxiety in patients
with life-threatening diseases.12 With the investigation of its basic
pharmacological and psychological effects, there is also rising
interest in the neuronal correlates of the LSD-induced altered state
of consciousness. Although several modern studies on psilocybin
have been conducted, recent data on LSD in humans are still very
limited.1
Functional neuroimaging provides a sensitive means of
examining how LSD acts on the brain. No data investigating LSD
effects on emotion processing have yet been published. The aim
of the present study was therefore to investigate these acute
effects of LSD using functional magnetic resonance imaging
(fMRI). Using a double-blind, randomised, cross-over study design,
placebo or 100 μg LSD were orally administered to 20 physically
and mentally healthy participants 2.5 h before the fMRI scan,
taking into account the subjective and pharmacological peak
effects of LSD.2,6 Subjects only had minimal lifetime exposure to
illicit drugs; notably, only two subjects had had prior experience
with a psychedelic, both on one occasion only. During the fMRI
scan, human fearful and neutral faces of a well-validated paradigm
were presented. To test our hypothesis that there were differences
between placebo and LSD during processing of emotional stimuli,
trials for fearful faces were contrasted against trials for neutral
faces. We thereby focused on the amygdala as one central part of
neural emotion processing, in particular, of anxiety13,14 and
additionally included two other regions (the fusiform gyrus and
the medial frontal gyrus) known to be responsive to fearful
faces.14 Differences between placebo and LSD conditions were
evaluated by second-level paired t-test analysis. In addition, the
amygdala response to fearful faces after LSD was correlated with
the subjective drug effect, as assessed by a visual analogue scale
directly before the scan. The primary and a priori-deﬁned study
hypothesis was that LSD would decrease the amygdala response
to fearful stimuli and that this decrease would be associated with
the subjective psychedelic effects.
MATERIALS AND METHODS
We used a randomised, placebo-controlled, double-blind, cross-over design.
Each participant completed two study sessions, with a washout period of at
least 7 days between the sessions. The study was approved by the Ethics
Committee for Northwest/Central Switzerland (EKNZ) and by the Federal
Ofﬁce of Public Health. Written informed consent was obtained from all the
participants. The study (including the a priori-deﬁned study end point) was
registered at clinicaltrials.gov before study start (NCT02308969).
Subjects
The subjects were recruited by advertisement and word of mouth. The
sample size was determined by power analysis based on previous data.15,16
The exclusion criteria were age o25 or 465 years, pregnancy (as
determined by urine test), nursing, hypertension (4140/90 mm Hg) or
hypotension (systolic blood pressureo85 mm Hg), cardiac or neurological
disorders, use of any regular medication, as determined by medical history
1Department of Psychiatry, Universitäre Psychiatrische Kliniken, University of Basel, Basel, Switzerland and 2Division of Clinical Pharmacology and Toxicology, Department of
Biomedicine and Clinical Research, University Hospital Basel, Basel, Switzerland. Correspondence: Professor S Borgwardt, Department of Psychiatry, Universitäre Psychiatrische
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and general medical examination including electrocardiography, blood
chemistry and haematology, use of illicit drugs (except cannabis) 410
times or any time within the previous 2 months (as assessed by the history
and urine test for benzodiazepines, cocaine, amphetamines, methadone,
opiates and barbiturates), smoking of 410 cigarettes per day, history of
drug dependence, personal or ﬁrst-degree relative with a history of
seizures, personal or ﬁrst-degree relative with an axis I major psychiatric
disorder (as determined by general medical history and a semi-structured
interview for Diagnostic and Statistical Manual of Mental Disorders, fourth
edition). The subjects provided written informed consent and received
monetary compensation for their participation.
Study procedure
The study included a screening visit, two 25 h test sessions and an end of
study visit. The experimental sessions took place in a quiet room in the
University Hospital of Basel, Switzerland. The study dates were between
December 2014 (ﬁrst subject screened) and September 2015 (last end of
study session). The participants were monitored for adverse reactions and
events during the study dates and at the end of study visit. All the adverse
events were recorded. The participants were instructed to abstain from any
illicit drugs during the whole study period and, additionally, to abstain from
caffeine, chocolate and alcohol for at least 8 h before the sessions. The urine
drug tests (for tetrahydrocannabinol, benzodiazepines, cocaine, ampheta-
mines, methadone, opiates and barbiturates) were taken randomly on one
of the two sessions. In women, pregnancy tests were performed before
every session. Except for tetrahydrocannabinol, which can be detected for
several weeks, detection of any drug of abuse resulted in study exclusion. A
light standardised breakfast was served at both the sessions. Placebo and
LSD were administered orally, 2.5 h before the MRI scan at 0900 h, taking
into account the subjective and pharmacological peak effects of LSD.2,6
Drugs and randomization
Gelatin capsules containing 100 μg D-lysergic acid diethylamide hydrate
(Lipomed, Arlesheim, Switzerland) and identical capsules containing
mannitol were prepared. Each subject received either placebo or LSD on
two study sessions in a counterbalanced manner. Only the person
dispensing the substance (who was not further involved in conducting the
study) was aware of the treatment assignment. Subjects and study
personnel were blind to the treatment order.
Image acquisition
Scanning was conducted on a 3 Tesla MRI system (Magnetom Prisma,
Siemens Healthcare, Erlangen, Germany), using a 20-channel phased array
radio frequency head coil. Functional MRI acquisition was based on an
interleaved T2*-weighted echo planar imaging sequence, with 39 axial
slices with a slice thickness of 3 mm, a 0.5 mm inter-slice gap, a ﬁeld-of-
view of 228× 228 cm2 and an in-plane image matrix size of 76× 76—
resulting in 3 × 3× 3 mm3 resolution. The corresponding repetition time
was 2.5 s, echo time 30 ms and bandwidth = 2350 Hz per pixel. In total, 152
volumes were acquired (including three dummy scan volumes to ensure
signal stabilization).
Subjective effect measurements
The visual analogue scale ‘Any subjective drug effects’ was used to assess
the overall subjective response to LSD before the scan. The visual analogue
scale was presented as a 100 mm horizontal line (0–100%) marked ‘not at
all’ on the left and ‘extreme’ on the right. The scale was rated by the
volunteers 2 h after the administration of LSD or placebo.
Plasma levels
The blood was collected into lithium heparin tubes 2 and 3 h after the
administration of LSD and placebo, respectively. The blood samples were
immediately centrifuged and rapidly stored at − 20 °C until analysis. LSD
concentrations in plasma were determined using a validated liquid
chromatography-tandem mass spectrometry method.6
fMRI paradigm
During the fMRI acquisition, the study subjects participated in a 6 min
experiment based on event-related design implemented with E-Prime 2.0
(Psychology Software Tools, Pittsburgh, PA, USA). During the task,
participants were presented with 10 different facial identities (pictures of
human faces from the Ekman & Friesen series of Pictures of Facial Affect),
each expressing 50 or 100% intensities of fear or a neutral expression.
There were thus 30 different facial stimuli in total. Each face was shown
twice for 2 s, resulting in a total of 60 stimuli during the paradigm. The
order of facial identities and expression type was pseudo-randomised to
prevent successive presentation of the same identity or facial expression
type. The length of the interstimulus interval, during which subjects
viewed a ﬁxation cross, was varied from 3 to 8 s according to a Poisson
distribution, with an average interval of 5.9 s. To ensure maximal attention
to the presented faces, subjects were requested to decide on the gender of
face stimuli by pressing a left or a right button. Accuracy and reaction
times were monitored and recorded.
Data analysis
The data analysis was performed using SPM12 (http://www.ﬁl.ion.ucl.ac.uk/
spm/). All the volumes were slice time corrected, realigned to the ﬁrst volume,
co-registered to the pre-processed T1-weighted structural volume, normalized
into a standard stereotactic space (Montreal Neurological Institute, MNI) and
smoothed with a 6 mm full width at half maximum Gaussian kernel. The
dummy scans were excluded from any further processing and the remaining
volumes were quality checked for severe head motion and image artefacts.
the subjects with head motion of 42 mm translation or 42° rotation were
excluded. During model speciﬁcation, the onset times for each trial of neutral,
50% and 100% fearful faces were convolved with a canonical haemodynamic
response function. The serial correlations were removed with a ﬁrst-order
autoregressive model and a high-pass ﬁlter (128 s) was applied to remove low
frequency noise. The six motion parameters for translation and rotation were
entered as nuisance covariates. In addition, time and dispersion derivatives
were included in the individual design matrix during the ﬁrst-level analysis.
Each trial for 50 and 100% fearful faces was then contrasted against neutral
faces, and then produced a subject-speciﬁc contrast image propagated to the
second-level analysis. One-sample t-tests were used to assess the activity
induced by the main effect task over all included subjects. The threshold over
the whole brain was set at P=0.05, corrected for multiple comparisons (family-
wise error, FWE). Differences between the LSD and placebo treatment were
evaluated by a second-level paired t-test. Whole-brain threshold was set at
P=0.001, uncorrected for multiple comparisons, with an extent threshold of
k=10 voxels. We restricted our analysis to three meta-analytically identiﬁed14
regions of interest, namely the amygdala, the fusiform gyrus and the medial
frontal gyrus. Those regions were speciﬁcally described to be involved in the
processing of fearful faces compared with neutral faces.14 Based on the
Harvard-Oxford Atlas for cortical and subcortical structures, a mask comprising
those regions was created. Small volume correction was used for clusters
observed within this hypothesized region of interest. The statistical threshold
was adjusted to provide a FWE of Po0.05, corrected for small volumes. The
small volume correction was performed in the global maximum, with a sphere
of 5 mm, in accordance with previous fMRI studies on amygdala activity.17,18
The correlation with the subjective effect of LSD in the visual analogue
scale was performed using the extracted beta values of the amygdala cluster
under the LSD condition. We thereby used the ‘100% fearful versus neutral
contrast’ to obtain the distinct effect of the fearful stimuli. The calculations
were performed using SPSS version 23.00 (IBM, Zurich, Switzerland).
RESULTS
We included data sets from 20 healthy subjects—9 men, 11 women;
mean age 32±10.2 years; range: 25–58 years, all right-handed and
all but one with an academic background, originally with 24 study
participants. The data sets from four subjects were excluded
because of artefacts due to head movements. The lifetime drug
use of the 20 included subjects is shown in Table 1. None of the
participants tested positive for any drug (including tetrahydrocan-
nabinol) in the screening or test session. No serious adverse
reactions or events occurred during the whole period of the study in
any of the participants. The plasma levels of LSD were determined
immediately before and after the scan and were 1.3 ± 0.6 ng ml−1
(mean± s.d.) and 1.1±0.5 ng ml−1 (mean± s.d.), respectively.
Task performance
The differences between the LSD and placebo conditions in task
performance were assessed using paired t-tests. The mean subject
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response times did not differ signiﬁcantly between the two
conditions (LSD: 964±128 ms (mean±s.d.); placebo: 910±289ms
(mean± s.d.); t21 =2.0, P=0.06). Furthermore, no signiﬁcant differ-
ences were found between the conditions in correctness of response
(LSD: 93.1±10.8% (mean±s.d.); placebo: 97.3±3.3% (mean± s.d.);
t21=−1.8, P=0.08) or absence of button presses (LSD: 4.5±9.3%
(mean± s.d.); placebo: 1.3±1.8% (mean±s.d.); t21 =1.5, P=0.16).
Effect of task
With both treatments (n= 40), viewing neutral faces versus
baseline was associated with bilateral activation in a network
comprising the cerebellum, fusiform gyrus, occipital gyrus and the
middle cingulate gyrus and lateral activation in the left frontal and
lingual gyrus (FWE-corrected at Po0.05).
Viewing 100 and 50% fearful faces versus baseline was
associated with bilateral activation in the cerebellum, fusiform
gyrus, occipital gyrus, middle superior parietal lobule and lateral
activation in the left cingulate and frontal gyrus (FWE-corrected at
Po0.05). Under the placebo condition, presentation of fearful
faces induced a signiﬁcant (small volume correction, Po0.05 FWE
cluster level) activation of the left amygdala (MNImax x=− 20,
y=− 12, z=− 12; cluster size 22; Z-score 3.59) compared with
presentation of neutral faces.
Effect of LSD on neural response to fearful versus neutral faces
Compared with placebo, administration of LSD reduced neural
response to fearful versus neutral faces in the left and right
amygdala and the medial frontal gyrus (Po0.001, k= 10; see
Figure 1). No increased activity was observed. After correction for
multiple comparisons (small volume correction, Po0.05 FWE),
signiﬁcantly reduced activity was observed in the left amygdala
(MNImax x=− 15, y= 9, z=− 14; cluster size 24; Z-score 3.12) and
the right medial frontal gyrus (MNImax x= 15, y= 42, z= 16; cluster
size 12; Z-score 3.78). In addition, there was a signiﬁcant negative
correlation between amygdala blood oxygen-level dependent
response to fearful stimuli under the LSD condition and the LSD-
induced subjective drug effects (r=− 0.46, Po0.05; see Figure 2).
DISCUSSION
In summary, the present study used fMRI for we believe the ﬁrst
time to investigate the effects of LSD on the neural substrate of
emotional processing. We found that LSD decreased amygdala
reactivity to fearful stimuli in healthy subjects. In addition,
amygdala deactivation by LSD was associated with its acute
subjective psychedelic effects. We administered 100 μg LSD, a
representative dose that produces typical and robust psychedelic
effects.19 In addition, subjects had only had a minimal exposure
to recreational drugs and were mostly psychedelic-naive, as is
probably the case in patients receiving LSD-assisted
Table 1. Cumulative lifetime use of legal and illicit drugs of the included subjects
Nicotine Stimulants
No. of subjects with regular use 6/20 No. of subjects who have ever used 4/20
Cigarettes per day (mean/s.d./range) 1.40/4.03/0–10 Lifetime occasions (mean/s.d./range) 0.35/0.5/0–2
Caffeine Sedatives
No. of subjects with regular use 20/20 No. of subjects who have ever used 0/20
Units per day (mean/s.d./range) 3.05/1.96/1–8 Lifetime occasions (mean/s.d./range) 0/0/0
Alcohol Psychedelics
No. of subjects with regular use 20/20 No. of subjects who have ever used 2/20
Units per week (mean/s.d./range) 4.50/2.89/1–10 Lifetime occasions (mean/s.d./range) 0.10/0/0–1
Cannabis Opioids
No. of subjects who have ever used 15/20 No. of subjects who have ever used 1/20
Lifetime occasions (mean/s.d./range) 7.85/13.39/1–50 Lifetime occasions (mean/s.d./range) 0.05/0/0–1
MDMA Others
No. of subjects who have ever used 6/20 No. subjects who have ever used 0/20
Lifetime occasions (mean/s.d./range) 0.60/0.89/0–3 Lifetime occasions (mean/s.d./range) 0/0/0
Abbreviation: MDMA, 3,4-methylenedioxymethamphetamine.
Figure 1. Neural response to fearful versus neutral faces after
placebo compared with LSD treatment. LSD decreased reactivity
(shown in red-yellow) to fearful faces in the amygdala (a) and the
right medial frontal gyrus (b). Regions of interest (amygdala,
fusiform gyrus, medial frontal gyrus) are shown in blue. Threshold
Po0.001, k= 10. Right is right side of the brain. LSD, lysergic acid
diethylamide.
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psychotherapy.12 Our results are consistent with our previously
reported ﬁndings in a facial emotion recognition task, showing
that LSD-impaired recognition of fearful faces compared with
placebo.20 Our results are also in line with ﬁndings obtained after
administration of psilocybin, where attenuated recognition of
negative facial expressions21,22 and reduced amygdala blood
oxygen-level dependent response to fearful faces23 were reported.
The psilocybin-induced attenuation of amygdala reactivity in
response to negative stimuli has consistently been shown to be
related to the psilocybin-induced increase in positive mood.23
It could be argued that the decreased responsiveness of the
amygdala under LSD was due to a drug-induced alteration in
visual perception, resulting in the inability to differentiate
between the presented facial expressions. However, our results
in two doses of LSD (100 μg and 200 μg, respectively) indicated,
that LSD speciﬁcally impaired recognition of fearful faces, while it
did not signiﬁcantly affect recognition of neutral, happy and angry
faces.20 Furthermore, subjects in the present study performed well
in the gender differentiation task and our whole brain results
showed activation in regions typically involved in processing of
neutral and fearful faces, respectively.14
We observed a signiﬁcant effect of LSD on the left amygdala.
Several studies suggest, that the left amygdala might be
particulary involved in processing of negative facial
expressions.24,25 It has also been reported that the left amygdala
shows lesser habituation to fearful stimuli compared with the right
amygdala, which might make it more likely to detect the blood
oxygen-level dependent changes in this area.26,27 However,
lateralization of the amygdala response is still controversial
discussed.28–30 The amygdala receives considerable serotonergic
innervation from the raphe nuclei.31,32 LSD mainly acts as an
agonist at the serotonin 5-HT2A receptor,
1,4 which is expressed in
most parts of the amygdala.33 Accordingly, this might provide a
psychopharmacological basis for the observed effect of LSD on
this structure. After administration of selective serotonin reuptake
inhibitors in healthy subjects, a decreased amygdala activity in
response to negative stimuli was reported.34,35 In depressed
patients, amygdala hyperreactivity was resolved after treatment
with a selective serotonin reuptake inhibitor.36,37 Those ﬁndings
indicate that the serotonin system is involved in the modulation of
the amygdala response to emotional stimuli.38 We also observed
decreased activity in the right medial prefrontal cortex (mPFC).
The mPFC is anatomically connected to the amygdala39 and
involved in emotional functions.40 Within the mPFC–amygdala
circuit, the more ventral parts of the mPFC have been implicated in
inhibitory functions,40 whereas the more dorsal parts are thought to
be part of an ‘aversive-ampliﬁcation circuit’.41 This mechanism has
been linked to negative affective bias in anxiety disorder.42,43
Consistent with our ﬁndings, serotonin depletion has been shown
to increase mPFC activity and functional connectivity between the
mPFC and the amygdala in response to fearful stimuli.44
The use of psychedelics as an additive in psychotherapy has
recently been rediscovered10,12,45 and our result is relevant for this
ﬁeld of research. Processing biases towards negative stimuli are a
feature of several mental diseases, such as depression and social
anxiety disorder, and are associated with increased reactivity of
the amygdala.46,47 Resolving this processing bias might thus
reﬂect one important and potentially therapeutically useful effect
of psychedelic substances by, for example, facilitating the
therapeutic alliance48,49 and reducing perception of negative
emotions and social cognitive deﬁcits. As we have recently
reported, LSD also exhibits some ‘empathogenic’ effects (such as
increased openness and trust),2,20 which are usually ascribed to
substances like 3,4-methylenedioxymethamphetamine (MDMA).
The attenuated amygdala reactivity observed in this study is in
good accordance with those ﬁndings and possibly reﬂects a
neural basis for such effects, which might also be therapeutically
beneﬁcial.49,50 However, and in contrast to substances like
selective serotonin reuptake inhibitors, the positive long-term
effects of psychedelics reported by recent studies8–12,15,51 outlast
the acute pharmacological effects. It should be further investi-
gated how psychological and biological factors, like
neuroplasticity,52 contribute to these long-term effects.
Our study has several limitations. First, although the trial was
formally double-blinded, assignment to placebo or LSD was
unavoidably unblinded by the obvious psychedelic effects caused
by the dose used. Second, we did not include in our analyses
measures of negative affect. Third, we can only provide data about
one moderate dose. Higher doses of psychedelics are possibly
difﬁcult to use with fMRI, because they are more likely to induce
anxiety,45 although the overall effects are still described as positive in
the higher doses investigated.2,45 The observed anxiolytic effect
probably also depends on personal and environmental factors and
might thus be different in the mentally ill or in uncontrolled settings.
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Background: Lysergic acid diethylamide (LSD) is a widely used recreational drug. The 
aim of this study was to develop and validate a liquid chromatography tandem mass 
spectrometry (LC- MS/MS) method for the quantification of LSD, iso- LSD, 
2- oxo- 3- hydroxy LSD (O- H- LSD), and nor- LSD in plasma samples from 24 healthy 
subjects after controlled administration of 100 μg LSD in a clinical trial. In addition, 
metabolites that have been recently described in in vitro studies, including lysergic 
acid	monoethylamide	(LAE),	lysergic	acid	ethyl-	2-	hydroxyethylamide	(LEO),	2-	oxo-	LSD,	
trioxylated- LSD, and 13/14-hydroxy-LSD, should be identified.
Methods: Separation of LSD and its metabolites was achieved on a reversed phase 
chromatography column after turbulent- flow online extraction. For the identification 
and quantification, a triple- stage quadrupole LC- MS/MS instrument was used.
Results: The validation data showed slight matrix effects for LSD, iso- LSD, O- H- LSD, 
or nor- LSD. Mean intraday and interday accuracy and precision were 105%/4.81% and 
105%/4.35% for LSD, 98.7%/5.75% and 99.4%/7.21% for iso- LSD, 106%/4.54% and 
99.4%/7.21% for O- H- LSD, and 107%/5.82% and 102%/5.88% for nor- LSD, respec-
tively. The limit of quantification was 0.05 ng/mL for LSD, iso- LSD, and nor- LSD and 
0.1 ng/mL for O- H- LSD. The limit of detection was 0.01 ng/mL for all compounds.
Conclusion: The method described herein was accurate, precise, and the calibration 
range within the range of expected plasma concentrations. LSD was quantified in the 
plasma samples of the 24 subjects of the clinical trial, whereas iso- LSD, O- H- LSD, 
	nor-	LSD,	LAE,	LEO,	13/14-hydroxy-LSD,	and	2-oxo-LSD	could	only	sporadically	be	
 detected but were too low for quantification.
K E Y W O R D S
controlled study, LC-MS, LSD, lysergic acid diethylamide, metabolism, plasma
1  | INTRODUCTION
Lysergic acid diethylamide (LSD) is a psychoactive substance that al-
ters states of consciousness and perception. Its psychedelic effects 
made it popular as a recreational drug, especially in the 1960s and 
1970s, but LSD is still widely used today.1 In addition, LSD has been 
reintroduced in psychiatric research2-16 and investigated as an adjunct 
to psychotherapy.17,18 Therefore, information about its metabolism 
and pharmacokinetics after controlled intake has received increasing 
interest. Doses that were used in recent clinical studies ranged from 
75 μg, i.v.,2-11 to 200 μg, p.o.,12-15,19 resulting in low blood and urine 
concentrations.12,20 Dolder et al. and Steuer et al. recently showed 
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that LSD and its main urinary metabolite 2- oxo- 3- hydroxy- LSD 
 (O- H- LSD) were detectable in plasma after controlled intake of 200 μg 
LSD in 16 healthy subjects12,20 and clinical toxicological cases of acute 
LSD overdose.21 Studies of in vitro metabolism have further identi-
fied	 lysergic	 acid	 monoethylamide	 (LAE),	 lysergic	 acid	 ethyl-2-hy-
droxyethylamide (LEO), 2- oxo- LSD, nor- LSD, trioxylated- LSD, and 
13/14-hydroxy-LSD as glucuronides,22,23 but no systematic infor-
mation is available regarding their presence in human plasma after 
controlled intake of LSD. However, recent investigations confirmed 
the presence of 2- oxo- LSD and 13/14-hydroxy-LSD (glucuronides) 
in plasma samples after controlled intake of 200 μg LSD.20 The aim 
of this study was to develop a sensitive turboflow liquid chromatog-
raphy tandem mass spectrometry (LC- MS/MS) method to quantify 
LSD,	 iso-	LSD,	 O-	H-	LSD,	 and	 nor-	LSD	 and	 potentially	 identify	 LAE,	
LEO, 2- oxo- LSD, trioxylated- LSD, and 13/14-hydroxy-LSD (glucuro-
nides) in human plasma samples. The method was developed using 
a triple- stage quadrupole LC- MS/MS instrument in selected reaction 
monitoring	(SRM)	mode	after	atmospheric	pressure	ionization	(APCI).	
Our method was established and successfully applied to the analysis 
of plasma samples from healthy volunteers after the intake of 100 μg 
LSD in a controlled clinical study.
2  | MATERIALS AND METHODS
2.1 | Chemicals and reagents
Acetonitrile,	 acetone,	methanol,	 2-	propanol,	 formic	 acid,	 and	 acetic	
acid with high- performance liquid chromatography (HPLC)- grade 
purity were all purchased from Merck (Darmstadt, Germany). HPLC- 
grade ammonium acetate and ammonium carbonate were obtained 
from Merck. Distilled water was obtained from an in- house installed 
purifier	 (ELGA,	 Bucks,	 UK).	 Drug-	free	 plasma	 samples	 (contain-
ing lithium- heparin as an anticoagulant) serving as negative control, 
and blank matrices were obtained from coworkers. LSD and LSD- d3 
as 1 mg/mL reference standards in acetonitrile were obtained from 
Lipomed	 (Arlesheim,	Switzerland).	O-	H-	LSD	and	 iso-	LSD	as	0.1	mg/
mL reference standards in acetonitrile were obtained from Cerilliant 
(Round	 Rock,	 TX,	 USA).	 Nor-	LSD	 in	 powder	 form	 was	 obtained	
from Toronto Research Chemicals (Toronto, Canada). The non- 
commercially	available	metabolites	LAE,	LEO,	2-	oxo-	LSD,	trioxylated-	
LSD, and 13/14-hydroxy-LSD (glucuronides) were extracted from 
pooled 24- h urine samples as described in Results section.
2.2 | LC- MS/MS analysis
2.2.1 | Equipment
The HPLC system (Transcend TLX1 HPLC; Thermo Scientific, Basel, 
Switzerland)	 consisted	 of	 two	 Accela	 1250	 pumps	 for	 loading	 and	
eluting. The autosampler and sample extraction system were con-
trolled	by	the	Aria	MX	2.1	software	(Thermo	Scientific).	A	cyclone	P	
turboflow column (Thermo Scientific) was used for extraction, and a 
Zorbax	Eclipse	XDB-	C8	column	 (Agilent,	Santa	Clara,	CA,	USA)	was	
used for chromatographic separation. The online extraction system 
was coupled to a TSQ Endura triple- stage mass spectrometer (Thermo 
Scientific)	using	APCI	 in	positive	mode	because	of	 its	better	perfor-
mance with regard to matrix effects.24,25
2.2.2 | Liquid chromatography method
For LC, three mobile phases were used in gradient mode for extrac-
tion	 and	 analytical	 chromatography.	 Mobile	 phase	 A	 consisted	 of	
20 mmol/L ammonium acetate in water and 0.1% formic acid. Mobile 
phase B consisted of 20 mmol/L ammonium acetate in methanol 
and acetonitrile (1:1) that contained 0.1% formic acid. Mobile phase 
C was an organic mixture of acetonitrile, acetone, and 2- propanol 
(1:1:1). Chromatography was run in isocratic mode with 70% mobile 
phase	A	and	30%	mobile	phase	B,	with	a	run	time	of	11	minutes	and	
four additional minutes for flushing and equilibration using mobile 
phase C.
2.2.3 | Mass spectrometry conditions
The positive ion discharge current was set to 5 μA.	 The	 vaporizer	
temperature was optimized to 400°C. Sheath and auxiliary gas pro-
vided the best results, with flow rates of 15 and 5 arbitrary units, 
respectively. The temperature of the ion transfer tube was set to 
300°C. The system was tuned and optimized for the detection of LSD. 
LSD and its metabolites were detected using SRM of the two to three 
most	 intense	 ion	transitions.	Analytes	were	 identified	when	quanti-
fier and qualifier ions were present within the given retention time. 
Structures, transitions, and respective collision energies are shown in 
Figure 1.
2.3 | Standard solutions
Stock solutions that contained 100 μg/mL LSD, 100 μg/mL LSD- d3, 
10 μg/mL iso- LSD, 10 μg/mL O- H- LSD, or 10 μg/mL nor- LSD in ace-
tonitrile were prepared and stored in light- protected brown glass vials 
at	−20°C.	All	of	the	solutions	were	prepared	in	duplicate	to	have	dif-
ferent sets for quality control (QC) and calibration samples. Working 
solutions of each analyte at 0.1 μg/mL in purified water/acetonitrile 
were used for the preparation of QC and calibration samples and ma-
trix and selectivity experiments. Because of the instability of LSD and 
to minimize possible degradation by various freeze- thaw cycles, 1 mL 
aliquots of stock and working solutions were prepared.
2.4 | Sample preparation
Study samples were sorted according to drug condition (LSD or pla-
cebo) and subject (S1- 24). Calibrators, controls and subject samples 
were thawed once, and 100 μL aliquots was taken to minimize the 
freeze- thaw cycles. To 100 μL of plasma, 110 μL of an acetonitrile/
LSD- d3 solution (0.01 μg/mL) was added. The samples were then vig-
orously vortexed and centrifuged for 10 minutes at 13 200 g, and the 
supernatant was then transferred to 96- well plates.
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2.5 | Experiments
2.5.1 | Calibration
Six calibration standards were prepared by spiking plasma samples 
with LSD, iso- LSD, and nor- LSD to concentrations of 0.05, 0.1, 0.5, 
1, 5, and 10 ng/mL plus blank (matrix only) and zero sample (ma-
trix plus internal standard). Five calibrators were used for O- H- LSD 
with concentrations of 0.05, 0.1, 0.5, 1, 5, and 10 ng/mL plus blank 
(matrix only) and zero sample (matrix plus internal standard). The 
highest calibration point in plasma was adopted from our previ-
ously developed method and pharmacokinetic- pharmacodynamic 
data.12,21 The calibration curves were linearly fitted using a weight-
ing factor of 1/x2.
2.5.2 | Selectivity
Following	U.S.	 Food	 and	Drug	Administration	 validation	 guidelines,26 
we collected plasma samples from six different healthy volunteers 
and tested them for interference to establish selectivity. We further 
analyzed samples from the placebo condition to confirm the absence 
of LSD.
2.5.3 | Matrix effects and recovery
Matrix effects, recovery, and process efficiency were measured and 
calculated according to Matuszewski et al.27 In regard of the vulner-
ability to light and air and because of the online extraction that was 
used in the present method, the extraction step comprised only pro-
tein	precipitation.	All	 of	 the	 samples	were	processed	 through	 the	
turbulent- flow extraction column. Five plasma samples were spiked 
to concentrations between 0.05 and 10 ng/mL for LSD, iso- LSD, 
O- H- LSD, and nor- LSD. The samples were measured before and 
after extraction and in neat solution. The peak areas of the spiked 
samples after extraction were then compared with the area of the 
spiked mobile phase to calculate matrix effects. Recovery values 
were calculated as the areas of standards that were spiked before 
extraction divided by the areas of standards that were spiked after 
extraction. The process efficiency was adopted from Matuszewski 
et al.27 and calculated as the ratio between the area of the stand-
ard spiked before extraction and the areas of the standard in neat 
solution.
2.5.4 | Stability
The determination of long- term stability was based on Li et al. and 
Klette et al., in which LSD is regarded as stable under storage condi-
tions	of	−20°C.28,29 However, LSD is known to be very unstable and 
vulnerable to air, light, and heat. Even ambient temperature (20- 25°C) 
and normal light conditions can lead to a decrease in LSD concentra-
tions. Therefore, we assessed bench- top stability and autosampler 
stability with multiple measurements of calibration and QC samples 
within 24 h. For autosampler stability, the samples were kept in light- 
protected, sealed, 96- well deep- well plates at 4°C in the autosampler 
until injection. During the study, the samples were drawn through 
an intravenous catheter into lithium- heparin tubes and directly 
F IGURE  1 Structure, retention time, ion transitions, and collision energies of lysergic acid diethylamide (LSD) and selected metabolites
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F IGURE  2  (A)	Chromatogram	of	selected	metabolites.	Lysergic	acid	diethylamide	(LSD),	iso-	LSD,	nor-	LSD,	and	2-	oxo-	3-	hydroxy-	LSD	are	
spiked at 1 ng/mL in plasma; the concentration of lysergic- acid monoethylamide, lysergic- acid- ethyl- 2- hydroxyethylamide, 13/14-hydroxy-LSD, 
and 2- oxo- LSD is unknown. (B) Chromatogram of a healthy volunteer 4 h after administration of 100 μg	LSD.	Arrows	are	indicating	peaks	of	
LSD (1), iso- LSD (2), nor- LSD (3) and 2- oxo- 3- hydroxy- LSD (4), lysergic- acid monoethylamide (5), lysergic- acid- ethyl- 2- hydroxyethylamide (6), 
13/14-hydroxy-LSD (7), and 2- oxo- LSD (8)
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centrifuged,	 and	 the	plasma	was	 stored	 at	 −20°C	 at	 the	 study	 site	
before transferring to the laboratory for analysis. Due to the known 
vulnerability of LSD, calibrators and quality controls were freshly 
weighted	 every	week	 and	 single	 aliquots	were	 stored	 at	 −20°C.	 A	
new calibration was run every day and with every study subject.
2.5.5 | Lower limits of detection and quantification
Drug- free plasma samples were spiked with different concentrations 
of LSD, iso- LSD, O- H- LSD, and nor- LSD for determination of the limit 
of quantification (LOQ) and the limit of detection (LOD). The LOQ con-
centrations had to give a response at least five times greater than the 
blank. In addition, precision had to be <20%, and accuracy had to be 
80%- 120% using at least five determinations per matrix and concen-
tration. The LOD concentration was determined as the lowest discrim-
inable peak in the region of a signal- to- noise ratio greater than five.
2.5.6 | Carryover
For the determination of the carryover, different blank plasma sam-
ples were run between patient samples, highest calibrations, and qual-
ity controls.
2.5.7 | Reproducibility
According	 to	 U.S.	 Food	 and	 Drug	 Administration	 guidelines,26 the 
reproducibility of quantification was determined by measuring each 
QC sample five times in 1 day to establish intraday precision and ac-
curacy. Each QC sample was also measured for five consecutive days 
to	determine	 interday	precision	and	accuracy.	All	of	 the	values	had	
to meet the criteria of a coefficient of variation (CV) <15%, response 
<20% at the LOQ, and accuracy of 80%- 120%. To demonstrate the 
accuracy and precision of the method, we used three QCs (low, me-
dium, and high). The QC concentrations were 0.05, 1, and 10 ng/mL 
for LSD, iso- LSD, and nor- LSD, and 0.1, 1, and 10 ng/mL for O- H- LSD, 
respectively.
3  | RESULTS
Lysergic acid diethylamide, LSD- d3, iso- LSD, and the metabolites 
nor-	LSD,	LAE,	LEO,	2-	oxo-	LSD,	trioxylated-	LSD,	and	13/14-hydroxy-
LSD (glucuronides) eluted between 4 and 11 minutes. The chroma-
tographic separation of spiked samples and selected metabolites is 
depicted	 in	Figure	2A,	 and	 the	 chromatogram	of	 a	 subject’s	 sample	
4 h after LSD administration is presented in Figure 2B.
3.1 | Selectivity
None of the six plasma samples showed any interference within the 
measured mass range and time frame (Figure 3). Furthermore, none 
of the measured plasma samples from the placebo condition showed 
any interference.
3.2 | Matrix effects and recovery
The plasma matrix effects were 125% for LSD, 119% for iso- LSD, 
103% for O- H- LSD, and 118% for nor- LSD at concentrations of 
10 ng/mL, consistent with a slight ion enhancement for LSD, iso- LSD, 
and nor- LSD. Recoveries were calculated as 70%- 90% for all sub-
stances at 10 ng/mL. Process efficiencies were 113% for LSD, 86% 
for iso- LSD, 77% for O- H- LSD, and 93% for nor- LSD.
3.3 | Stability
The concentrations of the processed samples decreased up to 
−60%	 within	 24	hours	 at	 ambient	 temperature	 (20-	23°C).	 The	
concentrations of the extracted and sealed plasma samples that 
F IGURE  3 Chromatogram of 6 blank plasma samples from six different subjects, and a blank sample containing lysergic acid diethylamide- d3
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were stored within the closed autosampler at 4°C were stable up 
to 24 hours.
3.4 | Lower limits of detection and quantification
The LOQ was 0.05 ng/mL for LSD, iso- LSD, and nor- LSD. For O- H- 
LSD, the respective concentration was 0.1 ng/mL. The LODs were 
0.01 ng/mL for all compounds.
3.5 | Carryover
No carryover was found for LSD, iso- LSD, O- H- LSD, or nor- LSD in 
the plasma samples. Despite these results as a preventive measure, a 
consecutive blank was always run after the highest calibrator (10 ng/
mL) and QC (10 ng/mL) during method development and the meas-
urement of the study samples.
3.6 | Linearity
Calibration curves in plasma were linear over the respective calibra-
tion ranges, with a mean correlation coefficient (R2) of 0.99. The cali-
bration curves (mean ± SEM) are shown in Figure 4.
3.7 | Reproducibility
All	of	the	substances	fulfilled	the	accuracy	and	precision	criteria.	The	
mean intraday accuracy and precision were 105% and 4.81% for LSD, 
98.7% and 5.75% for iso- LSD, 106% and 4.54% for O- H- LSD, and 
107% and 5.82% for nor- LSD, respectively. The mean interday accu-
racy and precision were 105% and 4.35% for LSD, 99.4% and 7.21% 
for iso- LSD, 99.4% and 7.21% for O- H- LSD, and 102% and 5.88% for 
nor- LSD, respectively.
3.8 | Identification of non- commercially available 
LSD metabolites
Lysergic acid diethylamide metabolites were extracted by liquid- liquid 
extraction from pooled LSD- positive 24- h urine samples (8 L) to reach 
high concentrations. One part of the concentrated metabolites was 
kept for eventual quantification, and the second part was extracted 
using industrial separation by automated thin- layer chromatography 
and purification. Separation was performed with generous support 
from Camag (Muttenz, Switzerland). Parent masses and selected tran-
sitions for LC- MS were adopted from Cai et al.22 and Canezin et al.23 
and replicated by injecting a mixture of the concentrated, extracted 
F IGURE  4 Calibration curves of lysergic acid diethylamide (LSD), iso- LSD, nor- LSD, and 2- oxo- 3- hydroxy- LSD in human plasma
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metabolites.	All	of	the	identified	metabolites	from	concentrated	urine	
samples	(LAE,	LEO,	2-	oxo-	LSD,	trioxylated-	LSD,	and	13/14-hydroxy-
LSD) were added to the quantification method before validation, for 
qualitative screening of the study samples.
3.9 | Samples
LSD (100 μg) and placebo were administered to 24 healthy  subjects 
(12 women, 12 men) in a double- blind, randomized, placebo- 
controlled, cross- over study. The study was conducted in  accordance 
with the Declaration of Helsinki and International Conference on 
Harmonization Guidelines in Good Clinical Practice (ICH- GCP) and 
approved by the Ethics Committee Northwest Switzerland and 
Swiss Federal Office for Public Health, Bern, Switzerland. The study 
was registered at ClinicalTrials.gov (NCT02308969). Plasma sam-
ples were collected at baseline and 1, 2, 3, 4, 6, 8, 10, 12, 16, and 
24 h after LSD  administration. Maximum LSD plasma concentra-
tions of 1.3 ± 0.17 ng/mL (mean ± SEM) were determined (Table 
1). Nor- LSD could only be quantified in two subjects (3 and 4 hours 
post-	administration),	and	LAE,	LEO,	2-	oxy	LSD,	and	13/14-hydroxy-
LSD were detected in some of the samples. 13/14-hydroxy-LSD 
glucuronides were undetectable because they were cleaved dur-
ing ionization. Detailed study descriptions, pharmacokinetic data, 
and pharmacokinetic- pharmacodynamic analyses will be published 
elsewhere.
4  | DISCUSSION AND CONCLUSION
With mean maximum plasma concentrations of LSD of ~1 ng/mL, the 
development of analytical methods for quantification remains a chal-
lenge and brings LC- MS technologies to their limits. For separation 
of the different analytes, various columns have been used. Especially, 
the separation of LSD and iso- LSD was challenging, and only achieved 
using the Zorbax Eclipse XDB- C8 column. However, the method 
was only developed to chromatographically separate LSD, iso- LSD, 
nor- LSD, and O- H- LSD. The non- commercially available metabolites 
were not available in sufficient amounts for extensive experiments. 
Further, to improve sensitivity, different sample preparation proce-
dures (eg, liquid- liquid extraction using chlorobutane and tert- butyl- 
methylether) have been performed but have not led to significant 
changes in the LOQ. Considering the light and air sensitivity of LSD 
and the manual workload that is caused by liquid- liquid extraction or 
solid- phase extraction, simple and fast protein precipitation has been 
favored	instead.	APCI	was	equally	to	ESI	regarding	signal	intensity	but	
gave slightly better results regarding matrix effects and was there-
fore favored. Overall, quantifying plasma samples between 12 and 
24 hours after LSD administration requires techniques that provide 
precise and sensitive measurements within the low picogram range. 
This poses a challenge to quantifying LSD concentrations and also 
makes it impossible to quantify or even identify new metabolites in 
plasma samples after controlled intake of 100 μg LSD. In our recent 
investigations,12 we detected quantifiable plasma levels of O- H- LSD T
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after the administration of 200 μg LSD. Steuer et al.20 additionally 
identified O- H- LSD and 13/14-hydroxy-LSD (glucuronides). We did 
not expect to detect quantifiable concentrations of LSD metabo-
lites after the administration of 100 μg LSD. The metabolites did not 
reach the LOD of our or other methods. Nevertheless, we sporadi-
cally detected the presence of metabolites in some plasma samples 
and	could	confirm	the	presence	of	O-	H-	LSD,	nor-	LSD,	LEO,	LAE,	and	
13/14-hydroxy-LSD in plasma. To investigate the metabolism of LSD 
more comprehensively, further studies that use higher doses of LSD 
are required and metabolites need to be commercially available to de-
velop comprehensive analytical methods for their quantification.
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Abstract
Background and Objective Lysergic acid diethylamide
(LSD) is used recreationally and in clinical research. The
aim of the present study was to characterize the pharma-
cokinetics and exposure–response relationship of oral LSD.
Methods We analyzed pharmacokinetic data from two
published placebo-controlled, double-blind, cross-over
studies using oral administration of LSD 100 and 200 lg in
24 and 16 subjects, respectively. The pharmacokinetics of
the 100-lg dose is shown for the first time and data for the
200-lg dose were reanalyzed and included. Plasma con-
centrations of LSD, subjective effects, and vital signs were
repeatedly assessed. Pharmacokinetic parameters were
determined using compartmental modeling. Concentration-
effect relationships were described using pharmacokinetic-
pharmacodynamic modeling.
Results Geometric mean (95% confidence interval) maxi-
mum plasma concentration values of 1.3 (1.2–1.9) and 3.1
(2.6–4.0) ng/mL were reached 1.4 and 1.5 h after admin-
istration of 100 and 200 lg LSD, respectively. The plasma
half-life was 2.6 h (2.2–3.4 h). The subjective effects las-
ted (mean ± standard deviation) 8.2 ± 2.1 and
11.6 ± 1.7 h for the 100- and 200-lg LSD doses, respec-
tively. Subjective peak effects were reached 2.8 and 2.5 h
after administration of LSD 100 and 200 lg, respectively.
A close relationship was observed between the LSD con-
centration and subjective response within subjects, with
moderate counterclockwise hysteresis. Half-maximal
effective concentration values were in the range of 1 ng/
mL. No correlations were found between plasma LSD
concentrations and the effects of LSD across subjects at or
near maximum plasma concentration and within dose
groups.
Conclusions The present pharmacokinetic data are
important for the evaluation of clinical study findings (e.g.,
functional magnetic resonance imaging studies) and the
interpretation of LSD intoxication. Oral LSD presented
dose-proportional pharmacokinetics and first-order elimi-
nation up to 12 h. The effects of LSD were related to
changes in plasma concentrations over time, with no evi-
dence of acute tolerance.
Trial registration: NCT02308969, NCT01878942.
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Key Points
The pharmacokinetics of lysergic acid diethylamide
was dose proportional and the subjective effects
were related to the time course of plasma
concentrations within subjects, with no evidence of
acute tolerance.
Between-subject differences in plasma
concentrations of lysergic acid diethylamide did not
predict the subjective response within a dose group
and when plasma concentrations were above the
half-maximal effective concentration of the response
measures.
1 Introduction
Lysergic acid diethylamide (LSD) is the prototypical hal-
lucinogen [1, 2]. Lysergic acid diethylamide has seen
worldwide interest with regard to pharmacology, psychia-
try, and society at large. Lysergic acid diethylamide con-
tinues to be used for recreational and personal purposes [3].
Additionally, considerable interest has been seen in its
therapeutic potential [4–9], and experimental clinical
research with LSD has recently been reinitiated [10–23].
However, basic pharmacokinetic information on LSD is
largely missing. A small study in five male subjects
reported a mean plasma elimination half-life of LSD of
175 min after intravenous administration (2 lg/kg) [24].
Another non-systematic study sampled blood after admin-
istration of LSD 160 lg in 13 subjects up to 2.5–5 h but
because of sparse and short sampling could not derive
pharmacokinetic parameters [25]. We recently reported the
first pharmacokinetic data for orally administered LSD
(200 lg) in 16 male and female subjects [23]. The con-
centrations of LSD were maximal after 1.5 h (median) and
gradually declined to very low levels by 12 h, with an
elimination half-life of 3.6 h [23].
Recent studies have reported the effects of LSD on
various neuronal correlates of brain activation
[12, 13, 16, 17]. However, plasma exposure and thus the
actual presence of LSD in the body have not been docu-
mented in any of these studies to date. Unknown are the
time point at which peak concentrations are reached and
the actual or predicted concentrations of LSD at the time
point at which pharmacodynamic outcomes were collected.
Therefore, the primary goal of the present study was to
describe the pharmacokinetics of a controlled administra-
tion of oral LSD by assessing the plasma concentration-
time profile of two doses of LSD (100 and 200 lg). A
second goal was to link the plasma concentration changes
over time within subjects to the acute subjective and
autonomic effects of LSD to derive half-maximal effective
concentration (EC50) values using standard pharmacoki-
netic-pharmacodynamic modeling.
Researchers have correlated subjective drug effects with
brain functional magnetic resonance imaging (fMRI) data
[12, 13, 16, 17]. This approach likely detects significant
correlations for subjective effects that show large between-
subject variance but not for subjective effects of the sub-
stance that are consistently present in all subjects. Plasma
concentrations of LSD have not been determined in any of
the published LSD fMRI studies to date; therefore, it is
unclear how LSD exposure in the body is linked to sub-
jective effects in these studies. Therefore, a further goal of
the present study was to assess associations across subjects
between plasma exposure to LSD and the pharmacody-
namic effects at corresponding times.
The present study combined data from two similar
clinical studies that tested 100- and 200-lg doses of LSD in
24 and 16 healthy subjects, respectively. The pharma-
cokinetic data and concentration–effect relationship of
100 lg LSD are presented. Similar data on 200 lg LSD
have been previously reported [23]. In the present study,
plasma concentrations after 200 lg LSD administration
were newly measured using a more sensitive and specific
analytical method. The results were included for compar-
isons with the 100-lg data and to newly evaluate
dose/concentration–response effects. The subjective effects
of LSD have been reported for both doses, but relationships
to plasma exposure were not evaluated [21].
2 Methods
2.1 Study Design
We performed the pharmacokinetic data analysis on two
similar previously performed studies [21–23] using double-
blind, placebo-controlled, cross-over designs with two
experimental test sessions (LSD and placebo) in a balanced
order. Study 1 used a dose of LSD 100 lg and placebo in
24 subjects. Study 2 used LSD 200 lg and placebo in 16
subjects. The washout periods between sessions were at
least 7 days. The studies were registered at ClinicalTri-
als.gov (NCT02308969, NCT01878942).
2.2 Participants
Forty healthy participants were recruited from the
University of Basel campus via an online advertisement.
Twenty-four subjects [12 men, 12 women; age
33 ± 11 years (mean ± standard deviation); range
P. C. Dolder et al.
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25–60 years; body weight: 68 ± 8 kg, 55–85 kg) partici-
pated in Study 1 (100 lg), and 16 subjects (eight men,
eight women; age 29 ± 6 years; range 25–51 years; body
weight: 72 ± 12 kg, 52–98 kg) participated in Study 2
(200 lg). The inclusion and exclusion criteria were iden-
tical for both studies. The exclusion criteria were
age\25 years or[65 years, pregnancy (urine pregnancy
test at screening and before each test session), personal or
family (first-degree relative) history of major psychiatric
disorders (assessed by the semi-structured clinical inter-
view for Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, Axis I disorders by the study
physician and an additional interview by a trained psy-
chiatrist), use of medications that may interfere with the
study drug, chronic or acute physical illness (abnormal
physical examination, electrocardiogram, or hematological
and chemical blood analyses), tobacco smoking (more than
ten cigarettes/day), lifetime prevalence of illicit drug use
more than ten times (except for tetrahydrocannabinol),
illicit drug use within the previous 2 months, and illicit drug
use during the study. We performed urine drug tests at
screening and before each test session, and no substances
were detected during the study. The subjects were asked to
abstain from excessive alcohol consumption between test
sessions and particularly limit their use to one standard drink
on the day before the test sessions. Additionally, the par-
ticipants were not allowed to drink xanthine-containing
liquids after midnight before the study day. The participants
did not regularly use medications that could potentially
interact with the study drug. No other medications aside
from LSD were used during the study sessions. Eleven
subjects had previously used a hallucinogen, including LSD
(six participants), one to three times during their lives, and
most of the subjects (29) were hallucinogen naive.
2.3 Study Procedures
Each study included a screening visit, a psychiatric inter-
view, two 25-h experimental sessions, and an end-of-study
visit. The experimental sessions were conducted in a quiet
standard hospital patient room. The participants were resting
in hospital beds except when going to the restroom. Only one
research subject and one investigator were present during
the experimental sessions. The participants could interact
with the investigator, rest quietly, and/or listen to music via
headphones, but no other entertainment was provided. LSD
or placebo was administered at 9:00 A.M. A standardized
lunch and dinner was served at 1:30 P.M. and 5.30 P.M.,
respectively. The subjects were never alone during the first
12 h after drug administration, and the investigator was in a
room next to the subject for up to 24 h while the subject was
asleep (mostly from 1:00 A.M. to 8:00 A.M.).
2.4 Study Drug
Lysergic acid diethylamide (d-lysergic acid diethylamide
hydrate, high-performance liquid chromatography pur-
ity[99%; Lipomed AG, Arlesheim, Switzerland) was
administered in a single oral dose of 100 or 200 lg as a
capsule (Bichsel Laboratories, Interlaken, Switzerland).
Both doses were within the range of doses that are taken for
recreational purposes [1]. The 200-lg dose (the same
capsules) was also used in LSD-assisted psychotherapy in
patients [6], and intravenous doses of 75–100 lg have been
used in fMRI studies in healthy subjects [13].
2.5 Measures
2.5.1 Blood Sampling
Blood was collected into lithium heparin tubes before and
0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD
administration. The 0.5-, 1.5-, and 2.5-h samples were not
collected in Study 1 (100 lg). The blood samples were
immediately centrifuged, and the plasma was rapidly stored
at -20 C and later at -80 C until analysis within
12 months. Long-term stability has been shown for LSD
when kept under refrigerated or frozen conditions [26, 27].
Samples were thawed for the first time for both analyses,
this was also the case for study 2 (200 lg) because separate
sets of samples were stored and used for the present [28]
and previous [29] analyses.
2.5.2 Analysis of Lysergic Acid Diethylamide
Concentrations
Lysergic acid diethylamide concentrations in plasma were
determined using sensitive and validated liquid chro-
matography-tandem mass spectrometry methods as repor-
ted in detail elsewhere [28, 29]. The lower limit of
quantification was 0.05 ng/mL in Study 1 (100 lg) [29]
and 0.01 ng/mL in Study 2 (200 lg) [28].
2.5.3 Subjective Mood
Visual analog scales (VASs) were repeatedly used to assess
subjective effects over time [21, 22]. The VASs included
separate measures for ‘‘any drug effect,’’ ‘‘good drug
effect,’’ and ‘‘bad drug effect’’ and were presented as
100-mm horizontal lines (0–100%) marked from ‘‘not at
all’’ on the left to ‘‘extremely’’ on the right. The VASs
were administered 1 h before and 0, 0.5, 1, 1.5, 2, 2.5, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 16, and 24 h after drug adminis-
tration. The 0.5- and 2.5-h ratings were not collected in
Study 1 (100 lg).
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2.5.4 Vital Signs
Blood pressure, heart rate, and body temperature were
assessed repeatedly 1 h before and 0, 0.5, 1, 1.5, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, and 24 h after drug administration.
Diastolic and systolic blood pressure and heart rate were
measured using an automatic oscillometric device
(OMRON Healthcare Europe NA, Hoofddorp, Nether-
lands). The measurements were performed in duplicate at
an interval of 1 min and after a resting time of at least
10 min. The averages were calculated for analysis. Core
(tympanic) temperature was measured using a GENIUSTM
2 ear thermometer (Tyco Healthcare Group LP, Water-
town, NY, USA). The 0.5- and 2.5-h measures were not
collected in Study 1 (100 lg).
2.6 Pharmacokinetic Analyses
and Pharmacokinetic-Pharmacodynamic
Modeling
All of the analyses were performed using Phoenix
WinNonlin 6.4 (Certara, Princeton, NJ, USA). Pharma-
cokinetic parameters were estimated using compartmental
modeling. A one-compartment model was used with first-
order input, first-order elimination, and no lag time. Initial
estimates for apparent volume of distribution and k were
derived from non-compartmental analyses.
The model fit was not relevantly improved by a two-
compartment model based on visual inspection of the plots.
The one-compartment model showed better Akaike infor-
mation criterion values in all subjects than a two-com-
partment model. The pharmacokinetic model was first
fitted and evaluated. The predicted concentrations were
then used as inputs to the pharmacodynamic model, treat-
ing the pharmacokinetic parameters as fixed and using the
classic pharmacokinetic/pharmacodynamic link model
module in WinNonlin. The model uses a first-order equi-
librium rate constant (keo) that related the observed phar-
macodynamic effects of LSD to the estimated LSD
concentrations at the effect site (Fig. S1) and accounts for
the lag between the plasma- and effect-site concentration
curves [30]. Initial estimates for keo values were obtained
using semi-compartmental modeling by collapsing the
hysteresis loop in the Ce vs. effect plots in WinNonlin. A
sigmoid maximum effect (Emax) model (EC50, Emax, c) was
selected for all pharmacodynamic effects. EC50 and Emax
estimates were taken from the pharmacokinetic-pharma-
codynamic plots. Lower and upper limits for Emax were set
to 0 and 100%, respectively, for all the VAS scores. Upper
limits for Emax for changes in heart rate, body temperature,
and diastolic and systolic blood pressure were set to
100/min, 2 C, 50 and 80 mm Hg, respectively. The sig-
moidal Emax model best described the relationship between
estimated effect-site concentrations and the effects of LSD
compared with a simple Emax model (plot inspection and
Akaike information criteria). Examples of diagnostic plots
are shown in Figs. S8 and S9.
2.7 Statistical Analyses
The LSD-induced subjective and autonomic effects were
determined as a difference from placebo in the same sub-
ject at the corresponding time point to control for circadian
changes and placebo effects [22]. The pharmacodynamic
effect changes after LSD administration for each time point
were plotted over time (effect-time curves) and against the
respective plasma concentrations of LSD and graphed as
concentration-effect curves. The onset, time to maximum
plasma concentration (Tmax), offset, and effect duration
were assessed for the model-predicted ‘‘any drug effect’’
VAS effect-time plots after LSD using a threshold of 10%
of the maximal possible effect of 100% using Phoenix
WinNonlin 6.4. Associations between concentrations and
effects were assessed using Pearson correlations, and
multiple regression analysis was used to exclude effects of
sex and body weight (Statistica 12 software; StatSoft,
Tulsa, OK, USA).
3 Results
3.1 Pharmacokinetics
The plasma concentration-time curves for the two LSD
doses are shown in Fig. 1a. The pharmacokinetic parame-
ters are shown in Table 1. In Study 1 (100 lg), LSD could
be quantified up to 8, 10, 12, 16, and 24 h in 24, 23, 22, 9,
and one subject, respectively. In Study 2 (200 lg), LSD
could be quantified up to 16 h in all 16 subjects and up to
cFig. 1 Pharmacokinetics and pharmacodynamics of lysergic acid
diethylamide (LSD). a LSD plasma concentration-time curves. The
corresponding semi-log plot is shown in Fig. S3. LSD effect-time
curves for Visual Analog Scale ratings (0–100%) of b ‘‘any drug
effect,’’ d ‘‘good drug effect,’’ and f ‘‘bad drug effect.’’ c, e, g In the
LSD concentration-effect plots (hysteresis curves), the subjective
effects of LSD showed moderate counterclockwise hysteresis,
indicating a relatively short delay in the effect of LSD relative to
the changes in plasma concentration over time. The plasma concen-
tration-effect site equilibration half-lives were in the range of
21–48 min according to the pharmacokinetic-pharmacodynamic link
model (Table 2). ‘‘Any drug effect’’ and ‘‘good drug effect’’ were
robustly and markedly increased in all subjects and paralleled the
changes in LSD concentration, whereas the mean ‘‘bad drug effect’’
increased only moderately after LSD owing to transient increases.
‘‘Bad drug effect’’ occurred mostly at the onset of the drug effect in
some subjects but also later in time in others. The data are expressed
as the mean ± standard error of the mean in 24 and 16 subjects after
administration of 100 and 200 lg LSD, respectively. The time of
sampling is noted next to each point. LSD was administered at t = 0
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24 h in 15 subjects (Fig. S2). Mean maximum plasma
concentration (Cmax) and area under the concentration-time
curve values were approximately twice as high for the
200-lg dose compared with the 100-lg dose. Dose-nor-
malized Cmax and area under the concentration-time curve
values were not statistically different between the dose
groups and the Tmax and plasma half-lives were also sim-
ilar, consistent with dose-proportional pharmacokinetics
(Table 1). Consistent with the fit of the one-compartment
model, inspection of the semi-logarithmic concentration-
time curves showed linear elimination kinetics for both
doses (Fig. S3) up to 12 h as previously reported for the
200-lg dose [23]. The individual-observed and model-
predicted LSD concentrations are shown in Fig. S2. Plasma
concentrations varied considerably between subjects,
especially at the lower 100-lg dose (Table 1; Fig. S2).
3.2 Pharmacodynamics
Lysergic acid diethylamide produced robust increases in
‘‘any drug effect’’ (Fig. 1b, Fig. S4) and ‘‘good drug
effect’’ (Fig. 1d, Fig. S5). Transient ‘‘bad drug effect’’ was
reported in some subjects, resulting in a moderate increase
in mean group ratings (Fig. 1f, Fig. S6). The corresponding
subjective peak effects have previously been reported and
were shown to be dose dependent [21]. ‘‘Any drug effect,’’
‘‘good drug effect,’’ and ‘‘bad drug effect’’ ratings for each
subject are shown in Figs. S4–6, respectively. After
administration of the 100-lg dose of LSD, the times of
onset and offset of the subjective response, assessed by the
‘‘any drug effect’’ VAS, were (mean ± standard deviation)
0.8 ± 0.4 h (range 0.1–1.7 h) and 9.0 ± 2.0 h (range
6.1–14.5 h), respectively. The mean effect duration was
8.2 ± 2.1 h (range 5–14 h). The time to peak drug effect
was 2.8 ± 0.8 h (range 1.2–4.6 h). After administration of
the 200-lg dose of LSD, the times of onset and offset of
the subjective response were 0.4 ± 0.3 h (range
0.04–1.2 h) and 11.6 ± 4.2 h (range 7.0–19.5 h), respec-
tively. The mean effect duration was 11.2 ± 4.2 h (range
6.4–19.3 h). The time to the subjective peak response was
2.5 ± 1.2 h (range 0.8–4.4 h). LSD increased diastolic and
systolic blood pressure, heart rate, and body temperature
compared with placebo to similar extents for both doses
(Fig. 2). The corresponding peak effect data and dose-re-
sponse statistics have been previously reported [21].
3.3 Pharmacokinetic-Pharmacodynamic Modeling
Figures 1 and 2 show the subjective, cardiovascular, and
thermogenic effects of LSD plotted against the plasma
concentration over time. A close relationship was found
between LSD concentrations and LSD effects over time.
Counterclockwise hysteresis was observed during the
assumed drug distribution phase (\2 h), especially for
body temperature (Fig. 2h). Model-predicted effects of
LSD on the VASs for ‘‘any drug effect,’’ ‘‘good drug
effect,’’ and ‘‘bad drug effect’’ are illustrated for each
subject in Figs. S4–6, respectively. Table 2 shows the
predicted concentrations of LSD at the effect site that
produced half-maximal effects (EC50 values). Mean EC50
Table 1 Pharmacokinetic parameters for LSD based on compartmental modeling
Dose N k01 (1/h) k (1/h) Vd (L) Cmax (ng/
mL)
tmax (h) t1/2 (h) AUC?
(ngh/mL)
CL/F (L/h)
100 lg 24 Geometric mean
(95% CI)
1.4
(1.2–4.1)
0.27
(0.24–0.31)
46
(35–76)
1.3
(1.2–1.9)
1.4
(1.3–2.1)
2.6
(2.4–3.0)
8.1
(7.5–11.1)
12.3
(7.8–24)
Range 0.31–9.9 0.17–0.50 24–270 0.3–3.7 0.4–3.2 1.4–4.2 1–19 5.2–103
200 lg 16 Geometric mean
(95% CI)
1.2
(0.68–4.6)
0.27
(0.22–0.35)
37
(32–46)
3.1
(2.6–4.0)
1.5
(1.3–2.4)
2.6
(2.2–3.4)
20.3
(17.3–26.2)
9.9
(8.3–12.8)
Range 0.27–10 0.12–0.59 18–66 1.9–7.1 0.4–3.8 1.2–5.6 11–39 5.1–18.5
AUC? area under the plasma concentration-time curve from time zero to infinity, Cmax estimated maximum plasma concentration, t1/2 estimated
plasma elimination half-life, tmax estimated time to reach Cmax, k01 first-order absorption coefficient, k first order elimination coefficient, Vd
volume of distribution
cFig. 2 Pharmacokinetics and autonomic effects in response to
lysergic acid diethylamide (LSD). The figure shows LSD effect-time
curves for a diastolic blood pressure, c systolic blood pressure, e heart
rate, and g changes in body temperature and corresponding b, d, f,
h LSD concentration-effect plots (hysteresis curves). The cardiovas-
cular stimulant effects of LSD at the higher 200-lg dose showed only
little counterclockwise hysteresis, indicating a short delay in the
effect of LSD relative to the changes in plasma concentration over
time and thus a close relationship between LSD concentration and
changes in cardiovascular effects over time within subjects. The
plasma concentration-effect site equilibration half-lives were in the
range of 13–34 min according to the pharmacokinetic-pharmacody-
namic link model (Table 2). In contrast, marked counterclockwise
hysteresis was observed in the LSD concentration-body temperature
change plot, indicating that the LSD-induced changes in body
temperature manifested themselves slowly and with a mean plasma
concentration-effect site equilibration half-life of 136 min for the
200-lg dose (Table 2). The data are expressed as the mean ± stan-
dard error of the meant in 24 and 16 subjects after administration of
LSD 100 and 200 lg, respectively. The pharmacodynamic values are
the mean ± standard error of the mean differences from placebo at
each time point. The time of sampling is noted next to each point.
LSD was administered at t = 0
P. C. Dolder et al.
84
Pharmacokinetics-Pharmacodynamics of LSD
85
values were in the range of 0.67–2.5 ng/mL and lower for
‘‘good drug effect’’ than for ‘‘bad drug effect’’ (Table 2).
‘‘Any drug effect’’ and ‘‘good drug effect’’ could be
modeled in all of the subjects, whereas no ‘‘bad drug
effect’’ (ratings \5% at any time point) was reported in
eight (33%) and five (31%) subjects after 100 and 200 lg,
respectively. Thus, the EC50 and keo values could not be
determined in these subjects. Similarly, vital signs did not
change sufficiently in a few subjects (one to three/outcome)
to determine these values.
The predicted Cmax of LSD did not correlate with the
predicted maximal response on the ‘‘any drug effect’’ VAS
when analyzed across subjects and separately for the two
dose groups (Rp = 0.38, p = 0.08, and Rp = 0, p = 0.9,
for the 100- and 200-lg doses, respectively). There was a
significant correlation in the pooled sample (Rp = 0.38,
p\ 0.05, n = 40, Fig. S7). The predicted area under the
concentration-time curve of LSD did not correlate with the
predicted area under the concentration-time curve for ‘‘any
drug effect’’, a measure of the overall pharmacodynamic
response (Rp = 0, p = 0.9, and Rp = 0.27, p = 0.4,
respectively). Additionally, there were generally no corre-
lations between plasma LSD concentrations and different
pharmacodynamic effects for matched time points across
subjects within dose groups (Table 3). A few correlations
were significant at the beginning (1 h) and end (8 and 12 h)
of the LSD effect. However, no significant associations
were found between plasma concentrations and effects
during the peak response to LSD (3–6 h). Multiple
regression analysis, including LSD concentration, body
weight, and sex, revealed no associations between the
effects of LSD and any of these possible predictors. Thus,
the plasma concentrations of LSD did not predict the
effects of LSD during the time it produced robust and
similar effects in all of the subjects (i.e., little between-
subject variability). In contrast, a close relationship was
found over time within subjects, as shown in the pharma-
cokinetic-pharmacodynamic analysis (Figs. 1, 2).
4 Discussion
The present study describes the pharmacokinetics and
concentration–effect relationship after oral administration
of LSD 100 lg. Additionally, the previously reported
pharmacokinetics and concentration–effect relationship for
the 200-lg dose of LSD [23] were reanalyzed and included
for comparison with the 100-lg dose. Compartmental
modeling predicted geometric mean peak plasma concen-
trations of 1.3 ng/mL, 1.4 h after administration of the
100-lg dose. Mean Cmax values of 3.1 ng/mL were reached
after 1.5 h after administration of the 200-lg dose. The
predicted mean half-lives of LSD were 2.6 h after both
doses. The plasma half-life in the present study was com-
parable to the value of 2.9 h after intravenous administra-
tion of 2 lg/kg of LSD [24] but shorter than the 3.6-h value
previously determined using non-compartmental analysis
[23]. Additionally, the plasma concentrations after admin-
istration of the 200-lg dose in the present study were lower
than those that were previously published in the same
research subjects [23]. This can be explained by the dif-
ferent analytical methods and modeling approach that were
Table 2 Pharmacodynamic parameter estimates (PK-PD link model)
Effect Dose EC50 (ng/mL) Emax (%) c keo (1/h) T1/2keo (min)
Any drug effect 100 lg 0.75 ± 0.4 95 ± 9 4.2 ± 1.2 1.8 ± 1.3 35 ± 23
200 lg 1.2 ± 0.7 97 ± 5 3.4 ± 1.5 3.4 ± 1.7 21 ± 17
Good drug effect 100 lg 0.71 ± 0.5 89 ± 15 3.9 ± 1.5 2.0 ± 1.6 39 ± 37
200 lg 0.94 ± 0.5 93 ± 9 3.2 ± 1.6 2.4 ± 1.8 32 ± 29
Bad drug effect 100 lg 1.5 ± 1.1 32 ± 37 4.7 ± 2.3 2.7 ± 2.2 42 ± 37
200 lg 2.5 ± 1.6 34 ± 35 3.2 ± 2.1 2.8 ± 2.0 48 ± 66
Heart rate increase 100 lg 0.67 ± 0.5 22 ± 25 3.7 ± 2.0 2.5 ± 1.9 46 ± 52
200 lg 1.9 ± 1.2 33 ± 28 2.7 ± 1.8 4.0 ± 2.0 13 ± 8
Body temperature increase 100 lg 0.75 ± 0.4 1.1 ± 0.6 2.2 ± 1.8 1.5 ± 1.6 107 ± 121
200 lg 1.8 ± 1.1 1.0 ± 0.6 3.6 ± 2.0 1.7 ± 1.9 136 ± 155
Diastolic blood pressure increase 100 lg 0.9 ± 0.6 23 ± 14 2.0 ± 1.6 2.6 ± 1.9 53 ± 70
200 lg 1.6 ± 0.9 18 ± 11 3.5 ± 1.6 3.4 ± 1.9 31 ± 42
Systolic blood pressure increase 100 lg 0.8 ± 0.5 30 ± 17 1.9 ± 1.6 2.6 ± 1.7 51 ± 78
200 lg 1.9 ± 1.4 30 ± 17 2.9 ± 1.9 3.2 ± 1.9 34 ± 41
Values are means ± standard deviations. T1/2keo = ln2/keo, calculated for each individual value
EC50 maximal effect predicted by the PK-PD link model, EC50 predicted drug concentration at effect site producing a half-maximal effect, c
sigmoid shape parameter, keo first-order rate constant for the equilibration process between plasma concentration and effect site (PK-PD model
link parameter), t1/2keo (min) plasma-effect-site equilibration half-life
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used in the present study, which predicts lower Cmax values
than the observed values. Overall, we observed linear dose
and elimination kinetics of LSD up to 12 h after drug
administration.
The present data on the plasma concentration-time
curves of LSD are important because many experimental
and therapeutic studies are currently being conducted or
have been published without this detailed information on
the presence of LSD in the human body. Specifically, the
effects of LSD on emotion processing after 100 and 200 lg
have been reported [23], but no pharmacokinetic data were
reported. Additionally, fMRI data were obtained in Study 1
(100 lg) in Basel and in an additional study in Zurich
(n = 22) that did not perform blood sampling. Doses of
100 lg were used in both studies. Thus, the present study
provides estimates of LSD concentrations in plasma over
time for these studies and the observed and predicted time
courses of the subjective and autonomic effects of LSD.
The 200-lg dose preparation of LSD has been used in
patients [5, 6], and the present phase I study provides the
pharmacokinetic data for these phase II studies.
In contrast, no data are currently available on the plasma
concentrations of LSD after intravenous administration of
75 lg of LSD base in saline [11], despite the publication of
extensive pharmacodynamic data using this preparation
and route of administration [10–19]. The intravenous 75-lg
dose of LSD produced comparably strong alterations in
consciousness to the 100-lg dose in the present study
[10, 31]. Additionally, the time-concentration curve for the
75-lg intravenous preparation remains unknown. Specifi-
cally, an intravenous bolus dose of LSD would be expected
to result in peak effects shortly after administration.
Indeed, early studies reported that intravenous adminis-
tration of LSD tartrate salt at a higher dose (2 lg/kg of
base) produced a rapid onset within seconds to minutes and
peak effects that occurred approximately 30 min after
administration [24, 32–34].
In the more recent studies that used the 75-lg dose
administered as the base, subjective drug effects reportedly
began within 5–15 min and peaked 45–90 min after
intravenous dosing, although further details were not
reported [13, 19]. Other hallucinogens with mechanisms of
action that are similar to those of LSD (e.g., serotonin
5-HT2A receptor stimulation [35]), such as dimetyl-
tryptamine or psilocybin, also produced subjective and
autonomic effects almost instantaneously and peak effects
within 2–5 min after intravenous administration [36–38].
In the present study, the mean effect onset and peak were
48 and 170 min, respectively, after oral administration of
LSD 100 lg. Thus, the effect began and peaked an average
Table 3 Correlations between plasma levels of LSD and its pharmacodynamic effects at the corresponding time points after administration
Effect 1 h 2 h 3 h 4 h 6 h 8 h 10 h 12 h
Any subjective drug effect 100 lg N = 24 0.17 0.13 -0.02 -0.04 -0.18 0.09 0.01 -0.03
200 lg N = 16 0.21 0.17 0.1 0.13 0.2 0.16 0.33 0.42
Both N = 40 0.36 0.35 0.19 0.04 0.06 0.41 0.46 0.49
Good drug effect 100 lg N = 24 0.6 0.3 0.23 0.15 -0.13 -0.2 -0.03 0.04
200 lg N = 16 0 -0.23 0.32 0.27 0.28 0.55 0.39 0.17
Both N = 40 0.39 0.34 0.36 0.31 0.24 0.42 0.35 0.23
Bad drug effect 100 lg N = 24 0.06 -0.11 -0.23 -0.1 -0.08 -0.03 0 -0.15
200 lg N = 16 0.34 -0.32 -0.27 0.07 0.2 0.35 -0.26 -0.16
Both N = 40 0.36 -0.16 0 0 0.1 0.29 0.05 0.07
Heart rate increase 100 lg N = 24 0.41 0.3 0.4 0.27 0.1 0.26 -0.4 0.027
200 lg N = 16 0.3 0.21 0.3 -0.06 -0.08 0.19 -0.16 -0.52
Both N = 40 0.44 0.41 0.33 0.08 -0.05 -0.02 0.03 -0.2
Body temperature increase 100 lg N = 24 0.12 -0.27 0.14 0.07 0.18 -0.06 -0.2 0.41
200 lg N = 16 0.09 -0.11 0.54 -0.1 -0.02 0.37 0.15 -0.19
Both N = 40 -0.08 -0.18 0.25 -0.15 -0.09 -0.12 0.02 0.06
Diastolic blood pressure increase 100 lg N = 24 0.16 -0.09 0.14 0.04 0.17 0.15 0.28 0.13
200 lg N = 16 -0.53 -0.22 0.2 -0.13 0.09 0.27 0.09 0.47
Both N = 40 -0.2 -0.03 0.07 0.03 -0.06 -0.01 0.01 0.07
Systolic blood pressure increase 100 lg N = 24 0.1 0.05 0.06 0 0.2 0.23 0.29 0.21
200 lg N = 16 -0.03 -0.4 -0.1 0.25 0 0.54 -0.02 0.19
Both N = 40 0 0.07 0.03 0.07 -0.07 0.11 0.05 0.08
Data are Pearson correlation coefficients between the LSD concentration in plasma and the corresponding time-matched effect of LSD. Bold
values indicate significant associations (p\ 0.05)
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of 30 and 100 min later, respectively, after oral adminis-
tration compared with intravenous administration of an
equivalent dose [13, 19]. Magnetic resonance imaging
scanning correctly started at approximately 70 and 150 min
in the studies that used intravenous [13] and oral (unpub-
lished data from Study 1, 100 lg) routes of LSD admin-
istration, respectively, coinciding with the maximal
response to LSD. Nevertheless, the plasma concentrations
of LSD and associated time-matched subjective responses
after intravenous LSD administration should also be
determined to better evaluate the considerable research
data that have been generated with this formulation.
After intravenous administration, a drug is rapidly
diluted and distributed within the blood. Peak plasma
concentrations are typically reached rapidly, and elimina-
tion begins immediately. Using the model parameters k and
keo from the present study, the Tmax for ‘‘any drug effect’’
after intravenous administration can be predicted to occur
at approximately 70 and 50 min for the 100- and 200-lg
doses and are thus similar to the recently observed times to
peak effects [13, 19]. In our model, the relatively long Tmax
of the effect of LSD is represented by the lag that is
attributable to distribution of the drug from plasma to the
hypothetical effect compartment. The cause for this lag is
unclear. Additional studies are needed to determine whe-
ther LSD is distributed slowly because it is present only in
small concentrations or slowly penetrates the blood–brain
barrier or whether there is a lag in the response mechanism.
The present study showed that LSD produced robust and
high subjective ‘‘any drug effect’’ and ‘‘good drug effect’’
in almost all of the subjects. The estimates of the corre-
sponding EC50 values were in the range of 0.71–1.2 ng/mL
and lower than the mean LSD Cmax values (1.3 and 3.1 ng/
mL for the 100- and 200-lg doses, respectively) observed
in the present study. ‘‘Bad drug effects’’ were moderate and
not present in every subject. Consistent with this finding,
the EC50 values were higher than those for ‘‘good drug
effect’’ and ‘‘any drug effect’’ (1.5–2.5 ng/mL). As previ-
ously reported, the subjective effects were dose dependent,
whereas the autonomic effects were comparable at both
doses [21]. When analyzed within subjects using pharma-
cokinetic-pharmacodynamic modeling, a close relationship
was found between plasma concentrations of LSD and the
effects of LSD, with moderate counterclockwise hysteresis.
Counterclockwise hysteresis typically reflects the time lag
that is caused by drug distribution to the effect site and the
response time associated with the mechanism of action.
The present study showed that the subjective and auto-
nomic effects establish themselves relatively slowly. On
average, the subjective ‘‘any drug effect’’ peak was reached
2.8 and 2.5 h after administration of the 100- and 200-lg
doses, respectively, and 1.1 and 0.6 h after the respective
peak LSD concentrations were reached. The lag times were
comparable for the increases in heart rate and blood pres-
sure but longer for the thermogenic response. No clockwise
hysteresis was found for any of the pharmacodynamic
outcome measures, and thus no evidence was found of
acute tolerance as described for other psychoactive sub-
stances, such as methylenedioxymethamphetamine [39] or
cocaine [40], or for repeated administration of LSD [41].
Thus, as long as relevant concentrations of LSD were
present in plasma, subjective and autonomic effects were
observed. The mean durations of the subjective effects of
LSD was 8 and 11 h after administration of the 100- and
200-lg doses, respectively, and the difference corre-
sponded to the plasma half-life of LSD.
The present analyses typically found no correlations
between LSD concentrations and the effects of LSD across
subjects within dose groups, likely because of the relatively
high concentrations of LSD and generally consistently high
subjective response ratings in most subjects. If relatively
high and similar doses of LSD are used that result in plasma
concentrations above the EC50 of a particular response
measures, then responses do not vary across subjects
because responses are close to maximal. This would typi-
cally also be the case with measures with a maximal effect
limit such as VAS ratings and some physiological effects
such as pupil size [42]. In fact, responses to LSD or other
drugs in a standardized experimental setting may vary only
if the response is not induced consistently in all subjects
(e.g., at the beginning and end of the response) because of
individual differences in drug absorption/distribution and
elimination. Correlations of plasma concentrations with the
subjective and cardiovascular effects of LSD or 3,4-
methylenedioxymethamphetamine [42] across subjects are
only weak during the peak response. This finding needs to
be considered when interpreting associations between sub-
jective responses and other measures, such as fMRI
parameters. fMRI findings may reflect the variance in LSD
plasma concentrations. The likelihood of detecting corre-
lations within a dose group increases for effects that are not
robustly induced in all subjects.
The present study has limitations. First, the two doses of
LSD were evaluated in two separate studies in different
participants and not within subjects. Second, the plasma
samples were analyzed in different laboratories. Nonethe-
less, the pharmacokinetic data were consistent across the
two studies and laboratories.
5 Conclusion
We gathered pharmacokinetic data for oral LSD that are
essential for interpreting the findings of clinical studies and
LSD intoxication. LSD had dose-proportional pharma-
cokinetics and first-order elimination up to 12 h. A close
P. C. Dolder et al.
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plasma concentration–effect relationship was found within
subjects over time, with moderate counterclockwise hys-
teresis because of a short lag of the response. Generally, no
association was found between plasma LSD concentrations
and its robust effects when analyzed across different sub-
jects and within a dose group. This has implications for
studies that interrelate different effects of LSD.
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Supplementary Figures 
 
 
Figure S1. Schematic representation of the pharmacokinetic-pharmacodynamic link model.   
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Figure S2. LSD plasma concentration-time curves. LSD was orally administered at a dose of 
100 µg (panels 1-16) or 200 µg (panels 17-40) at t = 0. The data represent individual 
observed LSD plasma concentrations as measured at the different time points (□ for 100 µg 
and ● for 200 µg LSD) and the LSD concentrations predicted by the one-compartment 
pharmacokinetic model (black lines). Note the interindividual variance in plasma 
concentrations, especially within the 100 µg LSD dose group (panels 1-16).   
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Figure S3. Plasma concentration-time curves of LSD. Filled circles (●) and empty squares 
(□) indicate the mean ± SEM concentrations after 100 and 200 µg LSD. The inset shows the 
semilogarithmic plot. First-order kinetics were observed up to 12 h. LSD was administered at 
t = 0. 
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Figure S4. Subjective responses to LSD. LSD was orally administered at a dose of 100 µg 
(panels 1-16) or 200 µg (panels 17-40) at t = 0. The data represent individual observed LSD 
responses on the “any drug effect” Visual Analog Scale (rated 0-100%) at the different time 
points (□ for 100 µg LSD and ● for 200 µg LSD) and the pharmacokinetic-pharmacodynamic 
model-predicted effect (black lines). 
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Figure S5. Subjective responses to LSD. LSD was orally administered at a dose of 100 µg 
(panels 1-16) or 200 µg (panels 17-40) at t = 0. The data represent individual observed LSD 
responses on the “good drug effect” Visual Analog Scale (rated 0-100%) at the different time 
points (□ for 100 µg and ● for 200 µg LSD) and the pharmacokinetic-pharmacodynamic 
model-predicted effect (black lines).   
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Figure S6. “Bad drug effect” of LSD. LSD was orally administered at a dose of 100 µg 
(panels 1-16) or 200 µg (panels 17-40) at t = 0. The data represent individual observed LSD 
responses on the “bad drug effect” Visual Analog Scale (rated 0-100%) at the different time 
points (□ for 100 µg and ● for 200 µg LSD) and the pharmacokinetic-pharmacodynamic 
model-predicted effect (black lines).  
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Figure S7. Association of LSD plasma concentrations (predicted Cmax levels) and peak 
subjective effects (predicted any drug effects) for both doses (100 and 200 µg) pooled 
(N=40, circles, left panel) and for the 200 µg dose alone (N=16, rectangles, right panel). 
Plasma concentrations of LSD are significantly correlated with its subjective effects across 
subjects in the pooled sample (Rp = 0.38, p < 0.05, N = 40, left panel). However, plasma 
peak concentrations are not significantly correlated with the subjective peak response within 
the 100 µg (Rp = 0.38, p = 0.08, N = 24) or the 200 µg (Rp = -0.04, p > 0.8, N = 16) dose 
groups.      
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Figure S8. Diagnostic plots for a representative subject of the 100 µg LSD dose study group. 
upper left panel: Observed and predicted concentrations of LSD vs. time. (see Figure S2 for 
all plots) upper right panel: Observed vs. predicted concentrations of LSD. Middle left panel: 
Residual vs. predicted concentrations of LSD. Middle right panel: Observed and predicted 
effects of LSD vs. time. (see Figure S4 for all plots). Lower left panel: Observed vs. predicted 
effects of LSD. Lower right panel: Residual vs. predicted effects of LSD.  
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Figure S9. Diagnostic plots for a representative subject of the 200 µg LSD dose study group. 
upper left panel: Observed and predicted concentrations of LSD vs. time. (see Figure S2 for 
all plots) upper right panel: Observed vs. predicted concentrations of LSD. Middle left panel: 
Residual vs. predicted concentrations of LSD. Middle right panel: Observed and predicted 
effects of LSD vs. time. (see Figure S4 for all plots). Lower left panel: Observed vs. predicted 
effects of LSD. Lower right panel: Residual vs. predicted effects of LSD.  
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4. Discussion  
 
4.1 Pharmacokinetics 
 
After no research in humans since the 1970s, we have successfully conducted two
double-blind, placebo-controlled, randomized, cross-over phase I studies in healthy
subjects. We investigated a high dose of 200 µg of LSD in 16 subjects and a 
lower dose of 100 µg of LSD in 24 healthy subjects, and characterized psycho-
logical, physiological, and pharmacokinetic effects (56, 68-71).
The development of a sensitive method for the measurement of LSD and its
metabolites was an analytical challenge. Due to the high potency of the substance,
only very low doses are administered and thus result in very low plasma and urine
concentrations. Additionally, the vulnerability of the compound to light and air
demands careful handling. Therefore, we decided to evade purification procedures
with solid-phase or liquid-liquid extraction. These can certainly increase the
concentration and lead to better sensitivity of the LC-MS/MS method, but also form a
time consuming procedure. We established a fast and reliable method for application
in emergency toxicological cases where time is a crucial factor. This method was
then successfully applied in five toxicology cases where consumption of LSD could
be confirmed four times in serum and once in urine (65). Further, we successfully
quantified concentrations of LSD, and its major (urinary) metabolite 2-oxo-3-hydroxy
LSD. Following the controlled administration of 200 µg LSD in our first study, the
metabolite was found to be present at around 10% of the LSD concentration in
plasma, and up to 20-fold the LSD concentration in urine. Confirmation of this
metabolite following the dose of 100 µg was difficult as peak plasma concentrations
of LSD were around 1.5 ng/ml what corresponds to 2-oxo-3-hydroxy LSD
concentrations of 0.15 ng/ml. This is already near to the limit of detection of many
LC-MS/MS methods. Nonetheless, we could confirm the presence of some in-vitro
identified metabolites (54) using more specific LC-MS/MS methods (67). We and
another group (79) were able to detect nor-LSD, LAE, LEO, 13- or 14-hydroxy-LSD,
and 2-oxo LSD in some of the plasma and urine samples after 100 and 200 µg LSD
(67, 79). Nevertheless, the complete metabolic faith of LSD, including involved
enzymes, is still unknown. Figure 1 gives an overview of currently identified and
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possible metabolites. Future studies should address this issue and use higher doses 
of LSD in humans for quantification of metabolites. Further,in vitro/in vivo studies 
should clear up the metabolism of LSD including the involved enzyme mechanisms. 
Additionally, metabolites need to be commercially available to develop 
comprehensive analytical methods for their quantification.  
 
Figure 2 shows possible and already identified metabolites of LSD. 
 
 
? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-oxo-LSD 
Present in rat, mice, guinea pigs, 
monkeys, and humans  (41-44) 
Inactive in humans (41) 
 
 
Iso-LSD 
Synthetic by-product, inactive 
Identical metabolism to LSD (47) 
13-OH-LSD > 14-OH-LSD 
 
 
 
? 
d-Lysergic-acid-diethylamide (LSD) 
2-oxo-3-hydroxy-LSD 
Major human metabolite (46,65,67,79) 
 
 
13- or 14-hydroxy-LSD 
Major metabolite in rat, guinea pigs (43) 
Present in humans (glucuronides) (67) 
13-OH-LSD possibly active (43) 
 
 
Lysergic-acid-ethyl-hydroxyethylamide 
(LEO) 
Present in humans (67) 
 
Lysergic-acid-monoethylamide (LAE) 
Present in rat, guinea pigs, monkeys, humans 
(43,67) 
Active in animal and human  
10-Hydroxy-9,10-dihydro-LSD  (lumi-LSD) 
Proposed but unconfirmed metabolite (43) 
Formed under UV light (48,49) 
“naphthostyril compound”  
Formed out of 2-oxo-LSD  
Present in monkey (43) 
pH>9 
? 
? 
Nor-LSD 
Present in humans (67,79) 
Identified in-vitro (47) 
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With the established LC-MS/MS methods we have assessed data on the plasma
concentration-time curves of LSD. This is crucial because many experimental and
therapeutic studies, some of which have started simultaneously to our studies, did
not determine plasma concentrations. Thus no information on the presence of LSD in
their subjects sample is available.
Maximum plasma concentrations (Cmax) and areas under the curve (AUC) values
were approximately twice as high for the 200 µg dose compared with the 100 µg
dose. Time point of peak plasma concentrations (Tmax) and plasma half-lifes were
similar, consistent with dose-proportional pharmacokinetics. Compartmental
modeling predicted a geometric mean Cmax of 1.3 ng/ml, 1.4 h after the administration
of 100 µg LSD. Geometric mean Cmax values of 3.1 ng/ml were reached 1.5 h after
the administration of 200 µg LSD. The predicted mean half-live of LSD was 2.6 h
after both doses and was thus comparable to the value of 2.9 hours found after
intravenous administration of 2 µg/kg LSD in the 1960s (48, 50-52) but shorter than
the 3.6 hours that we have determined using non-compartmental analysis (68).
Overall, we observed linear dose and elimination kinetics of LSD up to 12 hours after
drug administration.
The present data on the plasma concentration-time curves of LSD are important as
many studies that started investigating LSD did not perform blood sampling. There
are no data available on the plasma concentrations after intravenous administration
of 75 µg LSD base in saline (80), despite the publication of extensive
pharmacodynamic data (75, 80-87).
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4.2 Pharmacodynamics 
 
In the present studies, LSD produced robust and high subjective drug effects in 
almost all of the subjects. The subjective effects lasted 8.2 ± 2.1 hours and 11.6 ± 1.7 
hours (mean ± SD) for the 100 and 200 µg LSD doses, respectively. Subjective peak 
effects were reached 2.8 hours and 2.5 hours after administration of 100 and 200 µg 
LSD, respectively (68, 70, 71).  
Both doses of LSD induced subjective feelings of well-being, happiness, closeness to 
others, openness, and trust (70). LSD induced a profound altered state of 
consciousness on the five dimensions of altered consciousness questionnaire (5D-
ASC) including visual hallucinations, audiovisual synesthesia, positively experienced 
derealisation, and depersonalization phenomena (69). These mind altering effects 
were dose dependent and have recently been replicated by other research groups 
using different doses and routes of administration (12, 69, 75) (Figure 2). Recent 
investigations have further shown that these alterations in consciousness are 
completely blocked by pretreatment with the selective 5-HT2A antagonist ketanserin 
(12, 13). Thus, the 5-HT2A receptor is the main responsible receptor, whereas others 
only play a minor role in LSD’s mind altering effects. Further, the overall alterations of 
consciousness (5D-ASC total score) were significantly correlated with ratings of 
mystical experience on the Mystical Effects Questionnaire (MEQ) (69). These effects 
are of importance because strong mystical experiences were associated with positive 
long-term effects on mood and personality in healthy subjects and better therapeutic 
outcomes in patients with anxiety, depression, and substance use disorder in various 
psilocybin studies (24, 88-90). However, in our study with 200 µg LSD, we rarely 
observed strong mystical experiences. This raises questions regarding expectancy 
effects, placebo responses, and the role of the supervisor and therapist in mystical 
experiences. Ratings for a “Bad drug effect” were not present in every subject and 
inconsistently occurred throughout the sessions and were typically mild and short 
lasting. Adverse effects produced by doses of 100 µg and 200 µg LSD mostly 
included complaints like difficulty in concentrating, headache, dizziness, lack off 
appetite, nausea, and imbalance (70). All adverse effects completely subsided within 
24 - 72 hours. No severe acute adverse effects were observed in both studies and no 
reports of flash-back phenomena were registered.  
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4.3 Pharmacokinetics - Pharmacodynamics 
 
The estimates of the corresponding half maximal effective concentration (EC50) 
values were in the range of 0.71 - 1.2 ng/ml for positive experienced subjective 
effects, and between 1.5 - 2.5 ng/ml for ratings of bad drug effects (68, 71). In our 
studies, where relatively high and similar doses of LSD were used, the resulting 
plasma concentrations were above the EC50 of the particular response measures. 
Therefore responses did not vary across subjects because responses are close to 
the maximum. This is important to note and explains why we typically found no 
correlations between LSD concentrations and effects across subjects within dose 
groups. Probably because of the relatively high concentrations of LSD and the 
consistent very high subjective response ratings in most subjects. This finding needs 
to be considered when interpreting associations between subjective responses and 
other measures. However, these correlations of plasma concentrations with the 
subjective and cardiovascular effects of LSD are only weak during the peak response 
and typically the case with measures with a maximal effect limit such as subjective 
drug effect ratings across different questionnaires and some physiological effects like 
pupil size. Still we observed a close relationship between the LSD plasma 
concentration and subjective effects.  
In both studies, we found no evidence of acute pharmacological tolerance 
(represented by a counterclockwise hysteresis, shown in Figure 3) within 12 hours 
after the 100 μg dose and within 24 hours after the 200 μg dose. In contrast, other 
psychoactive substances, such as 3,4-methylenedioxymethamphetamine (MDMA), 
exhibit very marked acute pharmacological tolerance (represented by a clockwise 
hysteresis, shown in Fig 3), with a rapid decline of subjective and physiological 
effects of MDMA within 4 hours despite continuously high plasma levels. 
 
 
117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
F
ig
u
re
 4
 s
h
o
w
s
 t
h
e
 p
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 –
 e
ff
e
c
t 
re
la
ti
o
n
s
h
ip
s
 w
it
h
 c
o
u
n
te
rc
lo
c
k
w
is
e
 h
y
s
te
re
s
is
 (
n
o
 a
c
u
te
 
to
le
ra
n
c
e
) 
o
f 
L
S
D
 a
n
d
 c
lo
c
k
w
is
e
 h
y
s
te
re
s
is
 (
a
c
u
te
 t
o
le
ra
n
c
e
) 
o
f 
M
D
M
A
. 
 
 
118 
 
 
4.4 Emotion Recognition and Empathy 
 
Because of the use of LSD, mainly in psychiatric settings and the recreational use, 
information about the effects of LSD on social cognition are important. Social 
cognition includes aspects of emotion recognition and empathy which describe the 
ability to infer another’s thoughts, feelings, and intentions. Those are relevant for a 
better understanding of the human brain structures and functioning, as well as simple 
social interactions during clinical studies and mainly in psychotherapeutic settings. 
Results from earlier studies were primarily observational and thus very subjective.  
To allow for a better characterization of the social-cognitive effects of LSD, we used 
validated psychometric instruments that have been used with other drugs, such as 
MDMA, methylphenidate, and psilocybin (72-74, 76, 77). 
Interestingly, 100 and 200 µg LSD positively altered the processing of emotional 
information by decreasing the recognition of fearful faces and tended to impair the 
recognition of sad faces (70).  Further, 200 µg LSD significantly enhanced emotional 
empathy whereas the effects of 100 µg LSD did nearly not reach significance.  
Overall, these effects are similar to those observed following MDMA administration 
which similarly impaired the correct recognition of negative emotions and induced 
strong feelings of well-being, and empathy. Similar to LSD, psilocybin decreased the 
recognition of negative facial expressions and increased emotional empathy (76, 77). 
These findings indicate that LSD affects emotion processing similarly to MDMA and 
psilocybin. In line with the findings of impaired recognition of fear following LSD 
administration, we found that 100 µg of LSD reduced left amygdala reactivity to the 
presentation of fearful faces relative to placebo (78). Similarly, psilocybin and MDMA 
decreased amygdala reactivity to negative facial stimuli (91, 92).  
The emotional effects during the later phase of the acute LSD response (6-10 h) and 
the reduced perception of negative emotions/amygdala reactivity are likely beneficial 
in psychotherapeutic settings. Future research should therefore address the relative 
contributions of the empathic and emotional effects of LSD to its potential therapeutic 
effects. 
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5. Summary and Outlook 
 
The findings of the two clinical studies about the effects of LSD in healthy participants
have translational relevance for further medical investigations. First, we have shown
that LSD can be safely administrated to healthy subjects when closely monitored and
supervised by experienced investigators. Second, the PK-PD relationship shows that
the subjective effects are directly related to the plasma concentrations and that LSD
does not produce acute tolerance. Third, the increase in emotional empathy and the
bias towards the recognition of positive emotions in line with a decreased amygdala
reactivity, might reflect a potentially therapeutic effect by reducing perception of
negative emotions and facilitating the therapeutic alliance in LSD-assisted
psychotherapy (e.g. in anxiety disorders). Currently LSD-assisted psychotherapy is
offered by two psychiatrists to selected patients in Switzerland in the context of
compassionate use which is legally-authorized, but demands case-by-case
authorization by the Swiss Federal Office for Public Health (BAG).
Due to the study results and the pioneer work in the field of compassionate use, we
were able to get the approval for a new clinical phase II study, investigating LSD in
40 patients with anxiety (with or without life threatening diseases). Because the
higher dose of 200 µg LSD produced stronger subjective and emotional effects while
having comparable cardiovascular stimulation as the lower 100 µg dose, it was
selected to be used in this phase II trial. The study has just started and uses a dou-
ble-blind, placebo-controlled, within-subject, cross-over design with two LSD and 
two placebo sessions. Our hypothesis is that LSD will significantly reduce anxiety in 
these patients. The study will last until 2021.
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